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ABSTRACT

T he Effects ofRetinoic Acid on the Angiogenic
Growth Factors Produced
by Solid Tumors

by

Lynn C. Burgess, Doctor of Philosophy
Utah State University, 1998

Major Professor: Dr. Howard M. Deer
Program : Tox ico logy

T hese st udies investi gated the effects of retinoic acid (RA) on angiogenesis.
T hree human, neoplastic ce ll lines were used to examine angiogenic promotion a nd/or
inhibi ti on. The cell lines, U-373 MG glioblastoma , DU- 145 prostate carcinoma, and
TCCSUP bladder transitiona l cell carcinoma, were treated with the following: all-trans ,
9-cis, or 13 -cis RA , at doses from 0.000 I to I00 fiM. Hypoxia was used to ass ist the

express ion of the angiogenic phenotype. Conditioned media (CM) were prepa red by
growi ng the tumor cell s in the prese nce of RA and hypox ia for 24 hours, and then the
CM was transferred to bovine , capill ary endothelial ce ll s (EC) for 48 hours. T he EC
were co unted lor eac h CM and compared to control s. Mu lt iplex , reverse transcriptascpolyme rase chain reacti on (M RT-PCR) was used on tumor cell RNA to demonstrate

IV

that mRNA expression of several angiogenic growth factors was modified. Angiogenic
proteins in the C M were identified bY enzyme-linked immunosorbent assay (ELISA).
The CM from the U-373 and DU-145 cell s, but not the TCC SUP cells, treated
with all-trans or 9-cis RA caused significant increases (P<0.05) in EC proliferation.
RAin nonconditioned media inhibited EC proliferation. CM treated with 13-cis RA
did not increase EC proliferation.
MRT-PCR demonstrated that the tumor cells expressed vascular endothe lial
growth factor (VEGF), midkine, interleuki n-8 (rL-8), thrombospondin (TS P), and
leukemia inhibitory factor (LIF) mR'JAs. Increases VEG F mRNA corresponded to
increased EC proliferation. IL-8 mR.'JA increased at RA concentrations greater than
0.1 JiM . Midkine mRNA concentrations were generally unaffected by RA treatments.
ELISA demonstrated that VEGF was increased by all-trans RA. to a lesser degree by 9-

cis, and even less by 13-cis. fL-8 prote in secretion was inhibited by RA . T he
expression ofTSP and LIF mRN As 11as almost compl ete ly inhibited by hypoxia.
EC were grown with sodium hepari n at 0, 10, 100, 500, or 1000 Jlg/ml in C M
produced with DU-1 45 cell s and 0.(11_!0 1, 0.00 1, or I JiM all -trans RA . Heparin
increased EC proliferation at 10 flg ml and inhibited proliferation at hi gher
co nce nt ration s.
(2 18 pages)
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INTRODUCTION

Interest in retinoids began soon after the discovery of vitamin A. As early as
1500 B.C . the Egyptians recob'llized night blindness as a disease (I), for which
Hippocrates later suggested eating liver as a cure (2). In 1913, two groups
independentl y reported that rats fed diets with lard as the on ly source of lipids
developed a nutritional deficiency that resulted in xerophthalmia, dryness and
thickening of the conjunctiva. This deficiency could be corrected with the addition of
butter, egg yolk , or cod liver oil (2). They later called this substance, which was
capab le of preventing xerophthalmia and night blindness, " Fat Soluble A" ( I ).
A major breakthrough in the understandi ng of vitamin A and related retinoids
came in the early 1920 ' s. It was demonstrated that feeding experimental an imals a diet
deficient in retinoids caused hyperkeratinization, squamous metaplasia, and b'TOSS
tumors in some epi thelial tissues (3). These discoveries led to numerous studies of both
retinoids and their precursor, carotenoids, as cancer chemopreventive agents (4). In
addition , the findings led to a vast number of e pidemiological studies, which have
demonstrated an inverse correlation between e ither dietary intake or blood
conce ntrations of vitamin A (or carotenoids) and cancer risk for several epithelia l ce ll
types (5)
Ex periment s have shown that retinoids ca n inhibit carcinogenesis in both

in"'""

a nd m vitro systems, if app lied before or in conjunction with a chemical carc inogen or
ultravio let li ght (5). Retinoids are a factor in the control of epithe lia l cel l
differentiation and proliferation, and when ce ll s are de ficient in retinoids they have an

2
enhanced susceptibility to carcinogens (2) . Additional studies have investigated the
abi lity of natura l and synthetic retinoic acids to inhibit both metapl asia or carcinom a in
situ in hi gh ri sk groups, like tobacco users, or to treat fully developed cancers (6 ,7).

Retinoids and carote noids have been examined for their ability to act as
antioxidants and to enhance or maintain gap junctional communications between ce ll s
(8,9). T he antioxidant function may inh ibi t cell transformation, while the effects on
gap juncti on co mmunication may inhibit the progression of the transformed ce ll into a
tumor.
T here are numerous examples of the use of retinoids in the treatment o f cancer.
T he synthetic re tinoic acid , etretinate, reduced metaplasia in heavy smokers ( 10). A
phase Ill clinica l trial of loca ll y applied a ll -trans-retinoic acid in cervica l intraepithe lial
neoplasia showed a sign ifica nt effect of the all-trans-retinoic acid, with ei the r complete
regressio n or decreased progressio n of the neoplasia ( II ). Oral leukoplasia was
reduced by e ither 13-cis-retinoic acid or fenretinide, a synthetic retinoic ac id ( 12). In
23 patients with A IDS-related Kaposi 's sarcoma that were treated wi th all-lrarlsretinoic acid , 25% had majo r tumor reduction and 50% had a stab ilization oft he
disease lo r up to one year ( I I). 13-cis-retinoic ac id was used to treat patien ts wi th
sq uamous-ce ll carcinoma of the head and neck after they were disease- free following
primary treatmen t And, alit:r 32 month s on ly 4% of the 13-cls-retinoic acid treatme nt
group had

~econd

primary tumors (recurrences of the ca ncer in the sa me tissue type)

comparl!d to 2-t 0 o of the contro l group ( 13).
Rctinoids, used in an ima l mode ls, also have inhibited tum or growth . The

3
synthetic retinoid fenretinide significantly reduced tumor growth in rats that had been
inj ected with MLC cell s, an anaplastic, androgen-i ndependent human prostate
adenocarc inom a cell line ( 14). Another group reported that fenretinide reduced tumor
growth in N-m ethyl-ni trourea and testosterone propionate-treated Lobound-Wistar rats
that spontaneously develop prostatic adenocarcinoma ( 15 ). In nude mice, 13-cisretinoic acid had a synergistic effect with a ndrogen ablation (castration) in decreasing
tumors created by injecting a human prostatic carcinoma cell line ( 16). Several in vitro
studi es have shown that all-trans-, 9-cis- a nd 13-cis-retinoic acids significant ly reduced
the proliferation of neoplastic cell lines ( 17-19). The most promising result from the
use of retinoids as a cancer treatment has been with acute promyelocytic leukemia
where Chinese clinicians had a 85% rate of complete remission . In the weste rn world
there has been a report of 195 out of228 cases of remission (20).
Severa l research groups have reported either no therapeutic value from the use
of ret ino ids or found that the retinoids acted to promote tumor development.
Diethl ynitrosam ine, when fed in conjunction with N-ethyl-13-cis-retinamide, all -transethyl-retinami de, or all-trans-retinoic acid resulted in a significant increase in li ver
tumors and/or cancers over the dietary control s (2 1). Beta carotene, used as a
c hemopreve nti \'e for non-me lanoma skin ca ncer, produced no reducti on in new skin
ca nce rs in a 5-year study (22) . After 5 to 8 years of die tary s uppl e mentat ion with beta
carotene and/or' itami n E to Finn is h tobacco smokers, there was an 18% increase in
lung ca ncer dea ths among the group receiving the beta carotene (8). ln add ition , a 17%
increase in lun g ca ncer was see n in a study conducted in the United States, when
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smokers and asbestos workers were supplemented with beta carotene and vitamin A
(9) . In contrast, a trial with 13-cis-retinoic acid had improvement in one of 15 cats
treated for squamous cell carcinoma of the head (23 ).
T he use of retinoids in cancer treatment or prevention has, to date, shown
inconsistent results, especially when used to treat patients with full y developed cancers.
T he most promi sing results were from treatment of precancerous lesions and acute
prome locytic leukemia . Retinoids were thought to hold great promise as cancer
chemoprevention agents, but two major studies were stopped due to increases in ca ncer
deaths (8,9). Current information does not explain the interactive mechani sms of
retinoids and cancer. Research into the dose-responsive effects ofretinoids is lacking,
with most studi es having been conducted with a single concentration ofretinoids.
This, together with the research showing negative effects of retinoids used at a very
low dose for chemoprevention and evidence that hi gh doses inhibit neoplastic cell
pro li ferat ion, ind icates retinoids may have different cellular effects at di fferen t
conce ntra tions.
Retino ids have been shown to have angiogeni c activity , the creati on of new
blood vessels from preexisting vessels (20). Thi s activity may explain some of the
e ffects of retinoid s in the treatm ent of cance rous !,>TOwths. One possible amiangioge ni c
e ffect ofretinoic acid could be on the endothe lia l ce ll s that fonn ca pill aries a nd line
larger vesse ls. For examp le , e ndothe lial cc ll migrat ion was inhibited by all-trans- and
13-cis-retinoic acids (24). Using the chorioall anto ic membrane assay of the c hick
emb ryo (CA M assay), retinoic ac id inhibited angioge nes is (25). In additi o n, I 11M
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retinol exposure to endothe lial cell s resulted in 100% growth-inhibition (26).

A ll-trans- and 13-cis-retinoic acids affected the angiogenic phenotype expression of
neoplastic cell lines in vitro by inhibiting the secretion of IL-8 and TGF-b, which are
angioge ni c growth factors (24 ). Other growth factors have been shown to be indirectly
inhibited by retinoic acid. 13-cis-retinoi c acid altered the expression of the tumor
suppressor gene p5 3, which regulates the expression of thrombospondin-1, an
antiangiogenic growt h factor (27).
T he goal of this research was to detennine mechanisms by which retinoic acids
might cause interactive effects between neoplastic cell lines and angiogenic inhibition
or promotion . T he ce ll lines were se lected as in vitro model s of establi shed metastatic
tumors. The mai n questions exam ined were: I. Does the effect of retinoic aci d
treahnent of a cell line vary by the concentration of the retinoic acid, and 2. Does the
retinoic acid affect the production of angiogenic growth factors?
Due to the vast number ofretinoids (naturally occurring or synthetic), ca ncer
types, and the large number of pro- or antiangiogenic growt h factors that have been
iden tifi ed, onl y a limited number ofretinoids, cell types, and growth factors were
se lected for these studies. Thi s research was limited to three retinoic acids, all -trans-,

9-cis-, and 13-c is-retinoic acids. Three tumor cell lines were used to in vesti ga te thro::e
proangiogenic and two anti angiogen ic growth factors .

6

LITERATURE REVIEW

Cancer Defined
Cancer is a leading cause of death, second only to cardiovascu lar disease (28).
The American Cancer Society stated in 1993 that as a whole, cancer will develop in one
person in three in the United States and that one out of five deaths wi ll be due to
cancer.
Cancer is a common tenn that refers to a malignant growth or tumor. But this
tenn is too simplistic and needs to be described in detail. Cancer may be succinctly
defi ned as the loss of growth and spatial control. This means that tumor cells differ
from normal cells in their proliferative capacity, as we ll as in thei r abil ity to invade
adj acent ti ssues and metastasize (29). A ca ncer is thought of as the ma li gnant

~:,rrowth

of a tumor. There is no universally accepted definition for a tumor, but Rupert A.
Wi lli s defi ned it thi s way: " A tumor is an abnonnalmass of tissues, the growth of
which exceeds and is uncoordinated with that of the normal ti ssues, and persists in the
same expressive manner after cessation of the stim uli which evoked the change" (30: I).
In this definition, Willi s used the tenn tumor in the restricted or specific sense of a true
neoplasm. The word neoplasm means a new growth or an aberrant proli feratio n of
cell s; there fore, a neoplas ia is the di sease of ce ll s characterized by alteration of normal
growth-regu lating mechanisms. T he a lteration ofnonna l growth regu lato1y
mechani sms is the most imponant characteri stic of neoplasia. Neoplastic !,>TOwth ca n
be thought of as the abnormal activation of the mitotic cycle or the inactivation of
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growth inhibition and apoptosis (3 1). This release of growth control can occur by
numerous mechani sms. Examples of some of the mechanisms are as follow: a sessile
cell might become mobil e; a short-li ved cell might become long- li ved; a nondividi ng
ce ll might enter the cell cycle; a cell normally dependent on a hormone might become
independent of the stimulant; a ce ll may lose its program to progress to apoptosis.

Ca ncer Initiation
A normal cell genera lly progresses through three phases in becoming a
neoplastic cell. Boone reviewed the progression of epithelial cell change associated
with neoplastic changes (32). The first phase must be a heritable genetic alteration.
Thi s leaves the cell in the latent phase, in which the cell appears normal , but can
ex pand clonally, if conditi ons are changed. The second phase of change is ca ll ed
hyperplasia or an increase in the number of cells in a tissue, which may be seen as a
" local aberrant proliferation." Thi s area of the ce ll s appears normal except for
increased mitotic activity and may exhibit di sorgani zed architecture, frequentl y
including co mpression of surround ing normal ti ssue. Thi s can progress to a dysplasia,
which is an abnormal cellular proliferation with loss of norrnal architecture and
orientation. Dysplasia is usuall y graded into mild, moderate, or severe categories
dependin g on its extent above the basement membrane. A severe dysplasia which
extends the full thic kness oft he e pi thelium may be ca ll ed a carc inom a m s1tu. These
stages of neo plasm development ca n a lso be associated with metaplasia, whi c h is the
adapti ve substitution of one type of adult tissue for another. The final phase is refe rred
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to as neoplasia and termed invasive when the growth of cells traverses the basement
membrane, and metastasi s when cells separate from the main tumor mass and
di sseminate via vascular and lymphatic channels to form secondary growths at distant
sites . Once the tumor mass reaches the invasive neoplasia stage, most persons would
consider it to be a cancer.
The conditions of hyperplasia, metaplasia, or dysplasia are thought to be
reversible, if the stimuli are removed. This means that either the cells are replaced by
normal cells, the number of cells is reduced in the tissue, the abnormal cells are
replaced through growth of normal cells, or the abnormal cells return to normal growth
controls. This does not mean the genetic aberration has been repaired.
There is another criterion of a tumor which can be explained histologically.
Tumors are either benign or malignant. The benign tumor' s growth is ei ther slow or
stops and it does not traverse the basement membrane or metastasize. Benign tumors
are designated with the suffix "oma" to the cell type, e.g., fibroblasts-fibroma.
Malignant tumors a re called carcinomas if they are of epithelial cell ori gi n or sarcomas
if they originate from mesenchymal ti ssues. The tissue type is added as a prefi x. One
tissue that does not fit into this classification is the blood or lymph. Cancers of this
tissue have various names, but usuall y are referred to as leukemia, with the cell type as
a prefi x.
There is a different classification of cancer based on the molecu lar events
occurring in the cells. These are the actual causes of abnormal cell growth control.
So me of these changes can be seen as the histological changes previously described;
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others can be detected only at the DNA level and others are still unknown .
It is generall y accepted that tumors arise from clonal expansion of a si ngle or a
few transformed cells (29). Before the tumor forms , there are several events which
must occur. T he genetic defect that transforms a cell is acquired, i.e. induced by a
virus, toxic agents, or ionizing radiation (31,33). This genetic defect can be as small as
a single poi nt mutation or it might affect a whole chromosome (3 1). Tumor suppressor
genes normally function to maintain the nonmalignant phenotype by limiting growth,
invasiveness, and other properties found in malignant cells. Tumor suppressor gene
mutations are usually recessive; that is, inactivation of both normal copies of the gene
must occur before an alteration in the phenotype of the cells occurs (the two-hit
hypothesis) (33). In contrast, growth control in some cases can be located in another
cell , not the one that has lost its growth control. For example, a nontumor-formi ng cell
can fail to produce the correct growth factor or kill the transformed cell (3 1,34).
A generally accepted model for transform ation and progression of a cell to a
malignant mass of ce ll s was described by Yuspa in 1994 (35). The mutation occurs a nd
initiates transformation of a cell. This ce ll then receives a second environmental
exposure, which is usually epi genetic and referred to as a promoter. An example of thi s
is phorbol esters, which acti vate the PKC gene and acce lerate terminal differentiation
of normal keratinocytes. Initiated keratinocytes favor clonal outgrowth (35). This leads
to an early papi ll oma, a foca l aberrant proliferat ion, or mild dysplasia. Yuspa
considered the clone to be independent of surrounding cells and could progress witho ut
fa rther geneti c lesions or environmental factors. Thi s idea is still unproven and
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frequently debated. Bertram et a/. in 1987 wrote that chemoprevention of " this process
at any time prior to the onset of fra nk malignancy can be expected to delay the onset of
the di sease." T hey thought the ability to block the progression of malignant cells to
invasive or metastatic cells could not be blocked permanently (5). Other researchers
have shown that initiated cells can be controlled by treatment with retinoids, which
enhances the gap junction communication with nonna l cells (6,36). Thi s wi ll control
the growth of initiated cells.
There are several areas where genom ic damage can be repa ired or the
progression of the clone can be halted. The immune system might play a pivota l role in
the elimination of vociferous cells (3 1). However, the effectiveness of the immune
system in tumor prevention is not well understood.
The idea that the immune system can detect and e liminate tumor cell s, early in
their progression, dates back to as early as 1908 (37). Ehrlich speculated that tumor
cell s ari se frequentl y and bear specific anti gens which al low them to be e liminated by
the immune response of the host. A general concept of imm unological affects on
cancer is ca lled .. immu ne survei ll ance theo ry. " Thi s implies that ca ncer arise o nl y if
the immune system is somehow impaired or if the tumor cells maintain their
recogniti on as bei ng se lf, thereby a ll owing them to escape imm une detection and
destruct ion (2 8). T hi s idea has been questi oned for two reasons. First, som e immunecompromi st:d animal s and hu mans do not show increased tumors incidence (28), a nd
second, the immune system can on ly recogni ze a tumor ce ll if the tumor loses the
ability to ex press se lf(28,37). However, immune response to tumors has bee n
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demonstrated experimentally in animals, particularly with respect to viral induced
tumors and tumors induced by "strong" chemical carcinogens (37). This continues to
be an active area of research with several groups attempting to change neoplastic cells,
such that they will appear as nonselfto the immune system.
There are other normal functions in the body that reduce the incidence of
cancer. An affected cell will , by itself, try to repair its own genomic damage, and if
repairs fail, the cell may undergo apoptosis for the sake of the integrity and health of
the organism (3 1). The cell cycle is partly controlled by the p53 gene, which is a DNAbinding phosphoprotein that transduces a signal from damaged DNA to other genes
which are involved in controlling both cell cycle and apoptosis (33). When p53 is
activated it holds the cell cycle at the G I phase, and allows DNA repair mechanisms to
operate. lfDNA damage is excessive, then p53 initiates a sequence of events that
causes cell apoptosis. It has been estimated that 60-65% of human cancers have point
mutations at the p53 locus, which causes the p53 mutant proteins to have abnormal
DNA binding and transcriptional properties, leading to genetic instability (31 ).

Tumor Progression
The advanced stages of tumor growth occur when the tumor becomes invasive
and/or metastatic. When the tumor reaches these stages, cancer becomes a serious
disease . It is commonly assumed that the progression of a cell to a malignant tumor
requires a collection of genetic or epigenetic factors before the tumor is fully released
from nonnal growth control. To reach malignancy there are predictable genetic
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changes that result in activation of oncogenes and "switching off'' of tumor suppressor
genes. T hese alterations lead to phenotypic changes, such as increased proliferative
capacity or acquisition of metastatic competency. This confers a growth or survival
advantage to some cells within the tumor (29). These genetic changes or lose of growth
control can occur from exposure to carcinogenic chemicals (mutagens or mitogens)
which activate or inactivate genes by their DNA damage (32). The increased cell
divi sion can increase the amount of unprotected DNA exposed to normal , endogenous
mutagens such as reacti ve oxygen species, which are known to produce mutations (38).
Additionally, these cell divisions occur rapidly, which does not allow the time
necessary to repair DNA lesions. Also, these rapid mitotic divisions can cause genetic
instability on the chromosomal level and damage can occur, with karyotype of the cells
being changed dramatically (3 8).
A single ce ll can give rise to a monoclonal expansion and genetic changes will
eventually result in multiple subpopulations (29). A fully developed tumor can contain
diverse subpopul at ions that differ in characteristics. T he tumor heterogenicity
facilitates tumor survival because it minimizes the likelihood that a single ins ult will
eradicate all subpopulations. For example, if the local production of a certain growth
factor was termi nated, factor-dependent subpopulations would die, whereas factor
indepe ndent subpopulations would continue to thrive.

Tumor Invasion and Metastasis
Invasion starts when dysplastic cells traverse the basement membrane, and
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metastasis is characterized by individual cells or cell groups that separate from the
tumor mass and are disseminated via vascular or lymphatic channels (32). These cells
can form secondary growths at distant sites. When the neoplasm enters the invasive or
metastatic stage, the tumor prof,rression does not cease. Rather, it most likely
accelerates due to the increase in cell proliferation and the new environments in which
the neoplastic cells must survive. All stages of the neoplasia, from the first genetic
alteration to late metastasis, will evolve irreversibly through stages of increasing
deviation from normal structure and function . This is associated with increasing size,
growth rate, and invasiveness.
Genetic changes at some point in the tumor's development allow the production
of proteases which degrade basement membranes and surrounding normal tissues (29).
This protease production can be due to an activation of a protease gene or release of the
gene 's suppression. The invasive phenotype, the ability of the tumor cells to degrade
extracellular matrix and to violate adjacent tissue compartments, is assumed to be
largely sustained by pericellular proteolytic mechanisms. Many secreted or cell
surface-associated pro teases have bee n implicated in the invasion phenotype of tumor
cells. Among them are integral membrane proteins such as the membrane-type matrix
metalloprotease, urokinase plasminogen activator (29), meprins A and B, dipeptidyl
peptidases, and fibroblast activation protein a (39). There are other groups of proteases
that are associated with invasion and angiogenesis, including the cysteine protease
cathepsi n fJ, which will be discussed later with angiogenesis.
Several mechanistic explanations for pericellular proteolysis-associated tumor
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invasion have been developed . The "random proteolysis" explanation describes a
tumor as it grows, pushing into the surrounding host ti ssue (40). Its margi ns, in a
tumor-host interzone, are where the host ti ssue "melts away" as a result of extensive
ti ssue degradation. [n the other two expl anati ons, pericellular proteolysis is highly
organized and involves defined cellular structures, " invadopodia" and "phagosomes"
(39). [nvadopodia are cell-surface protrusions that appear on the tumor cell s, with
proteo lysis of the extracellular matri x being localized on the top of the protrusion. The
" phagosomes" are generated upon phagocytosis of the extracellular matri x a nd host cell
debris. The underlying idea is that aggressive tumor cells might have phagocytic
capacity (30 ,39). Thi s is possibl e, because even normal epithelial cells have the ability
to phagocytize apoptotic bodies from neighboring cells (39). All three mechani sms
may be exhibited in a tumor, especia lly considering the variation in microenvironments
present in the heterogeneous mass of cells. The phagocytic capacity of the tumor cell s
may be enhanced as they become invasive, allowi ng them to remove extrace llul ar
matrix and cell debris as they push into host tissue. A variety of factors can stimulate
the moti le response of tumor ce ll s (41 ). These include host-derived scatter factors,
growth factors, components of the extracellular matrix, hyaluronan, and tumor-secreted
factors . Motility stimulated by these factors ca n be chemokineses or chemotax in s,
either randomly or in response to a concentration grad ient.
Motili ty of tumor cell s was reported as early as 1863 when the amoeboid
movement of ce ll s from freshl y excised tumors was observed (30). In 1872, the
possible im portance of such motility in tumor invasion a nd metastasis was poi nted out.
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Later studies proved that these migrating cells were neoplastic and not migrating
macrophages. Motile tumor cells can produce and respond to autocrine motility factors.
The motility of tumor cells is aided by a reduction in homotypic cell-cell adhesion in
tumors. E-cadherin has been correlated with invasive behavior for many tumors (29).
Because tumor cells have undergone multiple genetic alterations, there is no
defined endpoint to their spread. Some cells might stop the invasive process, deposit a
new basement membrane, and cause various histopathologic lesions (42). Other cells
could be locally invasive but do not metastasize or lose their cell-cell adhesion. In
comparison, others cells are metastatic and have the ability to detach from the tumor,
survive in circulation, and to form either secondary tumors in other organs or detached
independent tumors in the peritoneal cavity (39).
Just because a tumor reaches a metastatic phenotype and it has access to
circulation, this does not guarantee metastatic tumor formation. Fewer than 0.1% of
circulating tumor cells estab lish a secondary tumor site. Interaction of tumor cells with
platelets and immune cells, including natural killer ce ll s and macrophages, likely
contro ls metastatic formation (29,41 ). The arrest of tumor cells in a distant capillary
bed and extravasation into the target organ parenchyma depend on a series of complex
interactions between tumor cell s and endotheli al cell s, basement membrane, and
extrace llular mat ri x (29).
Another important property of tumors that needs to be ex pl ained before tumor
growth and metastatis can be understood is that so lid tumors are "organoids" consisting
of hi ghl y heterogeneo us popu lations of ma li gnant stromal cells, infl ammatory cells, and
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dynamic extracellular matrix (43). Before any tumor can grow larger than 1 to 2 cubic
millimeters, it needs to develop a stroma. The stroma consists of: (a) a provisional
fibrinogen matrix; (b) new blood vessels; (c) inflammatory cells; and (d) connective
tissue. Cancer cells often occupy less than halfthe volume of a tumor. One to 10% of
the volume is blood vessels and the remaining area is filled with collagen-rich-matrix,
which forms the interstitium (44). This abundant interstitium usually creates
abnormally high pressure in the interstitial matrix and retards the passage of large
molecules from the blood vessels into the tumor.
The stroma and inflammatory cells in the tumor collaborate directly and
indirectly with malignant cells to produce promotors and/or inhibitors of fibrogenesis,
angiogenesis, and matrix-degrading enzymes (43 ). The balanced content of all these
facets will dictate the outcome of the malignant tumor.

Angiogenesis
Angiogenesis is defined as the formation of new blood vessels from existing
microvessels and the replication ofthe capillary endothelial cells (45,46). In contrast,
the development of new vessels from blood islands in early embryogenesis is termed
vasculogenesis. Vasculogenesis, although very similar to angiogenesis, does not
contribute to repair or disease in postembryonic life.
Angiogenesis is essential in reproduction, embryonic development, and wound
repair. Under these conditions, angiogenesis is highly regulated, turned on for brief
periods and then completely inhibited (4 7). There are two forms of angiogenesis:
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physiological and pathological. The pathological angiogenesis differs from the
transient and tightly controlled physiological form that occurs in an adult, by the
persistent proliferation of endothelial cells, and is a prominent feature of disease such
as proliferative retinopathy, rheumatoid arthritis, and psoriasi s. In addition , most
tumors are able to stimulate blood vessel growth from neighboring capillaries into the
tumor (48).
Angiogenesis is a complex, multistep process which can be initiated and
terminated by a large number of cell types. Numerous growth factors are involved in
intercellular communications. These are produced by some cell types and act on
endothelial cells and pericytes, which make up the capillaries. These two cell types
carry all the genetic information to form tubes, branches, and whole capillary networks
(47). The endothelial cells are the primary cells involved in angiogenesis. They
compose the lining of the lumen of all blood vessels and comprise the entirety of the
capillaries (49). Pericytes, which resemble smooth muscle cells, closely envelop
endothelial cells and are added in the latter stages of new vessel growth (45). They may
be important in inhibition of angiogenesis. Pericytes cultured with endothelial cells
produced TGF-(3 which can inhibit endothelial proliferation. Also, pericytes do not
reappear unti I mature capi I! aries are developed (47).
Endothelial ce ll s are quiescent when in a contact- inhibited state. This occurs
within existing vesse ls havi ng <0.01 % of the cells in cell cycle (49,50). When the
endothelial cells become stimulated, they can be one of the most rapidl y proliferating
cell types. The doubling time of capillary endothelium in normal tissues range from 47
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to 20,000 days, as opposed to 2. 14 to 13 days for capillary endothelium in tumors (5 1).
The endothe lium with in cancerous growths has been shown to have a mitotic index 50fold greater than that in nonmalignant tissues (52).
Once e ndothelial capillary cell s are stimulated, there is a complex process
which occurs to produce a capillary sprout. Vasodilation of the parent venule is an
early event in angiogenesis that occurs before the emergence of the first capi ll ary
sprout. This may stretch endothelial cells so that they become responsive to growth
factors (47). One of the main functions of this vasodil ation is to allow the clotti ng
protein, fibrinogen , into the extracellular spaces. Tumor cells show five times more
rapid permeability of plasma proteins than normal tissues (53). This fibrinogen leaks
from tumor blood vessels and is rapidly clotted and transglutaminated to crosslinked
fibrin. The fibrin is transformed over time into the perivascular, collegenous matrix
that constitutes mature tumor stroma (53).
The next process of angiogenesis that occurs is call ed "establishment of
vascu lar di scontinuity" (49) or the disruption of the basement membrane which holds
the capi ll ary cells together. The proteolytic enzymes which cause thi s breakdown are
the same type released by an invasive neopl asm. The enzymes are also released by
macrophages, damaged cells, and endotheli al cell s. Most are metalloproteinases and
plasminogen activators, which break down the col lagen that provide the structural
framework of the base ment membranes (39). Local cell death leads to the release of
lysosomal enzymes, which increases basement membrane permeability or destroys
basemen t membrane continuity, thereby mediating vasc ul ar di scontinuity (49). Thi s
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can occur from tumor cell necrosis, injury, hypoxia, or almost any other condition that
leads to angiogenesis.
The next major step in angiogenesis is the endothelial cell migration. This
migration is dependent on growth factor concentration gradients. The endothelial cells
move directionally toward an external source of migration inducing chemicals (49).
Cell-matrix adhesion may act as a deterrent to cell movement. This deterrent and the
concentration gradient of the chemoattractants may act to guide the cell mi gration in
the correct direction. During angiogenesis, the endothelial cells change their
morphology from tubular (as in established capillary) to flat and elongated (during
migration) and then back to tubular (47). The cell migration is supported by cell
proliferation. Not only do the endothelial cells become motile, but they are also pushed
by new cells. These cells are needed to form the new vessel.
Endothe li al cells grown in vitro, in the absence of angiogenic growth factors,
will begin to proliferate and go through several generations before they start to migrate.
But, when they encounte r a growth factor concentration gradient in vivo the migration
and proliferation occurs together (54). Endothelial cells in vivo migrate as wellorganized, tube-like sprouts, whereas large vessel endothelial cells migrate as a
coherent sheet with a we ll -defined leadi ng edge (45 ,50). All of the steps of
angiogenesis occur simultaneously at different sites of the proliferating vesse ls.
The last major step in a ngiogenesis is the three-d imensional structuring of the
cel ls into a tubule (49). There are two essential properties of endotheli al cells that
result in the formation of vessels. First, e ndothelial cells, even singly, have intrinsic
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polarity that is manifested by forming a closed loop. Secondly, endothelial cells have
the abili ty to form tight junctions with other endothelial cells, thus extending this loop
to generate a multicellular array that leads to tube formation. After the endothelial cells
have fonned a new capi ll ary tube, pericytes and new extracellular matrix forrn around
the capillary (45). If the growth factor stimulation is removed, the endothelial cells
become quiescent and are inhibited by contact with other endothelial cells.
Pathological angiogenesis is a major factor in many diseases. These diseases are
driven by persistent unregulated angiogenesis (5 1). This pathological angiogenesis is
characterized by persistent proliferation of endothelial cells, and is a prominent feature
of di seases such as prol iferative retinopathy, rheumatoid arthritis, psoriasis ( 48,55},
angiofibroma, arteriovenous malformation, atherosclerotic plaques, corneal graft
neovascularization, delayed wound healing, hemangioma, hemophilic joints,
hypertrophic scars, neovascular glaucoma., nonunion fractures, Osier-Weber Syndrome,
pyogenic granu loma, retrolental fibroplasia, scleroderma, trachoma, and vascul ar
adhesions (5 1). In addition, many tumors are able to attract blood vessels from
neighbori ng tissues (48).
Tumor-associated neovascularization is a prerequisite of rapi d tumor growth
and metastasis. Tumors do not grow beyond a few c ubic millim eters unless a
continuous blood supply is developed (45 ,47). As the tumor grows, it must continuall y
stimulate growth of new capillaries into the tumor. Unless the cancer cell s grow freely
and independentl y, the neoplasms are small enough, or the layer of growing cell s is thin
enough for their nutritional requirements to be met by diffusion, then these cell s a re

21
dependent on angiogenesis to provide a blood supplv (54). Slender intraepithelial
melanomas, dormant tumors, or carcinomas in situ are usually avascular. These
avascular neoplasms can be maintained for years in humans in an extemely slow
growi ng state, where cell death is about equal to cell proliferation (56). When a
sufficient number of cells switches to angiogenesis phenotype, neovascularization can
occur, and then the neoplasm can begin rapid growth (47).
Rapidly growing solid tumors show a clustering of vessels surrounding them.
T hese vessels are distinctive in that they are thin-walled and hi ghly permeable, follow
an irregular course without progressive diminution in caliber, and are prone to collapse
(54,57). These observations can be used to assist grading the mali gnancy (54,57-59).
Angiogenesis occurs early in tumor development and usually before a tumor can
be detected clinically. Once a tumor has become angiogenic, it has not only developed
a microenvironme nt which will support rapid cell proliferation, but a lso a less
formidable barrier to the escape of the tumor ce ll s. due to the fragi le and
hyperpermeable newly formed vesse ls (29). In addition, metastatic cells are more able
to initiate angiogenesis when they escape to a distiTK:t site.
T he switch to the angiogenic phenotype is a complex process (47). It was once
thought that angiogenesis cou ld be explained simp!\ by tumor cells releasing
angiogeni c growth factors . Th is idea was found
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simplistic. T umor cell s do release

angiogeni c growth facto rs, but it is unclea r how th i; release differs between
preangiogenic and angiogen ic tumor cells. In addinon, some angiogenic growth
factors, such as basic fibroblast growth factor (bFG:' '· lack a signal peptide, and the
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mechanism of export of the growth factor from the cell is unknown. Furthermore,
angiogenic activity is thought to be under control of tumor suppressor genes (54).
Normal cell s continually secrete proteins that are angiogenic suppressors but these are
down-regulated during tumorigenesi s. Stromal and nonnal surrounding cells may
produce factors that either induce or inhibit angiogenesis. The onset of angiogenic
activity is detenni ned by the balance of these factors (47,60). The rari ty of
inappropriate neovascularization suggests that the process is carefully and probably
redundantl y controlled.
What triggers a cluster of neoplastic cells to become angiogenic is not full y
understood . In some cases, the angiogenic phenotype has been seen in preneoplastic
lesions from rodent and human tissues (54). An active oncogene can make a cell
angiogenic. Experiments with a reconstituted murine prostate gland have shown that
expression of an activated ras oncogene induces dysplasia that is accompanied by a I 0fold increase in the number of new blood vessels in the tumor (34). This may be due to
the ras-induced synthesis of growth factor. Additiona ll y, due to the genetic instabi lity
of neopl astic ce ll s, it may be possible to accumulate genetic changes that activate
oncogenes and inactivate tumor suppression genes. It seems reasonabl e to suggest that,
in the case of ce ll s developing into solid tumors, one important result of these genetic
changes must be th e a lteration of the mi xture of mo lecul es produced by the cell s in
such a way as to result in the stimul ation of in vivo neovasculari zation (54). This has
been demonstrated repeatedl y in vitro. For exampl e, when the genes tor fibrob last
growth factors 1 or 4 have been transfected into MCF-7 breast carcinoma cells, they
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change from estrogen-dependent, poorly tumorigenic, poorly metastatic tumors into
aggressively tumorigenic, estrogen-resistant, and frequently metastatic tumors when
transplanted into mice (61 ). At least part of the phenotypic transition produced by
fibroblast t,>rowth factor transfection was due to increased angiogenesis . In addition,
when baby hamster kidney cells were transformed by polyomavirus, they became
tumori genic and also produced less of the gpl40 protein, an inhibitor of angiogenesis
(54).

Hypoxia
Hypoxia is a powerful inducer of angiogenesis and is thought to be the most
important inducer during wound healing (47). As a tumor grows beyond a few cubic
millimeters, it is unabl e to meet its oxygen and nutritional demands by diffus ion. The
resultant oxygen and nutritional deprivation induces extensive necrosis (62,63 ).
Multicellular spheroids have been used to demonstrate the triggering action of hypoxia
on a tumor' s angiogenic activity (64). T hese spheroids are three-dimensional aggregates
that are formed by culturing anchorage-dependent ce ll s on surfaces that do not support
cell adhesion. As the cell s proliferate, they aggregate into almost perfect spherical
masses. As they grow, diffusion of nutri ents, oxygen, and growth factors is restricted
from the center of the spheroid and necrosis appears. Diffusion is inadequate at
diameters greater tha n 300 fiM and a s ignificant fractio n of the cell s located in the inner
core cease to prolife rate. When these sphero ids are implanted in nude mice, they induce
growth of vessels that approach the spheroid radiall y. Growth o f the spheroid is
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delayed until a vascular bed is established. Vascular endothelial growth factor (VEGF)
express ion was markedly increased in the inner layers of the spheroid. If the spheroids
are incubated in hyperoxygenated medium, then VEGF expression is downregulated.
This shows that hypoxia plays an important role in VEGF expression.
Angiogenesis of wound healing may be less complex than tumor-associated
angiogenesis. Macrophages are the major source of angiogenic factors in a healing
wound (65). Macrophage-associated angiogenic activity is upregulated in the depths of
a wound when oxygen tension is low and lactate from anaerobic metabolism is high .
The hypoxic center of a tumor also recruits macrophages which produce angiogenic
growth factors (47). The concept of a tumor as a nonhealing wound is based in part on
this observation (53). Macrophages migrate to the necrotic centers of a tumor by
chemotacticall y followi ng a gradient of substances released by stressed cell s such as
lactate and/or angiogenic growth factors released by the tumor cells (66). Since
macrophage infiltration is so important to tumor progression and vascularization, it also
can be used as a tool to determine the prognosis of a tumor or as a target of
immunoinhibitory therapy. Macrophages also may release heparin , which can ampli fY
the effect of the growth factors (47). Hypoxia-induced endothelial cells produce
angioge ni c growth factors (50). Endotheli al cells produce basic fibrobl ast growth
factor (bFGF), whic h is deposited in the extracellular matri x or bound to the cell
mem brane. It is the n released by plasmin, hepa rinase, or typsin . Tumor cell s,
macrophages, e ndothelial cells, and many supporti ve cells have been shown to produce
both angiogenic and antiangiogenic growt h facto rs (45,47,48,54,65,67).
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Growth Factors for Endothelial Cells
There were two important developments in the late 1970s and early 1980s
which helped in the understanding of tumor-endothel ial cell communication. First was
development of methods to culture capillary endothelial cells (68). Aortic endothelium
had been cultured previously, but grew in sheets and did not form tubules. This was
very important to the study of angiogenesis because tumor-associated angiogenesis
takes place at capillary endothelium, not aortic endotheli um . Capillary endothelial
cells provided a quick and inexpensive test for the angiogenic activity of growth
factors. The second development that aided the understanding of tumor-associated
angiogenesis was the finding that growth factors derived from tumors have a strong
affinity for hepari n (69). This enabled these growth factors to be purified from tumor
ce ll culture media or from the extracellular matrix of tumors. These growth factors
were first named heparin-binding growth factors (70). They were angiogenic and
heparin enhanced their angiogenesis in vivo, although heparin by itse lf has not been
proven to be angiogenic.

Fibroblast Growth Factors
Two of the first growth factors isolated by the use of hepari n and shown to be
angiogenic were basic and acidic fibrobl ast growth factors (7 1). The two forms of
fibroblast growth factor share approximatel y 55% amino acid sequence identi ty (72).
The ac idi c fonn is found most ly in neural tissue with lesse r amounts in the kidneys,
smoot h musc les. and fibroblasts. The basic fonn is found in most normal ti ssues,
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includin g endothelial cells, and tumors. Fibroblast growth factors lack a signal peptide
required for transport out of the cell , which suggests that they may act either
intracellularly or after cell death (67). Fibroblast growth factors may be released from
the dead cells upon their degradation or mobilized by heparin (45 ,50). Fibroblast
growth factors are polytropic and stimulate the growth of endothelial cells, smooth
musclt:: cell s, fibroblasts, and certain epithelial cells (47). bFGF produced by
endothelial cells remains cell-associated. It also can stimul ate the growth of
e ndothelial cell s (50). The study of fibroblast growth factors has been important in the
understanding of angiogenesis. However, since these growth factors do not possess a
signal sequence for secretion, they are not generally released into culture medium and
therefore are not suited to use in investigating tumor-conditioned media.
There are numerous other growth factors that are angiogenic. These include
angiogenin, angiotropin, erythropoietin, hepatocyte growth factor (scatter factor),
insulin-like growth factor, inte rleukin-8 (45), midkine (73), platel et-acti vatin g factor ,
platelet-derived endotheli al cell growth factor, platelet-derived growth factor-BB ,
prolife rin , transform ing growth factors a. and (3 , tumor necrosis factor-a, and vascular
endothe li al gro"1h factor (also called vascular permeability factor) (45). Each of these
mol ecu les and manv more contribut e to angiogenes is at some time. Di ffere nt on es are
known to be expressed onl y during wound hea ling, during embryogenesis. or during
menstruation .
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Vascular Endothelial Growth Factors
In 1983, VEGF was first described as vascular permeability factor, a protein
with the ability to induce vascular leakage and protein extravasation (74). VEGF was
not recogni zed as an endothelial growth factor until 1989 when it was separated from
conditioned medium of the AT-20 pituitary cell line (75). VEGF was then partially
protein sequenced and was named vasculotropin. In 1990, the eDNA and amino acid
sequence for VEGF was determined from rat GS-96 glioma cell s (76). Later in 1991 ,
Ferrara was able to locate the gene for human VEGF and determine the protein
structure of multiple isoforms (74 ). At this time, Ferrara determined that the original
vascular permeability factor, vasculotropin, was the 189 ami no acid isoform ofVEGF.
VEGF was shown to be a basic, heparin-binding, homodimeric glycoprotein of 45 ,000
Daltons. VEGF exists in four different molecul ar species, having 12 1, 165, 189, and
206 amino acids, respectively (VEGF 121 , VEGF 165 , VEGF 189, VEGF206) (77).
VEGF 121 and VEGF 165 are readily secreted into culture medium . VEGF 189 and
VEGF2116 are secreted but are bound to extracellular heparin-containing proteoglycose
(77). VEGF 165 is the predominant isoform secreted by a variety of normal and
transformed cells, whereas VEGF,(!(, is a rare fonn , so far identified only in a hum an
fetal li ver eDNA library (55). The VEGF gene is organi zed in eight exons and the size
of its coding region has been estimated to be - 14 kb. The various isoform s a re
generated by a lt ernati ve splic ing of RNA , rather than transcription of separate genes.
The VEG F proteins may be made available to endothelial cells by at least two
different mechani sms, as free ly soluble proteins (VEG F

121

and VEGF 165) or followin g
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plasminogen activation and cleavage of the longer isoforms (VEGF 1s9 and VEGF,06)
(55). VEGF 189 was shown to be released from Chinese hamster ovary ce lls and cleaved
to a mature homodimer by serine proteases, urokinase, or plasmin (78). VEGF is
specifically targeted to endothelial cells (79) and evidence is mounting that VEGF may
be the primary regulator of normal and pathological angiogenesis (80). VEGF is
abundant during embryonic development and associated closely with rapidly
developing capillaries (79,81 ). During the entire menstrual cycle, mRNAs for VEGF
can be detected in human endometrium and myometrium (82). It was, therefore, not
unexpected to find VEGF mRNA in the epithelial cell s of an endometrial
adenocarcinoma (83). In addition, VEGF is expressed in numerous malignant brain
tumors. It was secreted by nine human malignant glioma cell lines (84), and several rat
glioma cell lines (85). In vivo, VEGF is expressed in human neural glioblastomas,
astrocytomas, (86) capillary hemangioblastomas, and other neoplasias (5 7). The VEGF
receptor was not seen in normal brain endothelium, but was upregul ated in tumor cell s
in vivo (86). Numerous other neoplasias have shown VEGF expression, such as
Kaposi's sarcomas (87), co lon carcinomas (88 ,89), renal cell carcinomas (90,9 1),
bladder carcinomas (9 1), chronic lymphocytic leukemias (92), and in tumor-infiltrating
lymphocytes (identifi ed as C D 3 ' peripheral blood T lymphocytes) (93) . VEGF was
ex pressed in bot h iso lated osteoblasts and homogenized bone ti ssues (94 ).
VEGF prote ins acc umulate in tumor blood vesse ls, but the mRNAs re main in

the adjace nt tum or cell s (95). The normal blood vessels in the same experimental
an im als showed no VEGF proteins in or near them . In contrast, basic fibroblast growth
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factor protein is usually found in the vascular basement membranes of normal tissues.
One of VEGF' s functions is to increase vascular permeability (64,96). This
function is thought to enable plasma fibrinogen to extravasate into the extravascular
space of the tumor and provide fibrin . Fibrin is important to normal wound healing and
is a major component of tumor stoma (53). VEGF increases, in a dose-dependent
manner, plasminogen activators, which are key mediators in the extracellular
proteolysis (96). This leads to the degradation of the basement membranes of the
parent vessel and aids in migration of endothelial cells. VEGF also may aid in
endothelial cell migration by affecting the actin filaments of the cytoskeleton, therefore
affecting cell s hape which leads to the loss of cell-cell and cell-substrate contract (97).
The production of VEGF and the switch of a tumor cell to become an1,>iogenic is
a complex process, which is still not fully understood. The two main factors in the upregulation of VEG F expression are cell-density and hypoxia. Using colon carc inoma
cells in vitro. the expression of steady-state VEGF mRNA increases with ce ll density
(88). T he most important factor in induc ing VEGF expression is hypoxia (62,63,98105). T hi s may be true in wound healing and tumor-associated angiogenesis. In wound
hea ling it is thought that macrophages are the main source of VEGF (65).
VEGI' m RNA express ion is dramatically increased within a few hours o f
contin uous exposure of cel l cultures to hypoxia, and they return to nonnal expression
when the oxygen supply is resumed (62). Thi s indicates that oxygen tension, itse lf: can
trigge r VEGF production. VEGF was induced by hypoxia in the heart (98). T he heart
has very littl e anaerobic capacity, indicating that lactate or other anaerobic metabo lic
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products might trigger VEGF expression. It has been proposed that VEGF expression is
controll ed by a n oxygen-sensi ng mechanism similar to the one used by the
erythropoietin gene (102). The VEGF gene has two regulatory elements, one of which
is related to the erythropoietin enhancer. VEGF and erythropoietin genes were
stimu lated by coba lt, suggesting that the mechanisms of oxygen sensing are probably
mediated by a similar heme-containing protein (99). The action of hypoxia was
mimicked by addition of cobalt, nickel , or manganese, which replaces iron in the heme
molecule and triggers the production ofVEGF in cardiac cells (106). Adenosine
induced VEGF production in a glioma cell line, which suggests that oxygen deprivation
or cellular ATP depletion was involved, since these conditions trigger adenosine release
in the cell (100). When cells were hypoxic, the half-life of the VEGF mRNA was
increased from 30-45 min to 6-8 h (63). Stabilization ofmRNA and also de novo gene
expression are the primary mechanisms responsible for the elevated mRNA of VEGF in
hypoxic cells (64).

Midkine
Midkine is another growth factor that may be important in tumor-associated
angiogenesis and retinoic acid treatment. Midkine was first described in 1988 and at
that time was named MK I ( I07). Thi s growth facto r was discovered when researchers
were investigating the retinoic acid-induced difTerentiation of HM-1 e mbryonal
carcinoma cel ls. These are stem ce ll s of teratocarcinoma and when treated with
retinoic acid, they are induced to differentiate. When eDNA was generated from these
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cell s, after a 24 h treatment with I

fiM

ofretinoic acid, it was found that one clone, MK-

1, had signi ficantl y increased RNA expression. A one kb poly (Ar RNA was detected
and was shown to be abundant in mid gestation (day 8 to day II ) of a mouse embryo.
Later the protein from the MK-1 clone was secreted by the HM-1 cells and has heparin
binding activity ( I 08). The new growth factor was later called midkine because it is
expressed in mid gestation and in the kidney (73). It was able to promote ne urona l
extension, as well as form networks and fasciculations of neurons ( I 09). Mid kine is
devoid of a signal sequence, has a molecular weight of 140,000, and is unusuall y rich in
cysteine and basic amino acids (107). The lack of a signal sequence is unusual, because
conditioned med ia produced from cells transfected with the midkine gene promoted the
growth of PC-12 Pheochromocytoma cells ( I08). The midkine genes from human and
mouse were compared and had an 87% homol ogy, which indicates a si milar and
important physiological function ( 110).
Midkine was intensely expressed in surgicall y removed Wilms' tumor
speci mens ( II I). Wilms' tumor is a kidney carci noma of embryonic origi n. When
antimidkine antibodies were added to cultures ofWilm ' s tumor ce ll s for 2 days, there
was a significa nt growth inhibition. Also, a large number of mouse and human ce ll
lines have shown moderate to intense expression of midkine. Midkine was fo und in
colorecta l and panc reati c adenocarcinomas, as well as hepatocellul ar, lung, gastric, and
esophagea l ca rc inomas. The on ly normal ti ssues to sign ifi cantly express midkine were
thyroid and sma ll intestines, with no midkine detected in li ver ( 11 2).
Midkine was first tested for angiogeni c acti vity because a 50% seq ue nce
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identity of amino acids was found when compared to pleiotrophin ( 113 ). These two
proteins have very similar functions and pleiotrophin has angiogenic activity. Later it
was reported that midkine was a mitogen for endothelial cells and that it had stimulated
angiogenesis in a number of in vitro and in vivo assays ( 114). Midkine has been found
with the development of bladder cancer. In addition, it was 4-fold higher in tumors
than in normal bladder and was higher in invasive than noninvasive tumors.
When F9 embryonal carcinoma cells and NTH 3T3 mouse fibroblasts were
treated with a synthetic retinoic acid, E5 166, the expression ofmidkine mRNA was
strongly enhanced ( 115). Midkine was expressed in the mandibular arch mesenchyme
of teeth when stimulated by local application ofretinoic acid (116). Therefore,
midkine is inducted by retinoic acids, as well as being produced by a large number of
tumors and is mitogenic to endothelial cell s. Induction of midkine was tested at only
two doses, I and I 0 J-IM, of retinoic acid and only in embryonal cell lines. No doseresponse or treatment of adult tumors has been conducted.

lntcrlcukin-8

lnterleukin-8 (fL-8), also called neutrophil activating peptide- I, is a 8.4
kilodalton protein and belongs to the chemokine famil y ( 117). Normal cells that
produce IL-8 include monocytes/macrophages, fibrobla st, endothelial cell s, synovial
cells, keratinocytes, epithelial cells ( 117), neutrophil s, mesangial cells, and he patocytes
( 118 ) IL-8 was thought to be exc lusive ly a chemotacti c/acti vating factor for
neutrophils during acute inflammation, but recently it has become apparent that IL-8 is

I·
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important in angiogenesis associated with tumorigenesis. IL-8 is produced by various
tumor cells, such as gastric cancer and neuroblastoma cells ( 117).
IL-8 production under normal conditions is not constitutive, but is primarily
induced by infl ammatory mediators such as tumor necrosis factor-a or interleukin-1
(1 18). When tL-8 production is seen in tumor cells, its production is constitutive and it
is produced at significantly higher concentrations than in normal tissues.
Using a neuroblastoma cell line, it was shown that all-trans-retinoic acid
induced IL-8 mRNA expression in a time- and dose-dependent fashion ( 11 9). In
addition, when a human epithelial ovarian cancer cell line was treated with all-transretinoic acid , IL-8 protein release was enhanced ( 117). This increase in JL-8 was not
seen below the I JlM dose.
Recombinant IL-8 increased both endothelial ce ll chemotactic and proliferative
activities, both in vitro and in vivo (118). The activity oflL-8 was si milar to basic
fibroblast growth factor, which also is produced by macrophages. IL-8 was found in
synovi a l nuids from rheumatoid arthritis patients. Thus, IL-8 may be a factor in the
pathological angiogenesis associated with this disease.
When IL-8 was administered at doses of25 pM, 250 pM, and 2,500 pM to rats
using a mesente ric-window angiogenesis assay, at 2,500 pM. the IL-8 produced de novo
angiogenesis in normally vascularized mammalian ti ss ue ( 120). IL-8 acted as a
promoter of huma n nonsmall cel l lung carcinoma growth ( 121 ). Neutralizing
antibod ies to IL- 8 reduced tumor size by greater than 40% and was assoc iated with a
dec lin e in tumor-assoc iated vascular density and angiogenic activity. IL-8 was not an

34
autocrine growth factor in nonsmall cell lung carcinoma. When several cell lines were
grown in the presence of recombinant LL-8 or neutralizing antibodies to IL-8, neither
addition altered cell proliferation.

Antiangiogenic Growth Factors
In the early 1970's an important concept about the control of tumor growth was
developed by Folkman (47). This concept stated that si nce tumors require blood
vessels in order to grow, inhibition of blood vessel development would provide a
strategy for preventing both the growth of primary tumors and the inhibition of
metastases. In addition, complete inhibition of angiogenesis should be well tolerated in
most adults because under normal conditions angiogenesis is required only for wound
healing and reproduction ( 122).
The present concept in tumor-associated angiogenesis is that tumor cells
produce factors which either induce or inhibit angiogenesis and that the onset of
angiogenic activity is determined by the balance of these factors (47). This is supported
by the evidence that tumor ce ll s simultaneously secrete proteases and their inhibitors,
as well as both angiogenic growth factors and antiangiogenic growth factors (60, 123 ).
When production of one angiogenic growth factor is changed, the angiogenic effects of
the tumor a re altered . By using antisense VEGF RNA , it was demonstrated that the
VEGF secreti on of the U87 MG, human gliob lastoma cell line was reduced, bot h in v1vo
and in vitro ( 124 ). This caused a marked decrease in their tumori geni c a nd angiogeni c
behaviors. In addition, angiogenesis by psoriatic keratinocytes is mediated by
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upregulation of IL-8 and downregulation of the angiogenic inhibitor thrombospondin
(60). Individual tumor cells reduce production ofthrombospondin to only 4-6% of that
produced by their normal precursor cells (125). Not only does the production of the
angiogenic growth factors vary as the tumor develops, but the clearance time for the
inhibitors and stimulators is also different. These growth factors move into the
surrounding ti ssues and into the circulatory system by diffusion. VEGF is cleared in
approximately 3 min and bFGF in about 30 min, but angiostatin, an angiogenesis
inhibitor, needs 5 days ( 123). This allows some inhibitors to accumulate in the body
and limits the effect of the stimulators to those cells very close to their production site.

Thrombospondin
Thrombospondin (TSP) is a high-molecular-weight, multifunctional
glycoprotein (126). lt was first described as a product of platelets, released from alpha
granules in response to activation by thrombin. TSP is found in tissues during
development and wound healing, and in malignant tumors ( 127). Most of the TSP is
not free in the circulation but is bound to extracellular matrix such as the basement
membrane of the vessel walls ( 128). Evidence exists to show that TSP acts as an
adhesive protein in a number of cell-cell and cell-substratum interactions ( 128). TSP
can interact with different macromolecul es, inc luding several components of the
extracellular matri x and with spec ific receptors on the cell surface. These inte ractions
have been reported to induce attachment , spreading, motility, and growth of several cell
types ( 126 ).
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TSP appears to play a role in tissue neoformation, healing, remodeling,
angiogenesis, and several pathologies ( 126). For example, it is synthesized by some
tumor cells, and concentrations in the tumor masses are higher than in normal tissues.
TSP concentrations are high at vascular and ti ssue injury sites. As with other
angiogenic proteins, TSP in the extracellular matrix is removable by heparitinase or
heparin-like molecules. In vitro production ofTSP depends on cell cycle, degree of
connuency, and level of differentiation. TSP acts as an autocrine growth regulatory
factor for smooth muscles cells.
TSP has been shown to be produced in vitro by a variety of cell types, including
fibroblasts, smooth muscle cells, pneumocytes, macrophages, keratinocytes, monocytes,
osteoblasts ( 126), and endothelial cells ( 128). In vivo TSP has been found in plasma,
on the surface of activated platelets, in endothelial cell cytoplasm, basement
membranes, and vessel walls ( 126).
TSP is produced by tumor cells ( 126, 128, 129). However, the expression of both
the mRN A and the protein was lost in Chinese hamster embryo cells after being
transformed by nickel compounds ( 130). Fibroblast cells that had lost the expression of
both p5 3 alleles, a tumor suppressor gene, had a reduction in the expression of the
thrombospondin-1 gene ( 131 ). Thrombospondin-1 was the first identi lied member of
the thrombospondin gene family ( 132).

In vitro, TSP inhibited the proliferation of endothe lial cells from rabbit corpus
luteum , bovine adrenal cortex, pulmonary artery, and human umbilical vein ( 127).
Endothelial cells induced to proliferate after treatment with bFGF were not ab le to grow
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when TSP was added to the medium ( 129).
Endothe lia l cells not only secrete TSP, but also possess cell surface receptors
for TSP ( 127). TSP is produced at higher concentrations by cultures of subconfluent
endothe lial cells and decreases significantly when these cells begin to form cords ( 133).
T he ability of TS P to be anti angiogenic is still being argued. TSP proteins are
absent from a reas where new vessels are forming in mouse embryos and in new wounds
( 134 ). It is present adjacent to vessels in wounds later, where neovascularization is
ending. Mouse and human macrophages produce TSP when resting, responsive, or
primed but stop producing it upon final activation . Endothelial cells appear to stop
producing TSP when cultured on collagen gels permissive to in vitr o angiogenesis.
TSP has one more antiangiogenic property worth noting, TSP may block endothelial
cell mi gration by altering contacts between endothelial cells and appropriate matrix
components.
TS P has been shown to be induced or inhibited by retinoi c acids, depending on
the cell type. Varani et al. published a series of papers in which they reported that alltrans-retinoic acid affected the production ofTSP ( 135). In human epidermal
keratinocytes, retinoic acid inhibited TSP production by more than 90%. Human
dennal fibroblasts increased TSP production wi th all-trans-retinoic acid treatment
( 136), but in human squamous epithelial cells TSP production was inhibited when
treated with all-tra n.1·-ret inoic acid above 0. 1 uglml ( 137). Simil ar affects on TSP
production also were reported by other researchers ( 138, 139). Thrombospondin-1 was
re ported to be rapidl y inducted by all -trans-retinoic acid in a ne uroblastoma cell line,
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and al so in a nontumorigenic epithelial cell line derived from rat dorsal-lateral prostate.
All of these pape rs that re ported TSP effects from retinoic acid treatments investigated
TSP as a cellular matri x component, as well as a factor that affects cell adhesion .

Leukemia lnhibitor·y Factor
There are certain honnones or growth fac tors that exert a broad range of effects.
One such protein is leukemia inhibitory factor (LIF) ( 140, 141 ). LIF was initially
described, purifi ed, and geneticall y cloned on the basis of its abili ty to induce the
differentiation and suppress the clonogenecity of the monocytic leukemia cell line, M I
( 141 ). LLF has several biologica l properties which resemble interleukin-1 , interleukin6, and tumor necrosis factor-a . LI F stimulates acute phase protein synthes is in
hepatocytes, induces bone reabsorption in

Vitro,

affects early embryogenesis, stimul ates

megakaryocyte production, acts as a trophic factor for cu ltured rodent neurons, inhibits
protein lipase acti vity in adipocytes, may induce cachexia in cancer pati ents, is essenti al
for blastocyst implantation, and suppresses embryoni c stern cell differentiation ( 142).
LIF' s e ffects on olid tumors are genera ll y unknown. T he human breast carc inoma cell
line MCF-7 is stimul ated to grow by LIF ( 143, 144 ). In comparison , cell proliferation
was suppressed in the HL-60 , prornyeloc:y1 ic leu kemi a ce ll line, and U-937, histiocyt ic
lymphoma ce ll li ne ( 140). In contrast, when LIF was added to cultures of A-498
primary kidney ce ll line a nd DU- 145 prostate cance r ce ll line, it did not affect th e
growth of the ce lls, but antibodi es to LIF signifi cantly suppressed their prolife ration .
T his suggests th at these cell lines were maximally stimulated by endogenous ly
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produced LI F ( 144 ). Therefore, LI F could act as both an endocrine and paracrine
growth factor.
LI F is expressed in both human and rodent immortalized or ma lignant ce ll lines
( 145). L! F mRNA was detected in 24 human carcinoma ce ll lines, including lung,
breast, stomach, colon, liver, gallbl adder, pancreas, and melanocyte ( 146). LI F was not
detected in un stimulated rodent osteoblast-like cell lines, MC 3T3-E l a nd Py l a ( 145).
However, it was detected when these cell lines were treated with li popolysaccharides,
transforming growth factor [3 , tumor necrosis factor-a., or inhibitors of prote in synthesis
(cyclohexinde, emeti re, puromycin, and anisomyin). It was reported that another
osteobl ast ce ll line, UMR 20 I, which was derived from newborn rat calvaria and
showed properties of an osteoblast precursor, was abl e to produce only LIF when
treated with retino ic ac id and tumor necrosis factor a (147). Not all cell lines are
induced by these treatments to produce LIF.
A relati onship between the amount of soluble LIF produced by a tumor cl one in
vivo, and the tumorige necity of the clone has been reported ( 148). The cell lines used

in thi s research were not affected by LI F as an autocrine growth factor; there fore, it was
concluded that LIF facilitated in vivo tumor growth by some other mechanism. U F
inhib ited angiogenesis in vitro ( 149). When both bovine aorti c and microvascula r
e ndothe lia l ce ll s were sti mul ated with the addition of e ither bFGF or VEG F in the
cu lture media, treatment with LI F decreased both endothe lia l ce ll proliferati on and
migrati on. T his treatment wit h LI F a lso decreased the proteol ytic activity of the
e ndothe lial cell s a nd increased the ir expression of pl asminogen activator inhi bitor- !.
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An increase in the expression of plasminogen activator inhibitor also would be
antiangiogenic.
UF has been reported to have similar nonangiogenic actions to midkine. This
may be due to the sequence similarities between midkine and LIF. However, the effects
ofLlF differ from midkine with respect to endothelial effects. Also, LIF production
was shown not to be induced by retinoic acid ( 150).

Heparin
Heparin is an important chemical in the function of endothelial cells and growth
factors. Due to the ability of many of the angiogenic growth factors to bind heparin, it
was possible to purity several growth factors from media used to culture tumor cells.
Heparin enhanced angiogenesis in the CAM assay of the chick embryo (151 ).
But, when heparin or heparin fragments were used to treat cells with cortisone or
steroids without glucocorticoid or mineralocorticoid activity, then the angiogenesis was
inhibited ( 15 1-153). Further studies in this area showed that a nonanticoagulating
derivative of heparin, heparin adipic hydrazide, could be chemically linked to cortisol
at 10 fiM. This combination suppressed the DNA synthesis of murine pulmonary
capillary endothelial cells.
Endoth elia l cells can bind and internalize heparin, inhibiting DNA synthesis and
reducing actual cell growth in a dose-dependent manner ( 154). When serum heparin
concentrations in these c ultures were increased to I 0%, the growth inhibition was
abolished. It is thought that the nonanticoagulant actions of heparin on endothelial
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cell s is due to interactions with fibrobl ast growth factors . Most FGF's are matrixassociated and act as an extracellular reservoi r, which may be released by the action of
heparin that is produced by mast cells ( 155) or by the addition of heparin. FGF- 1 can
increase endotheli al proliferation in vitro ( 156). This explains why heparin can
stimulant angiogenesis, but does not explain why hepari n alone inhibits proliferation of
fe tal bovine serum (FBS)-stimulated endothelial cells ( 157) or why increased levels of
serum blocked the hepari n inhibition ( 154). To add to the confusion, the heparindegrading e nzymes, heparinase I and Ifl, but not heparinase II, inhibit both
neovascularization in vivo and the proliferation ofbFGF stimulated capillary
endotheli al cell s in vitro ( 158).
Heparin and heparan-sulfate are hi ghly sul fated polysaccharides which exhibit a
hi gh degree of heterogeneity due to variations in size and in the amount of sui fat ion
( 159). Heparin and heparan-sulfate have been shown to affect the binding ofVEGF 165
to its receptors. This binding was inhibited by hepari n fragments of 16-18 sugar units,
whereas fragmen ts larger tha n 22 sugar units potentiated the binding. The more sulfur
units per molecule in the heparan-sulfate, the greater the binding. A simi lar experiment
using bFGF as an angiogenic st imulant and varied degrees of heparin sul fa tion
produced very simi la r results ( 160). Human aortic endothelial cells were grown in vitro
with VEGF on a fibrin glue ( 16 1). The addition of the heparin increased their growth .
These experiments showed that the variation in heparin was more important than the
angiogeni c growth facto r used to stimulate the endothel ial cell growth.
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Vitamin A and Retinoids Defined
Vitam in A is the generic term reserved to designate any compound possessing
the biological activity of retinol ( 162). The term retinoids includes both naturally
occurring form s o f vitamin A and the many synthetic analogs of retinol , with or without
bio logical activity. Vitamin A is used to refer to those substances which can restore
norma l growt h in e xperi mental animals mai ntained on a vitam in A de fi cient diet ( 163).
Retinol, a primary alcohol, is present in an esterified form in animal and saltwater fi sh
tissues, ma inl y in their livers (2). In most anima l ti ssues, all-trans-retinol is the
predominant retinoid. It is usually in the form of retinyl palmitate, but a lso as other
fa tty acid este rs, such as retinyl oleate and retinyl stearate ( 162).
Retino l and its derivatives are hydrophobic compounds that are highl y unstable
in the presence of oxygen or li ght. T hey can be fo und as a mi xture of dehydrated and
double-bonded products such as acids ( 162). T he acid products are retinoic acids that
natura lly occu r in cis or lrans configurations, as does retinol, around the doub le bonds
in the molecul es' side chain ( 163).
Retinoic acid shares some, but not all , of the actions of reti nol. Although
retinoic acid is ineffective in restorin g visua l or reproductive functi ons in ce rta in
species where retino l is effective, it is very potent in promoting growt h as we ll as
contro lling diOere ntiation and maintenance of epitheli a l ti ssues (2). Indeed , all -transretinoic acid (tretinoin) appears to be the active form of vi tamin A in all tissues except
the retina, and is I 0- to I00-fold more potent than retinol when tested in vitro.
Isomeri zation of this compound in the body yields 13-cis-retinoic acid (isotreti nion},
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which is nearly as potent as all-trans-retinoic acid in epithelial tissues. It may be as
much as 5-fold less potent in producing toxic symptoms of hypervitaminosis A (2).

Retinoic Acid Regulation
Retinoic acid acts on the cellular level by activating or stoppi ng gene
transcription ( 162). Ln 1987, a retinoic acid receptor (RARa), that belongs to the
fami ly of steroid/thyro id hormone receptors, was cloned independently by the groups of
Cham bon and Evans. This family of nuclear receptors consists of ligand-dependent
transcription factors that regulate gene expression by binding short DNA sequences
(hormone responsive elements or enhancers) in the vicinities of target genes ( 162, 164 ).
Subseq uentl y RARf3 and RARy receptors were cloned. Comparison of the amino acid
sequences of the three receptors shows that the interspecies conservation of each
member of the RAR subfamily is much higher than the conservation among the three
receptors within a given species, suggesting that RARa, RAR[3, and RARy each have
the ir own speci fic fu ncti on ( 162).
Another group of nucl ear reti noic acid receptors was identified as the retinoid X
receptors (RXR), which specifically bind and are act ivated by 9-cis-retinoic acid ( 165).
Three closel y related genes encoding the RXR types (a,f3,y) have been found .
Sequence comparisons reveal that the RXR types are conserved like the RARs,
suggesting that each RXR may perform specific fu nctions.
Due to the many retino ids, nuclear receptors, responsive e lements, and genes
contro ll ed by retinoids, a very complex pat1em of recogn ition and activation of genes is
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seen. The RARs and RXRs become involved in homo- and heterodimerization between
each other as well as with other members of the steroid/thyroid hormone receptor
family ( 163). Several hundred genes are induced or repressed by retinoids. This was
shown when retinol or retinoic acid were injected into vitamin A deficient rats and 15
min later the protein pattern was dramatically changed as indicated by two-dimensional
e lectrophoresis ( 162). Some older data also indicated that all effects ofretinoids are
not mediated via the nucleus, as retinoids effectively regulate several cell membrane
functions even in enucleated fibroblasts and erythrocytes.

The Effect of Retinoids on Cancer
T he rationa le for using retinoids in the treatment or prevention of cancer is
based partly on epidem iological studies that have shown food rich in vitamin A and
carotenoids may protect against some fonn s of cancer ( 162). Also, many reports of in

wtro and laboratory animals studies indicate that reti noids can interfere with
carcinogenesis. Experimentation was started in the 1920 ' s when a negative corre lation
between vitamin A intake and the incidence of malignant lesions in epithelial tissue
was noted. Thi s has been substantiated subsequently by numerous studies ( 163). The
a ntitumor activity of retinoids is exerted through inhibition of cell proliferation,
ind uction of ce ll differentiation, suppress ion of oncogene expression, inhibition of
angiogenes is (20), enhancement of host immune response ( 163, 166), enhancement of
ga p junct ional co mmun ication (6,7), and/or induction of apoptos is ( 167).
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Cell Differentiation and Retinoids
In the 1970' s, retinoids were shown to induce differentiation of several
transformed cell lines such as myelomonocytic leukemias, HL-60 and U-937,
neuroblastomas, LA-N-1 teratocarcinoma, and F9 embryonal carcinoma (20). Since
cancer is fundamentally a disorder of cell differentiation (1), and retinoids have long
been shown to be required for normal differentiation of epithelial tissues ( l63), it was
thought that treatment with retinoids could somehow reverse the undifferentiation of
neoplastic cells.
Cell differentiation can be thought of as maturation or specialization of a ce ll ,
when the function of the cell is expressed ( 168). Cell differentiation is often
characterized by reduced cell proliferation, increased cellular adhesion, reduced
invasiveness, and expression of cell -type specific genetic products. When retinoic acids
are used to treat cells, expression of many retinoic acid responsive genes is altered .
Most of the genes initially activated are encoding transcription factors, such as
homeoprotein s. Later, genes that encode for proteins which are more characteristic of
differentiated cells are activated. These include glycoproteins involved in the
production of extracellul ar matri x, stromelysin collagenase, keratins, and gap junctional
proteins. These gene products have known roles such as cell-cell adhesion , cellular
com muni cation, and the restructuring of extrace llul ar matrix. The last group of genes
to be activated by retinoi c acids encode for proteins for cell matrix adhesion or the
cytoarch itecture of mature differentiated cells. In contrast, there are al so exampl es of
retinoic acids that down-regulate genes. T he AP-I is a transcriptiona l activator
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composed of Jun and Fos proteins and it is required in cell proliferation and retinoic
ac id su ppresses the expression of AP-I complex ( 169).
A good example of retinoic acid controlling a neoplastic disease by inducing
differentiation is that of acute promyelocytic leukemia (APL). This form ofmeyeloid
leukemia accounts for approximately I 0% of all adult non lymphocytic leukemias ( 170).
The disease results from deregulation and clonal expansion of a hematopoietic
progenitor cell arrested at the promyelocytic stage of differentiation. It is caused by a
chromosomal translocation between chromosome 15 and 17, that fuses the RAR a. gene
to another gene named PML. This produces a 106-ki1oda1ton chimeric protein
containing most of the PML sequences fused to a large part of the RAR a., including its
DNA and hormone-binding domains. This protein contributes to leukemogenesis
through interference with promyelocytic differentiation ( 171 ). These cells are all-transretinoic sensitive ( 170) and treatment of patients with oral all-lrans-retinoic acid
achieves an 80% complete remission by inducing tenninal differentiation of the
leukemic bl ast ce ll s ( 170).

Cell Proliferation and Retinoids

Retinoids have the abi lity to alter the proliferation of both tumor cell s and
endot heli al cells (2 ,46, 167). Most reports have stated that retinoid s acted as cytotoxic
or cytostatic agents. The toxic effect of retinoids is time and concentration dependent,
as we ll as the cell line or tumor type treated ( 163). Exposure of most cell lines to
retinol or retinoic acid at I 00 ,uM causes immediate or delayed toxicity. Whe n retinol
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was added to culture medium for endothelial cells, concentrations above I0 JiM were
toxic, causing cell detachment from the substratum and eventually ce ll disintegration
(172). Retinoids and carotenoids begin to act like detergents at concentrations above
10 JiM , which may explain some of the cytotoxic effects (25).
Retinol, 13-c is-, and all-lrans-retinoic acids induced an increase in [ 3 H]
thymidine uptake by cultured endothelial cells between I and 10 JiM ( 173). These cells
were cu ltured with 10 11/ml of heparin and 10% NuSerum, which may have affected the
retinoids. However, thymidine uptake does not prove increased cell numbers. Another
group of researchers reported that all-trans- and 13-cis-retinoic acids had little effect on
endothelial ce ll proliferation ( 174). But, in this report the endothelial cell s were used at
cell passages of 15 or more, which may be past their genetic programming for
proliferation and be at a point when they typically migrate and reform loops.
The effect of retinols on neoplastic cells is varied. All-trans-retinoic acid
inhibits the growth of interleukin-6-dependent myeloma cells by downregulating
interleukin-6 receptor expression (I I). The addition of interferon-a was synergistic in
inhibiting the myeloma cell line. This same synergistic effect occurred with all -transor 13-cis-reti noic acids, with interferon-a when applied to a small cell lung cancer and
colon carcinoma cells. A ll -trans- , 13-cis-, 9-cls-retinoic acid, and the synthetic
retinoid, acitretion, inhibited the proliferation of five human transformed epithe li al cell
lines ( 167). Furthennore, a ll -trans-retinoic acid reduced the cell growth of two hum an
gli oblastoma cell lines, Hu70 and Hu 197, but on ly at 65 !lM ( 17). When vitamin Data
dose of 25 11M was used wit h retinoic acid at I 11M , plating etliciency of these cell lines
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was reduced by 80%.
Retinoids alter cell replication rates, by affecting DNA, RNA , and protein
synthesis. Autoradiographic studies with [' H)-thymidine for DNA, [3H]-uridine for
RNA, and [3 H]-leucine for protein synthesis in basal or squamous cell carcinomas
revealed that retinoids markedly inhibited DNA synthesis, RNA, and protein synthesis
( 175).

When retinoids were used to treat nontransformed cell lines, they acted as

mitogens ( 176). C ultured rat glomerular epithelial cells increased their growth rate by
3.5-fold when treated with 16.6 pM of retinoic acid whereas human skin fibroblasts,
when grown in the presence of6 pM retinol , had no growth increase (163). Mouse 3T3
fibroblasts exposed to I00 flM retinol revealed no cytotoxic effects after several days of
exposure. In contrast, an embryonal carcinoma cell line, PCL4.azal , was extremely
sensitive to the toxic effects of retinoic acid at as low as I 0 nM. One of the most
sensitive cancers to retinoic acid treatment is AIDS-related Kaposi ' s sarcoma ( 18). Alltrans- and 13-cis-retinoic acids reduced the growth of Kaposi's sarcoma cells in vitro in
a dose-depende nt manner with 50% inhibition at 0. 14

nM

and 4.7 nM, respectively , and

maximal inhibition at I 0 nM .

Gap Junction Communication and Retinoids
Ce ll s in a multicellul ar organism can communicate by the direct exchange of
mol ecul es between the cytoplasm of nei ghboring cells through channels located at gap
junctions. These channels are composed of two opposing hexameric protein structures,
connexin 43 , one in each cell (177). These form a pore between the cytoplasm of the
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two cells. Through thi s pore, polar molecules of weights less than I to 1.5-kilodaltons
may pass (7). As cells are transformed, they reduce their gap junction communicating
capacity. This reduces the growth inhibition usually caused by surrounding cells.
When these transformed cells are exposed to retinoids or carotenoids, the expression of
connexin 43 mRNAs is increased and restores gap junctional communication (6,7, 177).
When the transformed cells were distributed in colonies of less than I 0 cells, their
progression was held to essentially zero due to the retinoic acid enhanced gap junction
communication. The progressively larger colonies had increased transformation
frequency, up to 70% for colonies of2,000 cells (6). Therefore, the enhancement of
communication by retinoids may explain many of their effects as chemopreventive
agents (6).

Apoptosis a nd Retinoids
Apoptosis is a genetically controlled process of cell death ( 178). It is important
in the elimination of cells from morphogenesis during embryonic development, as well
as in many adu lt ti ssues, e.g. skin. Apoptosis is characteri zed by DNA fragmentation ,
which can easil y be detected ( 179). Apoptosis is regulated by a fami ly of genes (Myc,
Bcl-2, abl , p53) that either suppress or induce the process ( 180). Retinoids can mimic
events in mamm alian development by switching the apoptosis genes on or off. Thi s
may ca use cell s programmed for apoptosis to res ist the process or induce a cel l to start
the apoptosis process. When P 19 embryonal carcinoma ce lls were treated with I JiM of
all-lrans-reti noic acid, the DNA fragmen tation was observed within 36 h of treatme nt
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in 20% of the cells (179).
Retinoic acid suppressed TGase I and induced TGase II , genes involved in
apoptosis, in a rat tracheobronchial epithelial cell line. The TGase I gene was induced
during squamous cell differentiation and the TGase II gene was associated with
inducing apoptosis (178). Both of these processes, differentiation and apoptosis, lead to
irreversible growth arrest and with retinoic acid treatment the apoptosis pathway is
initiated.
Be 1-2 is a gene that suppresses apoptosis ( 180). Treatment with 9-cis-retinoic
acid down-regulates the expression of Be 1-2 and causes NB4-R I cells, a human
promyelocytic leukemia, to undergo apoptosis. This occurred, even when high
expression of Be 1-2 was present in these cells due to transfection with the Be 1-2 gene.
A good example of the induction of genes and the eventual death of cancer cells is the
treatment Ki-1 lymphoma cell line with all-trans-retinoic acid. Retinoic acid treatment
with an LD 50 , 0.6 fiM, caused an increase in the RARa receptor proteins, an increase in
transforming growt h factor 131 gene expression, and subsequently apoptosis at 48-72 h
after ex posure ( 181 ).

Rctinoids and Angiogenesis
Retinoids affect not onl y the angiogenic potential of tumor ce ll s, but also the
activity of normal endothelia l cells (26, 174, 182, 183). They can aflect the angiogenic
activity at almost any point in the process and either suppress or enhance angiogenesis.
Retinoids inhibit endothelial cell angiogenesis at the phases of proteolysis of the
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basement membrane ( 182), migration ( 174), proliferation (26), and production of
angiogenic growth factors (183). Retinoid treatment switches angiogenic growth factor
production from angiogenic to antiangiogenic types (24 ), to induce production of IL-8
( 117, 119), or a possible disruption of the golgi apparatus that inhibits secretion of
angiogenic growth factors ( 184 ).
Retinoids alter the expression of the p53 tumor suppressor gene, which has been
found to regulate the expression of thrombospondin-1 , an antiangiogenic growth factor
(27). When 13-cis-retinoic acid was used to treat hamsters orally at I 0 mglkg while
administering the carcinogen 7, 12-dimethylbenz[u]anthracene, there was a greater
number of tumors with a slightly smaller tumor burden than was found in the nonretinoic acid control animals. The retinoic acid treated animals had extremely dense
proliferating endothelial cell masses compared to animals with untreated tumors.
Retinoids have been reported to synergistically inhibit angiogenesis when used
in combination with other vitamins or immunological cytokines. All three natural
retinoic acid form s, when used with I, 25-dihydroxyvitamin D3 decreased tumorassociated angiogenesis in 4-6 week old Balb/c mice ( 185). When L-ascorbic acid was
used with either retinol , retinal , retinoic acid, retinyl acetate, or retinyl palmitate used
to treat cultured endotheli a l cell s, all but retinyl palmitate acted to enhance
plasminogen activator ( 186). Plasminogen activator is important in converting
pl asminogen to plasmin, which is needed in the formation of tumor stom a. Squamous
and basal cell carcinomas of the skin had a greater growth inhibition when retinoids are
used in combination with interferon-a than either indi vidual agent ( 187, 188). Thi s

52
inhibition is thought to result from inhibition of tumor transforming growth factor

!3,

which is a potent inhibitor of endothelial cell proliferation (46). Other researchers
could not explain the synergistic antitumor effect of retinoids and cytokines by a single
property of the drugs, but felt the inhibition could be due to multiple effects ( 188).

Studies of Retinoids: Cancer Prevention
and Treatment
Studies conducted to examine the ability of retinoids to ei ther prevent or cure
cancers have produced varied and conflicting results. Both the natural forms of
retinoids and carotenoids, along with several hundred synthetic analogues have been
assayed in vitro, whereas only a few dozen compounds have been eval uated in vivo for
their cancer chemopreventive activity (3 ). Retinoids have demonstrated promise of
anticancer activity in in vitro studies, but due to the huge combination of additive and
synergistic interactions between retinoids and other modulators of carcinogenesis, a
large number of a nimal studies are needed before the benefit of retinoids can be
confirmed.

Chemoprevention Studies
In the 1980 ' s, when cancer chemoprevention began to draw b'feat interest,
retinoids were st udied the most. The hope of preventing cancer with reti noids was
based on four facts (3): I) deficiency in vi tam in A increases the rate of ca nce r
development in experimental anima ls; 2) animals exposed to carcinogens developed
fewer cancers when supplemented with retinoids or carotenoids; 3) most primary
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human cancers arise in epithelial tissues that depend upon retinoids for normal cellular
differentiation; and 4) several epidemiological investigations noted an inverse
relationship between vitamin A or carotene intake and risk of cancer development.
An interesting study in the use of retinoic acids as chemoprevention agents was
completed in 1988 (189). In this study, patients with xeroderma pigrnentosum, an
extremely rare , autosomal recessive disorder characterized by sun sensitivity, a
deficiency in the repai r of ultraviolet-damaged DNA, and a skin cancer rate of more
than I ,000 times that of the general population, were given high oral doses of 13-cisretinoic acid for a 2-year period. Patients had a total of 121 tumors in the 2-year
pretreatment period and there was a 63% reduction in new tumors during the treatment
and the 1-year posttreatment period. This study was conducted on only five patients in
which two were withdrawn due to " persistent abnormalities in their laboratory tests."
The authors concluded that chemoprophylaxis of common skin cancers could be a
reality; however, one must view the data with caution in li ght of the small test
population.
In a study using patients with squamous-cell carcinomas of the neck and head,
13-cis-retinoic acid was administered orally for 12 months after the subjects were
declared tumor-free fo ll owi ng primary treatment ( 13). The median follow-up period
was 32 months. At the end of the foll ow-up, on ly 4% of the retinoic acid group had
second primary tumors compa red to 24% of the placebo gro up. Therefore, the
researchers concluded that a hi gh da ily dose of 13-cis-retinoic acid was effective in
red ucing second primary tumors in squamous-cell carc inomas. In compariso n, beta
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carotene was not shown to be an effective chemopreventive when I ,805 patients with
recent nonmelanoma skin carcinomas were given 50 mg of beta carotene daily for 5
years (21 ).
The results of using 13-cis-retinoic acid were encouraging, when used to prevent
squamous-cell carcinoma by treating a premalignant condition called oral leukoplakia
(4). These are white patches on the oral mucosa that have epidemiologic, geographic,
and etiologic similarities to oral squamous-cell carcinoma. When 13-cis-retinoic acid
was used to treat this condition for three months, there was a 67% reduction in lesions
in the retinoid group, compared to I 0% in the placebo group. The dysplastic lesions
were reversed completely by 54% of the retinoid group compared to only 10% of the
placebo group. T his study is important since oral leukoplakia is closely associated \vith
tobacco use. Furthermore, tobacco users receive repeated carcinogen exposure to the
entire epithelial surface of the respiratory and digestive tracts, causing multiple
independent premalignant foci , which can be reversed by the 13-cis-retinoic acid .
Several epidemio logic studies suggested that the ri sk of bladder and prostate
cancer may be linked either to dietary vitamin A content or plasma retinoid
concentration. These studies have indicated that decreased retinoid intake or plasma
concentrations increase the cancer risk ( 190). Several studies of bladder cancers and
serum retinol correlated lower serum retinol concentrations with hi gher incidence of
cancer, but a large study in western Maryland could find no relationship between
bladder cancer and serum retinol concentrations .
Reports of several studies indicated a hi gher ri sk of prostate cancer with lower
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serum retinol content and other studies found the opposite (190). When the intake of
lycopene, a carotenoid, was studied, a positive relationship between lycopene intake
and reduced prostate cancer risk was observed ( 191 , 192). The source of lycopene was
usually in the form of cooked tomato products.
There were two large, well conducted studies that examined the use of beta
carotene or retinol and produced very surprising results (8,9). Both studies focused on
high-risk lung cancer populations, that is, tobacco smokers or asbestos workers. The
first study, published in 1994, was conducted in Finland using 50-69 year old male
smokers (8). They were divided into groups which received vitamin E (alphatocophero l), beta carotene, or both. The follow-up was continued for 5 to 8 years and
the vitamin E group had no reduction in the incidence of lung cancer. The same was
observed for the vitami n E and beta carotene group. But, an unexpected 18% increase
in lung cancers, among the beta carotene group, was observed. This indicated that
these supplements may actua lly be harmful. In 1996, after the Finnish study was
completed, another large study, the Beta Carotene and Retinol Efficiency Trial
(CAR ET), was stopped early due to another increase in lung cancer death rate (9). In
this study, smokers, former smokers, and asbestos workers were given both 30 mg of
beta carotene and 25 ,000 IU of retinol daily. After 4 years, the study was stopped 21
months ea rly. The active treatment group of beta carotene and retinol had a 28% higher
incidence of lung cancer than the placebo group, and the overa ll mortality rate was 17%
for lung cancer. T hese studies, along with three others with simi lar protocols and
results, have reduced the enthusiasm about the efficacy of supp lementa l beta carotene
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or retinol in certain populations.

In Vitro Chemotherapeutics Studies
In vitro studies have been used extensively to examine the effects of retinoids

on cancer cells. Hundreds of retinoid isoforms have been examined and their
mechanisms of action have been partly revealed. Since natural retinoids be can toxic in
experimental animals or human subjects, the in vitro studies have been used with
synthetic forms of retinoids that maintain a drug efficacy but have reduced toxicity. For
example, the synthetic retinoid fenretinide or 4HPR (N-4-hydroxyphenylretinamide)
was studied as a treatment for prostate cancer (193). When used with rat and human
prostate or bovine endothelial cells, it produced cytotoxicity at one log dose lower than
that produced by all-trans or 13-cis-retinoic acids .
Treatment of cultured head and neck squamous-cell carcinoma cells with all trans-retinoic acid resulted in an inhibition of proliferation and suppression of
squamous diffe rentiation ( 194 ). The degree of effect varied among the cell lines. A
decrease in the expression of RARP mRNA was seen in the malignant ce lls when
compared to nonnal cells. In the same report, expression of RARP was restored in vivo
with treatment with 13-cis-retinoic acid . In contrast, the RARP I isoform, which is
normall y cx pre sed in fe tal tissues, was expressed in live of seven ma ll -ce ll lung
carcinoma lines without retinoid treatment but not in normal adu lt tissues ( 195).
Diffe rent retinoic ac ids can induce or suppress several isofonn s of RAR or R.XR
( 196). T herefore, in som e cases, treatment with a retinoic acid can inhibit a n RAR
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expression and control a malignant tissue, or aid the expression of the receptor that
causes the malignancy. There are reti noids that do not bind known receptors, yet have
potent biologic effects. 4HPR does not bind RARs or RXRs, but has activity in the
prevention of prostate, bladder, and breast cancer, and as well as in vitro induction of
apoptotic cell death in several cancer cell lines.

Animal Studies
ln 1991 , 4HPR was effective in reducing prostate cancer when used in a rat
prostate cancer model ( 15). T he cancer was induced with the carcinogen Nmethylnitrosourea given by an i.v. injection in conjunction with a s.c. implant of slowrelease testosterone proprionate. Seven months later the 4HPR was added to the rat' s
diet. Prostate tumors developed in 88% of the control rats and only 2 1% of the treated
rats. When 4HPR treatment was used with a mouse prostate reconstitution model that
induces cancer with transduction the of ras and myc oncogenes, there was a 49%
reduction in tumor incidence and a 51% reduction in tumor mass ( 193 ).
The oral administration of 13-cis-retinoic acid was effective in reducing the
incidence of tumors produced by the application of7, 12-dimethylbenz[a]anthrocene to
the buccal mucosa or to the tongue of hamsters ( 175, 197). A synergistic effect of
retinoic acid was seen when 13-cis-reti noic acid was combined with a ndrogen ablation
(castration) in treati ng athymic nude mice that had transplanted human prostatic
carcinomas ( 16). This treatment combination eliminated tumors in 50% of the mice.

I'
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Cl inical Studies with Humans

Over the last 30 years, retinoids have become available in many countri es to
treat a variety of di sorders of keratini zation and other dermatological conditions (2) and
have all owed cli nicians to use retinoids in the treatment of other diseases, such as
cancer. Th is non label use resulted in the need for contro lled efficacy studies. A study
in 1982 was conducted in France with retinoid treatment of heavy cigarette smokers
( 10). During 6 months of treatment, the synthetic retinoid etretinate was administered
at 25 mg!day. For each patient, exami nation

''~t h

a bronchoscope and a biopsy was

used to determine the amount of metapl asia before and after treatment. The metaplasia
in the bi opsy sa mple was sib'Tlificantl y reduced after retinoid treatment.
In phase 11 studies, 13-c:is-retinoic acid was used to treat ma lignant astrocytomas
and used in conjunction with a-2a-interferon to treat advanced squamous-cell lung
cancer ( 198, 199). The astrocytomas were reduced in I I%, 35% remai ned stable, and
54% had disease progression in the patients. In compari son, the squamous ce ll lung
cancer patients were not he lped by the treatment. Thi s un fo rtunate result was repeated
in a phase II study usi ng all -trans-retinoic acid to treat eleven patients with metastatic
nonsma ll cell lun g carcinoma (200). In addition, all -tmns-retinoic acid was shown not
to be e ffecti ve in a recent study when used to treat hormone-refractory prostate cancer
(20 I). Seventeen patients received the retinoic acid ora ll y for 2 weeks, no treatment for
I wee k, and then the treatment was repeated. The researchers inc luded a
pharmacokine tic analysis wi th thi s study and reponed that the clearance of the retinoic
acid doub led during the 2-week treat ment and the all-trans-retinoic acid did not convert
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to 13-cis-retinoic acid.

Problems with Retinoids as
Pharmaceuticals

During the past few years, many serious questions have been asked about the
use of retinoids in cancer prevention and treatment. De Luca, in 1993, in a review of
vi tamin A mechanisms, asked the important question, " Why was the tumor rate in
some patients in clinical studies higher after retinoic acid treatment than before?"
(202). Another concern is, why do retinoids seem to be effective with some cancers
and show no effect with others? These questions emphasize only part of the difficulty
in the use of re tinoids. The toxicity and other side-effects also can greatly hinder the
use of retinoids.
There is solid evidence from the numerous clinical, in vilro, and in vivo studi es
that retinoic acid inhibits or differentiates neoplastic cells. Why then are retinoic acids
not used more to tTeat cancers clinically? Retinoic acids are morphogens and
tcratogens. They are toxic at very low doses and the te ratogenic effects can occur up to
2 years after cessation of the drug (2). Some oral leukoplakia patients treated with
retinoic acids develop cheilitis, facial erythema, skin dryness, peeling of the skin,
conjunctivitis, hypertriglyceridemia, and photophobia ( 12). These ymptoms will
resolve with reduction of the dose or stopping treatment. Both natural and syntheti c
retinoids are toxi c compounds that can cause acute effects, including elevated
intracranial pressure and desquamation of the skin, as well as chronic effects, including
bone remodeling, hepatic toxicity, and skin erythema (5). The retinoids are also highl y
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teratogenic, producing multiple malformations. Plasma retinoid concentrations are not
maintained over long-termed treatment and may be reduced to very low concentrations,
due to changes in pharmacokinetics (II). This appears to be the mechanism that
reduces the effect of retinoids during cancer treatment (5). Retinoids are rapidly
sequestered by the liver in the form of fatty acid esters. The disappearance ofretinoic
acid from the plasma also can be related to the induction of P450 catabolic enzymes.
Another contributing factor for an increase in plasma drug clearance of retinoic acid
may be the upregulation of cellular retinoic acid binding protein, increasing the amount
of intracellular retinoic acid ( II ). ln one study, the conversion of 13-cis-retinoic acid to
4-oxo-13-cis-retinoic acid, in patients with squamous-cell carcinomas of the cervix or
the head and neck, was quicker than the normal volunteers (203). The 4-oxo metabolite
has lower biologica l activity than the parent compound. Retinoic acid treatments can
be aided by changing the dose schedule or by administering inhibitors of the P450
catabolic enzymes ( I I). Intermittent treatment with retinoic acid may have potential
advantages over continuous admi nistration .
Severa l synthetic aromatic retinoids have been developed in an attempt to
minimize the toxicity and prevent the decreasing plasma concentrations during
treatm ent. These sy nthetic retinoids have shown anticancer act ivity in vitro (204) but a
synthetic retinoid does not exist that is ready to be used in clinica l treatm ents. Studies
have shown that use of the synthetic reti noid fenretinide is effective against breast
cancer (205). The drawback of admi ni stration of fenretinide is that it lowers circulating
retinol and may a ffect ni ght vision. Thi s reduction in retinol is greater in women over
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55 years of age with a hi gher percentage of adipose tissue (206). In addition, 4HPR,

13-cts-retinoic acid , and all -/rans-retinoic acid reduce retinol concentrations by
interfering with vitamin A metaboli sm (207). All three retinoids inhibited liver and
intestina l retinal reductase. These acyltransferases are primary vitam in A-esterifying
enzymes and the reductase is involved in conversion of beta carotene.

Solid Tumor Cell Lines Selected for Study
The selection factors for the cancer types used in this research were their
angiogenic potential and potent ial response to retinoid treatment. The three cancer lines
are hi ghly invasive, indicati ng a high angiogenic potential. All three of these cancer ce ll
lines show epi thelial -l ike cell morphology, which would indicate that they may be
responsive to retinoids. In addition, prostate, bladder, and brain tumors are difficult to
manage with surgery and chemotherapy; therefore, they are good candidates for
alternative therapies. The gliob lastoma was se lected because it was from a high-grade
tumor which indicated a poorly differentiated, malignant tumor. These glioblastoma
multifonn tumors are the most common a nd most malignant glial tumors. In addition,
they show vascularization with proliferating endothelial cells. Patients with these
tumors have a mean surviva l time of approximately one year and no successful
treatment is availab le (85 , 86). These tumors are a prototype, suitab le for
anti angiogenic therapy (86). The U-373 MG cell line has been reported to produce
VEGF (84,208).

The bl adder, transitional-cell carcinoma was se lected because bladder cancer is
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the fifth most common cancer in the United States and its incidence appears to be
increasing, especially in women (209). Treatment is frequently ineffective. An
invasive disease, such as this, carries an extremely poor prognosis. Five-year survival
rates of patients with thi s type of cancer rarely exceed 50%. These cancers have been
shown to be angiogenic, which can lead to a 2.5 times higher mortality rate, and they
have both VEGF and midkine growth factors mRNA production.
The prostate cancer cell line was selected due to its angiogenic and metastatic
potential. Presently, prostate cancer is the most commonly diagnosed cancer among
men and is a major cause of death. When a prostatic cancer becomes metastatic, it is
incurable (2 10). Androgen ablation has usuall y been the only available treatment (211 ).
However, once these cancers are metastatic, they become hormone independent.
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SPECIFIC GOALS OF THIS RESEARCH

Retinoids have a long hi story of being associated with the prevention and
treatment of cancer in human and laboratory animals. It has been known for over 70
years that a deficiency in vitamin A intake can lead to some types of cancer (3).
Retinoids are well known for their ability to reduce the carcinogenicity of some
chemicals and ultraviolet light (5). This association with retinoids and cancer has
stimulated a large quantity of research, including numerous chemoprevention and
clinical studies. This research has shown that retinoids can affect neoplastic
development at almost all points of the process. Retinoids can be used to e nhance the
differentiation of some cell types and can cause some cancer cells to become terminal
(23). Retinoids may be cytostatic to some neoplastic cells, stopping or reducing thei r
proliferation ( I I, 17, 167). Retinoids maintain gap junction communication between
adjacent cells, helpin g to reduce the proliferation of transformed cells or small cell
masses that have not grown too large (6,7, 177). Retinoids also have been shown to
induce apopto is in some neoplastic cell lines ( 179). This may be re lated to the ab ility
ofretinoids to enhance differentiation, which may lead to a preprogrammed apoptosis
in some cell s. Lastly, retinoids affect the angiogenic potential of many so lid tumors
and tum or-deri ved cell lines (26, 174, 182, 183).
Th is research served to investigate the effects of retinoids on angiogenesi s. The
proj ect was focu sed on the treatment of neoplastic ce ll s with three naturall y occurring
retinoic acids and their angiogenic potential. All-Iran.,-, 9-cis-, and 13-cts-retinoic
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acids were used to treat neoplastic cells from solid tumors.
Prior to this research, my preliminary hypothesis was developed from the
available published literature. This preliminary hypothesis stated: Treatment with
retinoic acids will inhibit the production of angiogenic growth factors produced by the
neoplastic cells, therefore reducing the growth of vascular endothelial cells.

Primary Goals
Goal I: Determine whether all-trans-, 9-cis- or 13-cis-retinoic acid treatment of
human neoplastic cell lines, derived from solid tumors that showed angiogenic activity
in vivo, could affect the neoplastic cells' production and/or secretion of angiogenic

growth factors . These treatments will be applied in a range of doses in order to
determine the dose-response relationship of the retinoic acids' effects.
Goal 2: Determine which growth factors are being affected by the retinoic acids
and whether the effects are at the translation of mRNA or secretion of protein product.
This will be determined by measuring the mRNA expressed in the treated cancer cells
and the protein concentrations in the media of the cu ltured cancer cell s.

Supportive Goa ls
Goa1 3: Determine the elfect on the proliferation and survivability of neoplastic
cell s cultured with varying doses of all-tran1·, 9-cis, or 13-cis-retinoi c acid .
Goa14: Determine if all-/ram·, 9-c is, or 13-C/S·retinoic acid treatment s affect
the proliferation of the endothelia l cells.
Goa l 5: Determine if the addition of sodium heparin to the retinoic acid
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treatment changes the effect of the retinoic acid treatment.

Purpose of These Goals
These goals have a 2-fold purpose. The first will be to detennine parameters
and conditions necessary for conducting this research in vilro. The second purpose will
be to attempt to delineate the mechanism(s) of retinoid effects on angiogenesis. How
retinoids affect an angiogenic tumor mass is not well understood at this time.
Therefore, it will be useful to know if retinoids can affect growth factor gene
expression. Furthennore, infonnation about the dose-response of retinoids and
angiogenesis is lacking. The supportive goals, numbers 3 and 4, are needed to
detennine what concentrations of retinoids decrease cell proliferation or trigger
increased apoptosis in these cell lines.
The main goals were developed in an attempt to explain the observation
produced by retinoids used to treat solid tumors in clinica l studies. Retinoids have
reduced angiogenic activity when tested in several assays that use actual blood vessel
growth in chicken eggs, rabbit eyes, or hamster cheek pouches (208). Retinoid
treatment has therapeutic value in the treatment of several diseases, like psoriasis and
rheumatoid arthritis, that have pathological angiogenesis as a common element. This
indicates that retinoids have an effect on angiogenesis ei ther at the production or
function of growth factors . Because angiogenesis is a normal function and , except for
menstruation and wound repair, is usually inhibited in adults, thi s is a poss ib le area of
treatment which could be applicable to a large number of cancers. Therefore, a better
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understanding of the mechanism of angiogenesis will be useful in developing
antiangiogenic treatments. Not only is there a therapeutic need to inhibit angiogenesis,
but the ability to increase angiogenesis also could be useful in treating several diseases
that are characterized by reduced angiogenesis.

67
MATERIALS, METHODS, AND JUSTIFICATIONS

Cell Lines
All of the ce ll lines were purchased from American Type C ulture Collection,
(ATCC) (Rockville, MD). The three neoplastic cell lines were of human origin and the
endotheli al cell line was of bovine ori gi n, because a human cell line was not available.

Glioblastoma
The g lioblastoma, U-373 MG (ATCC; HTB-17), was from a 6 1-year-old
Caucasian ma le, blood type A+. The cells' morphology was epithelial-like and the
ce ll s formed spind le-shaped cells, consistent with a hi gh grade astrocytoma when
grown in culture. Furthermore, in nude mice they actually formed a grade Ill
astrocytoma.

Transitional Cell Carcinoma
T he bladder cancer ce ll s were from an anaplastic transitional -ce ll carcinoma
and ca ll ed TCCSUP (ATCC; HTB-5). They were from a 67-year-old femal e. The
ce ll s' morphology was epithe li al-like. Thi s ce ll line was a grade IV with morphology
consistent wit h a high-grade transitional cell carci noma in vitro.

Pr·ostate Adenocarcinoma
The prostate adenocarcinoma ce ll s were DU- 145 (A TCC; HTB-8 1). These ce ll s
were isolated from a metastati c brain lesion of a 69-year-old Caucasian male with
blood type 0+. The cell s' morphology was epi thelial-like and when grown in culture,
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the cells appeared as undifferentiated malignant tumor cells and were androgen
independent. When grown in nude mice, they formed grade II adenocarcinomas,
consistent with a primary prostatic tumor.

Endothelial Cells
The endothelial cells, EJG (ATCC: CRL-8659), were derived from bovine
adrenal medulla capillaries. The cellular morphology was that of capillary
endothelium. The cells formed linearly-oriented confluent cultures. These bovine
endothelial cells were the only capillary cells available from ATCC. These cells grow
rapidly, survive repeated passages, and maintain a hi gh plating efficiency (68).

Selection of Cell Lines
An essential factor in the selection of the cell lines was the need to move
medium from the tumor cell cu ltures to the endothelial cells. Thus, all cell lines had to
be cultured in the same medium. With thi s procedure, the medium could be
"conditioned" by growing tumor cell s in the medium before usi ng the medium to
culture the endothelial ce ll s. Since no transfer of med ium was made between cancer
ce ll s, the selection of cancer ce ll s culture cond ition was based on the recommended
medium for the e ndothelial cell s.

Cell C ulture t>rocedures
All ce ll s were cultured with Minimum Essentia l Medium with Earl e ' s Balanced
Salts (MEMIE BSS) and nonessential amino acids (Hyclone Laboratories, Inc .. Logan.
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UT). This medium contained 2.0 mM L-gl utamine, with an additional 2.0 mM Lglutamine added. In addition, 1.0 mM pryuvate and penici llin-streptomycin at 100
l.U ./ml and 100 JJg/ml, respectively, were added. Cells were cultured at 370C in a
humidified 5% C0 2- 95% air environment. All cells were first plated in either 75cm 2 or
175cm 2 , canted neck, vented cap culture flasks. The first plating was with MEMIEBSS
media supplemented with I0% fetal bovine serum (FBS) (Hyclone). After cells
reached confluence, the cells were maintained with the addition of 10% bovine calf
serum (CS) (Hyclone) supplemented media. The medium was removed by aspiration
three times weekly and replaced with fresh medium . Cells were passed as needed by
rinsing once with Hank 's Balanced Salts Solution (HBSS), then tumor cells were
removed with a 0.25% solution of porcine trypsin in HBSS with EDTA, without
calcium and magnesium (Hyclone). Endothelial cells were similarity rinsed and
removed with 0.05% trypsin solution.
Tumor cells to be retinoic acid treated were cultured to confluence in 25 cm 2
canted neck , vented cap culture flasks. The endothelial cells for treatment with the
conditioned media were plated into 24-well plates with a 1.88 cm 2 flat surface growing
area per well. Cytotoxicity studies of both the tumor and endothelial cells were
conducted using 24-well plates.

Cytotoxicity of Retinoic Acid to Tumor·
Cells, Justification
The toxicity of the three reti noic acids to the three tumor ce ll lines was
determined under the conditions used to produce the conditioned media. It was
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important to determine if the retinoic acids would significantly reduce the number of
tumor cells being cu ltured and at what dose the retinoic acids became toxic. The
experimental design of the ce ll proliferation study assumed a uniform number of cells
in each flask; therefore, the amount of growth factor secretion would not be
significantly affected by variation in cell density. The tumor ce ll s were grown in
optimum conditions for 2 weeks after being seeded into the flask or plates. T hi s was
necessary for two reasons. The first reason was to ensure that the same numbers of
cells would be present in each container, assum ing that the cells would grow to a
confluent monolayer and fill all the available space. This was evaluated by growing
cells for 2 weeks and counting multipl e sampl es and confirming that there was not a
stati sti cally sign ificant difference in cell numbers. Secondly, the cells were grown to
maximum density to partially recreate the growing conditions of cells in a tumor mass
in vivo. In tumors which are angiogenic, the cell s are densely packed and most of the

ce ll s in these tumor masses are not ab le to divide unless space and nutrie nts are made
avai labl e. This dense pack ing of cell s he lped to switch more ce ll s to the angiogenic
phenotype. The increase in ce ll density and in angiogenic phenotype was reported by
Koura el a/. in 1996 (88).
A hypoxic culture co nditi on was added to ensure that the sa mples would express
angiogeni c activitv. Hypoxia has been shown to be prese nt in the small masses of
ca ncer cell s be fore neovasc ul ari zation occurs (65 , 102) Hypoxia has been used in
severa l experim ents to stimulate VEGF production and switch ce ll s to the angiogeni c
phenotype (98 , 99. 101 , 103). T he use of hypoxia in thi s resea rch had two advantages.
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First, the hypoxia switched more tumor cells to the angiogenic phenotype, which
increased the amount of growth factors in the conditioned media. Second, it increased
the stability of the growth factor mRNA ' s, therefore making these mRNA 's more
abundant. This increased stability of the mRNA ' s under hypoxic conditions was
demonstrated by Shima eta/. with VEGF, where the VEGF mRNAs increased their
half-life from 30-45 min to 6-8 h (63). The hypoxic conditions were created by placing
the culture plates or flasks in a sealed, acrylic chamber which was placed in a 37"C
incubator and flushed continuously with water-saturated N 2 gas (I 0 I). The N 2 gas was
filtered through a 0.2 pM filter before entering the incubator.
Another assumption in this research was that these tumor cells would grow in a
protein-free medium (no added serum) and still be functional , and the cells would
secrete various proteins as if they were in vivo. This procedure was developed by
Alderman

e/

a/. in 1985. They showed that a human colon tumor cell line was able to

be cultured in a protein-free synthetic cell growth medium for more than 120 days
(2 12). Ce ll proliferation was minimal under these conditions, but the cells were able to
secrete growth factors and other proteins.

Procedure for Tumor Cell Cytotoxicity
Each of the tumor ce ll lines was seeded onto 24-well plates and maintained for
14 days. They were then treated with the retinoic acids by aspirating the media, rin sed
once with 3 ml/well of HBSS at pH 7.2, and then the HBSS was aspirated. This was
necessary in order to remove the serum and unattached cells.
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A stock of each of the retinoic acids was made by dissolving each in acetone to
I 0 mM. Th is stock was further diluted in acetone and then added to the medium to
produce a concentration range of seven log doses from 0.000 I to I00 pM. A control
without retinoic acid a lso was prepared. The final acetone concentration in the media
was I%. This concentration of acetone was shown, in preliminary trials, not to be toxic
to any of the cell lines used and still maintained each of the retinoic acids in so lution.
Stock solutions were stored at -8o•c in the dark. All retinoic acid so lutions were
protected from li ght exposure during all procedures. T hese procedures were conducted
under a subdued yellow light and incubation was in the dark .
Since the hypoxic incubation conditions did not have the 5% C0 2 atmosphere, it
was necessary to add I 0 mM of HEPES buffer (N-2-hydroxyethyl piperazine-N-2ethanesul fonic acid) to prevent major pH fluctation s (98). HEPES has a pKa of7.3 1
and a bufferin g range of pH 6.6-8.0 at 37"C. When used in conjunction with a normal
phosphate-bicarbonate buffi ng system, it provides more effective buffe ring in the
optima l pH ra nge of7.2-7.4 at 37•c . HEPES buffer and its technical infonmation were
supplied by Sigma Chemical (St. Louis, MO).
The cells were ma inta ined in hypoxic conditions for 24 h, then each well was
rinsed with 2 ml of HBSS, aspirated , and I ml of0.25% trypsin was added . After the
cell s detached from the we ll s, a pipette was used triturate the cells into a suspension.
T he ce ll suspe nsion was tran sfe rred to 20 ml of phosphate-bu ffered sa line (PBS)
solution, containin g 200 pi CS as a trypsin inhibitor. The cells were then counted with a
Coulter Counter by Co ulter Electronic, Inc. (H ialeah, FL) ( 127).
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Six wells of each retinoic acid dose were counted, and a mean was determined.
The mean from the control set of samples, without retinoic acid, was compared to the
mean from the seven doses of retinoic acid to determine the concentrations at which
retinoic acid reduced the number of attached cells.
No statistical testing was used with this experiment, as the data derived were to
be used in only determining the dosage range to be employed. Therefore, only one
sample per treatment was performed. The six well s counted were all drawn from the
same pool of cells and therefore were not independent samples (2 13). A standard error
of the mean was calculated for the groups of the six wells. This was used only for
graphic illustration and was intended to show the variation between the six wells. This
value was not be used to compare between treatments. The standard error was
calculated as the standard deviation of the wells divided by the square root of the
number of wells.

Endoth elia l Cell Proliferation with Retinoic
Acid Treatment, Justification
The rate of endothelia l cell proliferation during exposure to retinoic acids at
graded concentrations was determined. Conditioned media used to treat the endothelial
cells would still contain retinoic acids. Since it is not practical to remove reti noic acids
from conditi oned media, a compari son of endothelia l cell proliferation when treated
with retinoic acids alone and when treated with the conditioned med ia containing
retinoic acid was needed . This wou ld provide information about cytotoxicity due to the
reti noic acids and would demonstrate whether the retinoic acids independent ly affected
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endothelial cell proliferation. In addition, exposure to both tumor-produced factors and
the retinoic acids results in conditions that more closely approximate the conditions that
would occur with treatment in vivo.

Procedures for Endothelial Cell Proliferation
with Retinoic Acid
Endothelial cells were rinsed with HBSS, aspirated, and treated with 0.05%
trypsin to remove the cells from the culture flasks . The endothelial cells used for all
experiments were at six or less passages from the original cells obtained from ATCC.
Prior to plating, the cells were mixed in a beaker with a magnetic stirring rod to
produce a uniform suspension of cells. This ensured that an equal number of cells were
added to each well of the 24-well plates. The cells were initially seeded in MEMIEBSS
medium with I 0% CS and additives as described previously. The suspension of cells
was sampl ed and counted to ensure adequate cells per well. Cells were seeded at a low
density to allow space for rapid cell growth. These plates were incubated for 2 h under
normal conditions to all ow cell attachment. The plates were then rinsed with HBSS to
remove unatlached cells and serum . Nonserum medium with 10 mM HEPES,
containing on e of seven concentrations ofretinoic acids or a control in 1% acetone was
added at 1.0 ml per well. Three additional controls were included, each without
HE PES or aceto ne. Nonscrum , I0% CS, or I0% FBS containing media were each
added to four wells. These samples were used to develop a profil e of endothelial
proliferation to show that the ce ll s were full y capable of proliferating from one
experiment to the next. T his was necessary, because endothelial cells can quickly
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switch from rapid proliferating, to migrating, and to tubule forming. Also, this
demonstrated the status of each pool of cell s.
The plates were incubated in the hypoxic chamber for 48 h, media aspirated,
rinsed once with 2 ml of 1-lBSS, and aspirated. The cells were then detached with 0.05%
trypsin, placed in 20 ml PBS containing 200 ul CS, and counted as previously
described. Six wells of endothelial cells were counted at 2 h after plating. These well s
were selected randomly during the process of seeding the plates prior to retinoic acid
treatment. T his was necessary in order to verify that the distribution of cells was
uniform , and to establish an initial count of cells for each trial. The initial count was
used instead of the seeded cell numbers, beca use variation in cell attachment between
trials is not uncommon .
The endot helial cell growth was statistically ana lyzed with the Mann-Whitney
U-test (2 14 ). All endothelial cell treatments were replicated in triplet, with four wells
per treatment in each replicate. The four wells of each treatment were averaged and
this was used as the sampl e data point for each replicate. There were, therefore, three
samp le points per treatment. Each treatme nt was compared to the control , which was
the zero dose ofretinoic acid, to determine if the treatment increased or decreased the
number of cells. A Mann-Wh itney U-test for a one-tai led U value was used . A
significant difference was set at P<0.05. This test was se lected because it is app licabl e
in situati ons in which sa mp les are drawn from the same population but different
treatments are used on each (2 14). The results of the ce ll counts were calculated as a
percent of the control va lue (+/-S EM) with control s set as 100%, as previousl y
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described by lruela-Arizpe et a/. ( 133 ). These results were graphed as percent of
contro l as a means of controlling for differences in the starting number of cells per well
in each trial.

Endothelial Cell Growth with Conditioned
Media, Justification
T umor cells were treated with retinoic acid to produce conditioned media which
were then used to cu lture endothelial cells. A sample from each of the conditioned
media was used to determine concentrations ofVEGF and £L-8 proteins. The treated
tumor cells were used to collect total RNAs and used for determination of mRNA
expression for the growth factors of interest. These experiments determined the
combined effect of the exposure to residua l retinoic acids and any tumor secreted
growth factors in the conditioned media on the proli fe ration of the endothelial cell s.
T hi s served to approximate conditions of retinoic acid treated cell s in vivo, where both
the tumor and e ndothelia l cell s would be exposed and the tumor cell s could be
ex pressing both angiogenic and antiangiogenic growth factors.

Procedures for Endothelial Cell Growth
in Conditioned Media
After tla sks of tumor ce ll s were cul tured for 2 weeks and had reached maximum
ce ll density, the fl asks were aspirated, rinsed once with 7 ml ofHBSS to re move
detac hed ce ll s and serum , an d aspirated. The ce ll s were th en treated with 7 ml of
nonserum MEMIE BSS contai ning one of the retinoic acid treatments, I% acetone, and
I 0 mM II EPES, as described for the endothelia l ce ll s in the previou section.
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Retinoic acid concentrations were 0, 0.0001, 0.001, 0.01 0.1, I, 10, or 100

flM

the media. The flasks were cultured under hypoxic conditions for 24 has previously
described. The medium was then removed, placed in 15 ml centrifuge tubes, and
centrifuged for 2 min at 2,000 rpm . This was performed to remove any suspended
cells. The flasks of cells were immediately frozen at -80"C for later use in the
extraction of RNAs. The conditioned media were added to the previously plated
endothelial cells as described in the previous section. Each well received I ml of
conditioned media and the remaining media was frozen at -80"C for protein analyses.
The 24-well plates of endothelial cells were incubated for 48 h in a humidified 5%
C0,/95% ai r atmosphere at 37"C. The incubation period of 48 h was previously
determined to be optimal and will be described in the next section. After 48 h, the
medium was removed by aspiration, the cells were rinsed with 2 ml ofHBSS, and
aspirated. This rinse removed detached cells. The attached cells were released with
0.05% trypsin in HBSS , placed in 20 ml of PBS contain ing 200 pi CS, and counted as
previously described. During each trial , three flasks were treated per dose of retinoic
acid and four well s of endothe lial cells were treated from each flask, for a total of 12
wells. Four additional wells of endothelial cells were treated with nonserum , I 0% CS
and I 0% FBS containing media as described in the previous section.
The e ndothelial ce ll growth was statisticall y ana lyzed as described in the
prev ious section.

in
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Endothelial Cell Proliferation in Conditioned
Media -Timed Study, Justification
The same experiment as described in the preceding section was conducted,
using only a partial set of retinoic acid concentrations. Cells were counted either every
8 or 12 h for 48 h. For the DU- 145 cell s, counts were every 8 h, with an additional cell
count performed at 72 h. After the experi ment with the first cell fine, it was determined
that the cell s need not be counted as frequently; therefore, the other two cell lines were
counted every 12 h. This procedure determined the time necessary for the optimal
endothelial cell growth . This timed study was also used to determine whether the
changes to the endothelial cell proliferation was caused by an artifact of the sampling
time, nutrient depletion, or treatment effect.
No statisti cal testing was applied to these results. A standard error was
calculated as described previously.

Lactate Analysis of Conditioned Media
Tissue hypoxia is associated wi th lactate production. Lactate quantification can
be utilized to verity anaerobic metabolism. In thi s study, lactate concentrations of the
conditio ned media from the hypoxia cultured tumor ce ll s were determined. These
concentrations were compared to the lactate concentrations from condi tioned media
prepa red under nonnoxic conditi ons. An increase in lactate concentrations wou ld then
veri fy that hypoxic c ulture conditions were attained. Si nce these lactate concentrations
were determined for media fro m the various retinoic acid treatments, it could be
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determined whether there was synergistic effect of retinoic acids on the lactate
production induced by hypoxia.
A quantitative, enzymatic determination of lactate in the media was conducted
using a kit (Sigma Diagnostics, St. Louis, MO). All procedures were performed
according to manufacturer's instructions, except that 5 pi of standards and samples
were added to 500 pi of lactate reagent. Briefly, 5 pi of each sample or standards, at

20, 40, 80, and 120 mg/dl , was added to microcentrifuge tubes. The lactate reagent was
reconstituted by adding I 0 ml of deionized water and mixed. Then, 500 pi of the
reagent was added to each microcentrifuge tube, mixed, and incubated for 5-10 min.
Triplet subsamples from each tube were placed in a 96-well, flat-bottom plate, then
read at 540 nm with background subtraction at 690 nm . A regression equation was
determined from the blank and standards. This equation was used with the mean of the
triplet subsamples to determine the lactate concentration.

Detection of Growth Factor
mRNAs, .Justification
Growth factor gene express ions were examined by a reverse transcriptasepolymerase chain reaction (RT-PCR) method using primers specific for selected
angiogenic growth factors . This was to determine whether the growth facto rs were
being expressed and whether the expression was being a ltered by the ret inoi c acid
treatments in a dose-dependent fashion . T he experiment was designed to determine if
the retinoic acids were affecting the gene expression of the growth factors at the DNA
tra nscription leve l.
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Procedures for RNA Separation
The tota l RNA was separated from samples of the seven doses of each retinoic
acid, hypoxia controls, untreated/normoxic controls, and normoxic control s with I%
acetone and I0 mM HEPES. The culture flasks were stored at -80°C until processed.
The RNA was processed with the use ofRNeasy miniprep kits (Qiagen, Inc.,
C hatsworth , CA), according to the manufacturer' s instructions. The flasks were thawed
briefly at room temperature, then 700 pl of lysis buffer was added to each 25 em ' flask
(approximate numbers of cells per flask was 3.1X l0 6). This buffer not only lysed the
cell membranes but contained

~-mercaptoethanol

to create a hi ghly denaturing

condition that inactivates RNases and ensures iso lation of intact RNAs. The lysates
were homogenized usi ng QIA shredders (Qiagen). The lysis buffer and cells were
pi petted into the shredder column and centri fuged at 13,000 rpm for I min, and then the
lysate was removed to a fresh microcentrifuge tube. One volume of70% ethanol was
added and thi s so lution was placed in a RNeasy spin column to bind the RNA and
remove the other materials. Th is separation method used the selective bindin g
properti es of a silica gel-based membrane and high-speed centri fugin g. The co lumns
were centrifuged at I 0,000 rpm for 15 s. The flow-through was discarded. Thi s process
was repeated to accommodate the entire lysate soluti on. The spin column was then
washed with 700 J1 l of was h buffer RWl. Then the tubes were inc ubated for 5 min to
he lp remove contaminating DNA. The co lumn was centri fuged for 15 s at 10,000

RPM. T he flow-through was di scarded . The column was washed with 500 J1 l of wash
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buffer RPE which contained ethanol. The column was centrifuged as described and the
flow-through discarded. The column was again rinsed with wash buffer RPE and
centrifuged, this time for 2 min at 10,000 rpm to dry the membrane. The flow-through
was discarded and the column was moved to a fresh microcentrifuge tube. The RNA
was eluted with 50 ,ul of diethylpyrocarbonate (DEPC)-treated di sti lled water. The
DEPC was added to the water to remove RNase activity in the water. The column ' s
membrane was incubated with the water for 10 min and warmed to 55°C to increase
RNA removal. The column was centrifuged for 60s at 10,000 rpm . The eluted RNA
was stored at -80°C. RNA concentrations were calculated based on the spectral
absorbance fTom a Shimadzu UV-160 spectrophotometer (Shimadzu Corp., Kyoto,
Japan). The RNA was diluted in DEPC water at 5 ,ul or 10 ,ul per I ml of water,
placed into quartz curvettes, and read at both 260 and 280 nm .

Reverse Transcriptasc, Justification
Si ngle strand DNA is replicated from the total cellular RNA . This eDNA is
then used in the PCR procedure (2 15). A poly (dT) oligo primer is used as the initial
primer to increase the selection ofmRNAs replicated to eDNA, due to the poly-A tail s
common to mRNA s.

Procedures for· Reverse Transcriptasc
Reactions
AMV reverse transcriptase (Promega Corp., Madison, WI) was used according
to the manufacturer's instructions. In a 0.6 ml microcentrifuge tube, 5 ,ug of total RNA
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was added with 2.5 pg of the primer in a total water volume of 15 pi _ The solution
was heated to 70"C for 5 min to disrupt RNA secondary structures, then chill ed on ice
for 5 min to anneal the primers. To each tube the following were added: 5 pi of AMY
RT reaction buffer, 2.5 pi of I 0 mMdNTP mix, 40 units of RNasin ribonuclease
inhibitor, 2.5 pi of 40 mM sodium pyrophosphate, and 30 units of AMY RT enzyme.
T hen the reaction was incubated for I hat 42-44"C. These eDNA samples were stored
at -80"C until used in the PCR procedures.

Multiplex RT-PCR, Justification
A PCR method was designed to si multaneously amplifY more than one gene
(2 16). This method is referred to as multiplex PCR and requires primers that lead to
amplification of unique regions of DNA. This method was chosen because it was not
only sensiti ve but also discriminating (2 17)_Therefore, it can be used to di stingui sh
between closely related transcripts, whether generated by alternative splicing or
sy nthesized from a lternative start ites of transcription_ The multiplex PCR was needed
to include a housekeeping gene in the reaction . Thi s housekeeping gene was selected
because it would be ubiquitously expressed and produced during hypoxic conditions.
This gene could then be used to demonstrate that the PCR reaction was success ful even
when the growth factor gene may have been expressed be low detection limits or not at
all. The hou sekeepi ng gene product also cou ld be used to adjust the densitometry data
and correct for variation in the amount of eDNA in the PCR reactions or errors in
load ing the DNA into the gels_
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RT-PCR Procedures
RT-PCR reactions were adjusted for each set of primers and genera lly followed
the method of Ogretman and Sa fa (218), except for the use of an oligo(dT) primer and
50 ,ul of tota l sol ution . The gene-specific primers for each growth factor and the

housekeeping gene were designed usi ng sequence information from the GenBank and
Wisconsin Package Version 8. 1 software (Genetic Computer Group, Inc., Madison,
WI). T he primers were developed using Oligo 4.03 Primer Analysis Software (National
Biosciences, Inc. Plymouth, MN). Each primer set was compared to the housekeepi ng
primers set by use of the Oligo 4.03 program to ensure that no primer-primer
interactions or false priming sites were available (214). After a primer-primer
annealing was identified in preliminary studies, all primer sets were compared for
primer-primer anneali ng in all possible combinations.
A "hot start" PCR used 8 ul of the eDNA solution (approximately eq ual to I ,ug
of total RNA) in 50 ,ul of solution in a 0.65 ml microcentrifuge tube. Each sample
contained 2.5 U of Tag DNA polymerase (Fisher Scientific, Pittsburgh, PA) or (S igma),
50

fiM

of each dNTP (Promega), 40 pmoles of eac h gene- specific primers, 1.5 mM

MgCI 2 , buffer of I 0 mM Tri s HCL at pH 8.3, and 50 mM KCI with a mineral oil overlay.
The sa mpl es were placed in a Coy TempCycler II (Coy Corp., Glass Lake, Ml) . The
sam pl es contai ning eDNA , primers, and MgCI 2 were " hot started" at 95"C for 5 min .
The Tag and buffer sol ution was added to each tube and a programmed cyc le, specific
for each primer, was used (description in the next section )
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VEGF Primer and PCR Conditions

A VEGF specific primer set was synthesized by GibcoBRL Customs Primers,
(Gaithersberg, MD). These primers were 22 bases in length with the upstream 5'GGGCCTCCGAAACCATGAACTT-3' at eDNA positions 43-55 and downstream 5'CGGCTCACCGCCTCGGCTTGT-3' at eDNA positions 593-615. Guanine-cytosine
(GC) percentage was 54% for upstream and 72% for downstream, with an annealing
temperature of 59°C. The primers were chosen outside the splice variance regions of
VEGF so that all the isofonns expressed would be detected.
PCR cycles after the hot start were 940C for 60s for denaturing the eDNA, then
59"C for 30 s to anneal the prim er, and 72°C for 60s for primer extension. This was
repeated for 30 cycles followed by two cycles with a 2-min extension time.

IL-8 Primer and PCR Conditions

An LL-8 specific primer set was synthesized by Gibco BRL. These primers were
22 bases in length with the upstream 5'-AACITrCAGAGACAGCAGAGCA-3' at
eDNA positions 15-27, downstream 5'-GCCCTCTTCAAAAACTTCTCCA-3' at eDNA
positions 345-367. GC percentage was 45% for both upstream and downstream . The
primers were chosen to include two intron regions so the replication of genomic DNA
wou ld be apparent.
The PCR cvcles and temperatures for IL-8 were 94"C for 60s for denaturing,
55"C for 30 s for annealing, and 72"C for 60 s for extension , repeated for 30 cyc les, then
two cyc les with a 2-min extension time.

85

Mid kine Primer and PCR Conditions

A midkine specifi c primer set was synthesized by Genosys, Biotech. Inc. (The
Woodsland , TX ). These primers were 25 bases in length with the upstream 5'CCTCCTCACCCTCCTCGCCCTGCTG-3' at eDNA positions 21-46 and dovmstream
5'-TAGTCCTTTCCCTTCCCTTTCTTGG-3' at eDNA positions 382-407. GC
percentage for upstream was 72% and downstream was 63%. These primers were
chosen to cover the enti re protein coding region and the introns occurring in this region
so repli cation of genomi c DNA wou ld be detected. The PCR cycles and temperatures
for midkine we re 94°C for 60 s for denaturing, 6 1.7°C for 30 s for annealing, and 72"C
for 60s for exte nsion and repeated for 30 cycles, then two cycles with a 2-m in
extension time.

Thrombospondin Primer and PCR
Conditions

A thrombospondin gene speci fi c primer set was synthesized by Operon Tech.
Inc. (A lameda, CA). These primers were 20 bases in length with upstream 5'AA TGCTGTCCTCGCTGTTGG-3' at eDNA positions 1175-11 95 and downstream 5'CTGCCTGA TCTGGGTTGTGG-3' at eDNA positions 2395 -24 15. GC percentage for
upstream was 55% and downstream was 60%. These prime rs were chosen not to
repli ca te the th ro mbospondin- 1 isofonn but only the larger isofonn . The la rger TSP
isoform 's seque nce was obtained from a eDNA library constructed from human
endotheli al cell mRNA (2 19). Sequence data were not avai lable to detai l the location
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of introns for this gene; therefore, the primers were positioned over a large area of
protein coding region in an effort to include any intron region.
The PCR cycles and temperatures for thrombospondin were 94°C for 60 s for
denaturing, then 59.2°C for 30 s for annealing, and 72°C for 90s for extension and
repeated for 35 cycles, then four cycles with a 4-min extension ti me.

Leukemia rnhibitory Factor Prime r
a nd PC R Co nditions
A leukemia inhibitory factor gene specific primer set was generated by Operon.
These primers were 20 bases in length with upstream
5'-TGGAAACATGGGGCGGGGAG-3' at eDNA positions 2500-2520 and downstream
5'-GCGTGGAAGGGCGGGAAGTC-3' at eDNA positions 3386-3406. GC percen tage
was 65% for upstream and 70% for downstream. These primers were chosen from
different exons with a 694 base pair intron separating them . This would ensure
detection of PCR products from genomic DNA.
The PCR cycles a nd temperatures were 94°C for 60s for denaturing, then 64°C
for 30 s fo r annealing and 72"C for 60s fo r extension, repeated 35 cycles and then two
cycles wi th a 2-m in extension tim e.

G lycerald ehydc-3- Ph osphate Dehydrogenase
Prim er and PC R Conditions
In order to permit semiquantitative analysis, primers recognizing the eDNA
encodin g glycera ldehyde 3-phosphatedehydrogenase (G APDH ) were included in the
PCR react ions (92). GAPDI-1 is an enzyme involved in the glycolysis pathway of
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glucose metabolism. GAPDH catalyzes the first energy producing step in glycolysis
leading to the formation of a molecule of ATP and the phosphorolation of 0glyceraldehyde 3-phosphate to 3-phosphoglyceroyl phosphate (220). GAPDH is an
exce ll ent housekeeping gene, especia lly when the cells are cultured under hypoxic
conditions. Glycolysis during hypoxia is the main source the cell has for energy
production and gl ucose in the available energy source in the media. GAPDH is
expressed during hypoxic conditions and normoxic condition because of the constant
requirement for the enzyme.
Three gene-specific primer sets for GAPDH were used. The first set of primers
was synthesized by Gibco BRL and was used with the VEGF and IL -8 primers. These
primers were 20 bases in length wi th upstream 5'-ATCCCA TCACCATCTTCCAG-3' at
eDNA positions 275-295 and downstream 5'-GGGGCCATCCACAGTCTTCT-3' at
eDNA positions 594-614. GC percentage was 50% for upstream and 60% for
downstream . This primer set produced a 25 7 base pair product with an optimum
annea ling tempe rature at 57"C.
The second set ofGAPDH primers was synthesized by Operon. These were
used with the midkine primers. Thi s new set was needed because the first set of
primers annea led to the midkine primers, which removed both sets of primers from the
PCR reaction . These primers were 20 bases in length with upstream 5'TCTGCCCCCTCTGCTGA TGC-3' at eDNA posi tions 424-444 a nd downstream 5'CCACCACCCTGTTGCTGTAG-3' at eDNA positions 997-1017. GC percentage was
65% lor upstream a nd 60% for downstream . Thi s primer set produced a 6 13 base pair
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PCR products with an optimum annealing temperature at 58.5"C.
The third set ofGAPDH primers was a mi xture of the first two sets. These were
used with TSP and LIF primers. The upstream primer was the same upstream as the
primer from the first set at eDNA positions 275 -295 . The downstream primer was the
downstream primer from the second set of eDNA positions 997-1017. This
combinati on of primers produced a 762 base pairs PCR product at an optimum
annea ling temperature of58. 1°C. It was necessary to create this new combination due
to the primer-primer annealing that occurred with other primers from the origina l two
sets. All three combi nations of these primer sets produced PCR products that had
overlapping regions and very had similar annea ling temperatures.
PCR temperatures and cycling conditions for all three GAPDH primer sets were
the same as the growth factor primer sets they were used with , and were well within the
conditions needed for the GAPDH primers.

Agarose Gel Electrophoresis and Gel Ana lyses
T he PCR products were separated by submarine electrophoresis using 2% (w/v)
agarose ge ls a nd a previously described method (22 1). The gel size was 120 X 125 X 5
mm with 12 wells in a Horizonta l Electrophoresis Model A4 Gel Apparatus (Owl
Scientilic Plastics, Inc., Cambrid ge, MA ). T he agarose was a 50:50 mi xture o f hi gh
melt and low melt agarose. The e lectrophores is bu ffe r was Tris-acetic aci d-ETDA
fTAE) . The gel was dry- loaded prior to submersion into the gel apparatus. The dry
load procedure ensured that the entire 50 .ul PCR reaction so lution was pi petted into an
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empty well in the geL The PCR products were mixed with 8 ,ul of bromophenol blue
and glycerol DNA loading buffer before loading the geL After the wells were loaded,
including one containing a DNA base ladder marker, the gel was placed in the
electrophoresis apparatus and buffer was added to the top of the gel without allowing
the buffer to enter the wells. An electrical current was applied for 5 min to move the
DNA and dye into the agarose, and then buffer was added to cover the gel completely.
The electrical current of 1V/cm 2 was reapplied for approximately 2 h from a Bio Rad
Model 3000xi, computer controlled Electrophoresis Power Supply (Bio Rad
Laboratories, Inc., Richmond, CA).
After DNA separation, the gel was stained with 100 ,ug/ml ethidium bromide in
T AE buffer for 30 min, then destained until viewable on an UV screen. The gel was
photographed, and analyzed by densitometry. The ge l was scanned by a DocuGel

rv

(Scanalytics, Billerica, MA) and stored on a computer disk. The scan was quantified
with the Zero Scan software program (Scanalytics).
After the gels with the PCR products from primers were scanned, the raw
density for each of the bands was divided by the raw density value for the GAPDH band
from the same PCR reaction (retinoic acid treatment). This was converted to percent of
the con trol , the zero dose value, and graphed. These va lues were from single samples
and could not be tested statisticall y but were used to indicate trends that might explain
the result s seen during the ce ll counts. All of the results were expressed as ratios of the
intensity of the band of the growth factor genes to the intensity of the band used as the
standard , GAPDH. This procedure assumed a constant expression of the GAPDH gene
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product, allowing corrections for variations in pi petting and gel loading. Finally, the
ratio of band intensities was expressed as the percentage of the control band, with thi s
being 100% .
No stati stical testing was conducted for the mRNA samples because these
samples were developed from single samples.

Procedure for Identification of RT-PCR
Products by Sequencing
The eDNA produced by the RT-PCR procedures was sequenced to confirm that
the primers designed for VEGF, midkine, IL-8 , TSP, and UF produced a eDNA
fragment from the m.RNA for that particular gene. After the PCR materials had been
sepa rated on a 2% agarose gel and scanned, the band of eDNA was cut from the gel and
placed in a microcentrifuge tube. Then, 300 pl ofTE buffer (IOmM Tris-CI , I mM
EDTA, pH 8.0) was added, the agarose melted at 65°C, and the tube vortex.ed until
homogeneous. After th is, 500 pl of water-saturated phenol was added and mixed until
homogeneou s. The tube was centrifuged at 13,000 rpm for 2 min . The aq ueous layer
was removed and placed in a clean tube and extracted with 500 pl of
phenol:chloroform:isoamyl a lcohol (25 :24 : I), vortexed for I min , and centrifuged at
13,000 rpm for 2 min. The aqueous layer was removed and placed in a fres h tube, then
I 5 p i of 5 M NaCI was added a nd mixed . One ml of isopropyl alcohol was added and
the tube was placed in a -20"C freezer for 20 min , then centrifuged at 13,000 rpm for 10
min. The supernatant was aspirated . The pellet was resuspended in I 00 pl of I SO

111 1

NaCI , followed by the addition of250 pi of 100% ethanol and mi xed . The tube was
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placed in a -20°C freezer for 20 min, then centrifuged for 10 min at 13,000 rpm. The
supernatant was removed and the pellet was rinsed once with I ml of ice-cold 70%
ethanol, then centrifuged briefly to pellet. The ethanol was removed by aspiration and
the pellet was air dried. The pellet was di ssolved in 50 ,ul ofTE buffer. The
absorbance of a 10 ,ul sample of the solution was measured on the spectrophotometer
(Shimadzu) at 260 and 280 nm to determine the eDNA concentration. Two ,ul of
sampl e was loaded on to a small 2% agarose gel and separated for I h and then strained
as previously described to determine if the sample produced a single band of the correct
size. Once the purity of the eDNA fragment was determined, a sample was sequenced
by the Utah State University, Biotechnology Center, Service Laboratory using the same
primers as used for the PCR procedure. The eDNA sequence was compared to al l
known sequences in GenBank to determine if this sequence matched the growth factor
that the primers were designed to detect.

Protein Analyses of Conditioned
Media, Justification
Enzyme- linked immunoassays (ELISA) were used to determine the amounts of
VEGF and IL-8 in samples of conditioned media removed from the tumor cells. This
was undertaken to determine the effects of retinoic acid treatments on the growt h factor
protein express ion. ELI SAs were not commercia lly avai lable for midkine, TSP or LIF
!,>rowth factors.
Express ion of growth factor mRNA is not directly proportional to the total
amount of growth factor proteins in the conditioned media . The amount of mRNA in
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the cells was determined at a single time point, but the protein secreted into the media
had accumul ated for 24 h. There are many influences on mRNA half-life and
translation of mRNA. There also are influences on the processing and secretion of the
protein after mR NA translation. There has been some di sc ussion ofretinoic acids
affecting the cell 's ability to secrete proteins (184 ). Therefore, the level of protein for
VEGF and IL-8 were determined in the conditioned media.

VEGF ELISA
A CYT Elisa kit (CYT Immune Sciences, Inc., College Park, MD) was used for
the VEGF quantification. This kit had a sensitivity of 12.5 pg/ml and a range of
detection of 12.5 pg/ml to 2000 pg/ml w ith <0.5% cross-reactivity to other cytokines.
T hi s kit was a sandwich-type assay which measures all free isofonns of VEGF. Each
plate consisted of96 wells, which allowed for duplicate sets of VEGF standards and
triplicate of each samp le. One plate was used to analyze the condition media from the
three retinoic acid treatments of one tumor ce ll type. Each sample of conditio ned
media was diluted I: 10 with fresh MEM-EBSS media. Procedures from the
manufacturer were followed , except the plate was read at 490 nm in stead of 492 nm on
a Bio-Rad Microplate Reader Model 450 (B io Rad Laboratories, Inc., Richmond , CA ).
The triplicate va lues from each of the samp les were averaged. The two values
from each standard were averaged, and then a polynomia l regression equation was
developed by the use of the Statview stati stical software (Abacus Co ncepts, Inc .,
Berkeley CA). T hi s eq uat ion was utilized fo r the mathematic determinations of the
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sample concentrations.

IL-8 ELISA
A Pelikine Compact ELI SA kit (Central Laboratory of the Netherlands Red
Cross Blood Transfusion Service, Amsterdam, Netherlands) was used to quantify the
lL-8 protein concentrations in the conditioned media. This kit was a sandwich-type
assay using a monoclonal, antihuman, lL-8 antibody. The sensitivity of the kit was 1-8
pgfml depending on the incubation procedure used. T he plate layout and dilution of
samples were the same as used with the VEGF ELISA's. The standard curve was from
I to 240 pglml. Procedures for the ELISAs were as directed by the manufacturer and
the plates were read at 450 nm with a BioTEK Microplate Autoreader (Bio-Tek
Instruments, Winooski, VT). T he IL-8 concentrations were calculated using the same
method as the VEGF ELISA's.

Heparin and Endothelial Cell
Prolife ration, Justification

T he effect of sodium heparin treatment on endothelial cell proliferation when
c ultured with a ll-trans-retinoic acid conditioned media from DU- 145 ce ll s was
investigated. Thi s experiment was to determine if low doses of heparin increased
endothelia l ce ll proliferation and if heparin at a hi gh dose could inhibit the endothelial
ce ll pro liferation. Thi s was based on the hypothesi s that heparin aids the growth fa ctors
in binding to the receptors on the endothe lial cells, and that at hi gher conce ntrations the
heparin may competit ively inhibit growth facto r binding of the receptor ( 154)
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Heparin and Endothelial Cell
Proliferation Procedures
This expe riment was conducted using the DU-145 prostate cell s and all-transretino ic acid at three doses, with a zero dose of retinoic acid as a control. The retinoic
ac id concentrations were 0.00 I, 0.0 I, and I jiM Conditioned media was produced , as
previously described. Endothe lial cells were plated in 24 wells plates, as previously
described. After 2 h the I 0% CS medium was removed and an initial count was
determined from six well s, a nd then I ml of conditioned media was added to 20 well s
for each retinoic acid treatment and control s. Twenty additional wel ls were treated wi th
nonconditioned, serum-free media. Each set of wells was treated by the addition of
sodium hepari n at 0, 10, 100, or 1000 jig/mi. There were six well s fo r each retinoic
acid concentration, the control , and nonserum media, at each concentration of hepari n.
The plates were

gT0\'111

for 48 h and e lectronica lly counted, as previously described.

There were several other growth factors that were examined as possible
angioge nic activity. The mRNA expression after treatment with retinoic acids of th e
tum or cell s was studi ed. T he growth factors were determ ined not to be of s uffic ient
importance to study further The information conce rning these growth factors is located
in Appendix A.
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RESULTS

Cytotoxicity of Retinoic Acids to Tumor Cells
Total Cell Counts-Untreated. The cell counts per fl ask or we ll between trials
were variable. Cell counts of the control cells in the all-trans-retinoic acid trial with U373 cells had a mean of 18,845 cells/count and a range of 18,411 to 20,741 cell s/count.
Absolute numbers of cells/well were not calculated since the cell counts were directly
proportional to that in each well. The 9-cis-retinoic ac id trial had control cell counts
with a mean of 10,778 cells/count and a range of9,095 to 12,478 cells/count. The 13cis-retinoic acid trial had a mean of25,680 cell s/count for controls and a range of
24,644 to 27,505 cells/count.
The DU-145 cells also had vari abil ity trial to trial. The control ce ll counts for
the all-trans-retinoic aci d trial with the DU-145 cells had a mean was 2 1,898
cel ls/count and a range of 19,292 to 23,39 1 cell s/count. The control cell s in the 9-cisretinoic acid trial had a mean 11 329 cells/count and range of I 0,43 1 to 12, 145
ce ll s/count. T he 13-cis-reti no ic acid trial had a mean of 13,3 42 ce ll s/count for controls
and a range of 12,445 to 14,223 cells/count.
The control cell co unts of the all-lrans-retinoic acid trial with TCCSUP cell s
had a mean of 3 1,253 cell s/count with a range of 25,740 to 34,568 cell s/count. The
co ntrol s in the 9-cJs-reti noic acid trial had a mean of 2 1, 149 cells/cou nt with a range of
19,390 to 25 ,057 ce ll s/count. The 13-cis-retinoic acid trial control ce ll counts had a
mean of 32,816 ce ll s/count and a range of 29,822 to 3 8,659 cell s/count.
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U-373 Cells: Cytotox icity with the Retinoic Acids. No cytotoxicity, as
detennined by reduction in ce ll numbers, was observed for any of the retin oic ac ids at
concentrations less than 0.0 I f/M , but vari able results were found at concentrations
between 0.0 I and I00

fiM

their numbers until 100

(Fig. I). Cultures wi th all-trans-retinoic ac id maintained

fiM . when

vast decreases in cel l co unts were observed. In

comparison, w ith 9-cis-retinoi c acid there was a sli ght increase in ce ll counts from
0.00 I to 0. 1 pM. At concentrati ons hi gher than 0.1 fiM , the cell counts decreased . T hi s
effect was I00-fold lower than the all-trans-retinoic acid trial. The 13-cis-retinoic acid
appeared to be I 0-fold more toxic than the 9-cis-reti noic acid treatm ent. T he 13-cisretinoic acid resulted in a loss of cells at 0.0 I
above

O.OifiM . with

fiM .

the largest reductions at 100

Th is continued for a ll concentrations

fiM .

OlJ-145 Cells: Cytotoxicity with Reti noic Acids. Variable results in the ce ll
cou nts for the DU -145 cell s were observed (Fig. 2). The all-trans-retinoic acid
treatme nl cell counts had a sli ght decrease in the three lowest concentrations and the
I00 f/M dose. The 9-cis-reti noi c acid cell counts had a dramatic decrease in the ce ll
counts at greater than 0.0 I f'M . The 13-cis-retino ic acid ce ll counts had the largest
reducti on in the cell counts at I 00

fiM .

TCCS rP Cells: Cytotox icity with Retinoic Acids. No cytotoxicity, as
determined by lost of ce ll numbers, was obse rved for a ny of the retinoic acids at
conce ntrations k ss tha n 10 f'M (Fig. 3). The ce ll s treated with all-truns- retino ic ac id had
the largest decrease in ce ll co unts at 10 and 100

fiM .

T he 9-cis- and 13-cls-retinoic acids
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Fig. 1. Electronically counted glioblastoma (U-373) cells, after 24 h growth under
hypoxic conditions in the presence of log doses of all-trans-, 9-cis-, or 13-c ts-retinoic
ac ids. Cells were grown in MEM-EBSS media without serum. Six wells of cells were
used for each treatment. Cell counts are expressed as the percent of the control cell
counts. Control samples had no retinoic acid, but were exposed to hypoxic conditions.
Error bars represent standard error of the mean for eac h treatment.
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Fig. 2. Electronically counted prostate adenocarcinoma (DU-145) cells, after 24 h
growth under hypoxic cond itions in the presence of log doses of all-lrans-, 9-cis-, or 13cis-retinoic acids. Cells were grown in MEM-EBSS media without serum. Six well s of
ce lls were used fo r each treatment. Cell counts are expressed as the percent of control
ce ll counts. Control samples had no reti noic acid, but were exposed to hypoxic
conditions. Error bars represent standard error of the mean for each treatment.
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Fig. 3. Electronically counted bladder transitional cell carcinoma (TCCSUP) cells,
after 24 h growth under hypoxic condi tions in the presence of log doses of all-trans-, 9cis-, or 13-cis -retinoic acids. Cell s were grown in MEM-EBSS media without serum .
Six well s of cell s were used for each treatment. Cell counts are expressed as the percent
of control cell counts. Control samples had no retinoic acid, but were exposed to
hypox ic conditions. Error bars represent standa rd error of the mean for each treatment.
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treatments did not affect the ce ll counts until I00 pM . The 9-cis-retinoic acid cell
counts were more variable, but did not reveal a definite trend_

E ndoth elial Cell Proliferation with
Conditioned Media-Timed Studies
DU-1 45 Cell Condition ed Media. The first trial using DU-145 conditioned
media included treatment of endothelial cells with nonserum media, 10% CS, 10%
FBS, and conditioned media without retinoic acid (Fig_4). Cell proliferation continued
for 48 h. In addition, cells were maintained in cultures and continued to grow for up to
72 h. This included cultures grown in conditioned med ia_There was no difference in
ce ll counts between nonserum and condit ioned media treatments. Beginning with the
32-h sam pl es, the nonserum and conditioned media treated cell s proliferated at
different rates than the two serum containing media. In addition , cell proliferation was
not limited due to cell density, as shown by a 7.7-fold increase in the cell counts for
I0% FBS. This compares to the 1.37-fold increase in nonserum cell s.
The second trial , using DU-145 cell in conditioned media, investigated the
growth effects of conditioned med ia with and without retinoic acid (Fig. 5). All of the
sa mples had an increase in cell counts after 8 h and this continued until the 40- h
samples. All of the 48-h counts were sli ghtl y lower than the 40-h counts except those
of the I0% CS. At the last time point , count s among the treatment s were more
va ri ab le, demonstrating an effect of the different treatments. At the 48-h time point the
10% CS samples had a 3-fold increase over the initial count and were still increasing,
indicating healthy endothelial cell s were used. T he sma llest increase in cell cou nts,

101

35000

--o· -{]-· -

30000

25000

"'c

::1
0

···-{;.···

-----

cond.media
no serum
10"/oCS
10"/o FBS

I

It

I

,'~

I

///_.i.l
20000

u

,•"

-.; 15000

. ~/

,','

u

,''

10000

,......

_/_.------":.•• ---···..IJ.··········4

5000

•

111

0 h

Sh

.4

'

n----a~~---····e=·:···~---=::::g::::::~""

D

0
16 h

24 h

32h

40h

48h

72 h

Time

Fig. 4. Electronically counted endothelial cell s that were grown through 72 h in
nonserum , 10% calf serum , 10% feta l bovine serum, or conditioned media . The
conditioned media were prepared by 24 h exposure ofMEM-EBSS media to DU- 145,
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a 2-fo ld increase over the initial count, was the zero dose conditioned medium .
U-373 Cell Conditioned Media. Proliferation of the U-373 cells continued
throughout the 48-h observation period for all treatments (Fig. 6). The I 0% FBS (not
displayed in Fig. 6) and I0% CS cell counts increased 6.38- and 3.24-fold , respectively,
over the initial seeding count This indicated healthy endothelial cells were used at the
start of the trial. The zero dose control and the nonserum treatments had similar
growths and counts were very close at 48 h, indicating that the conditioned media was
still adequate for cell growth. The 0.1

flM

samples matched the zero dose grO\vth . The

0.00 I

flM

treatment resulted in cell counts that were greater than the zero dose control.

At I0

flM

there was a flattening of growth curve at 24 h, with a sli ghtl y increased cell

count at 48 h. Thus, the endothelial cells were affected by the varied retinoic acid
treatments. In addition , these cells were still replicating after 48 h of culture with the
conditioned media.
TCCSUP Cell Conditioned Media. Proliferation of the TCCSUP cells
continued throughout the 48 h observation period for all treatments (Fig. 7). In thi s
tri al, 10% FBS (not di splayed in Fig. 7) and 10% CS control s increased cell counts
6.84- and 2. 11-fold, respectively, which was very close to the cell proliferation seen in
the DU-145 and U-373 studies. The nonserum_treated cells had a I 5-fold increase in
ce ll count s, which was sli ght ly more than the 1.39-fold increase see n with the zero dose
control. All of the ce ll cou nts from cond itioned media sampl es dec li ned at the 24 -h
point without large standard errors. The 0.001 f.JM treatment increased cell counts by
I 12- fold by 48 h. the 0. 1 flM cell counts increased 1.39-fold, a result similar to that of
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Fig. 6. Electronically counted endotheli al cells that were grown through 48 h in
nonserum , 10% calf serum, or cond itioned media. The conditioned media were
prepared by 24 h exposure of MEM-EBSS media to U-3 73, gli oblastoma cell s, under
hypoxic conditions and 0, 0.00 1, 0. 1, or 10 f/M ofa ll-/rans-retinoic acid . Cell s were
e lectronically cou nted. Six we ll s of cell s were used for each treatment. Error bars
represen t standard error of the mea n for each treatment.
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the zero dose control. The I 0 !JM sample had a 1.2-fold increase at48 h. Both the I 0
and 0.00 I IJM treatments had ce ll counts that leveled off after 40 h. The results of each
treatment indicated that the cells were sti ll replicating at 48 h.

Endothelial Cell Proliferation with
Retinoic Acids
The a ll-trans-retinoic acid had no detectable effect on endothelia l cell
proliferation until the concentration reached 0.1 IJM (Fig. 8). After that, th e three
highest concentrations caused a significant decrease in cell counts (P<0.05) when
compared to the controls. In addition, the I 00 IJM treatment differed from the I and I0
IJM

treatm ents (P<O.OS). Based on cell counts, some cell proliferation was observed at

eac h all -tra ns- retinoic acid concentration.
T he 9-c is-reti noic acid treatment reduced the cell counts at lower concentrations
than the all-trans-retinoic acid (Fig. 8). There was a significant reduction in ce ll counts
at concentrations~ 0.01 IJM (P<O.OS). Base on cell counts some cell proliferation was
observed at a ll 9-cls-retinoic acid concentrations.
The I J-c is-retinoic acid treatments caused a fairly linear reduction in cell counts
between 0.001 and I JiM (Fi g. 8). AI 10 IJM, there was a more dramatic decrease in cell
counts. Ce ll counts we re significantly decreased at

concentration s ~

I IJM . The cell

co unts at I to I 00 pM were less tha n the numbers of cell s seeded to the plate at the
begi nning of treatment.
See appendix B for the tables contai nin g the statistical data from this
experim ent.

107

120

..

100

0

c0
u

80
\
\

80

\

\
\

c"'

\

,.
0

u

\

\\

40

.......

\
----()--

20

~d

_,/"

h'"c

all-trans

-·--{}-··· 9-cis
-- ts- · 13 cis

0 ~~----~~----.-----r-----r-----~-----r----~---

Control

0.0001

0 .001

0 .01

0.1

10

100

Concentration (uM)

Fig. 8. Electronjcally counted endothelia l cell growth after 48 h in the presence of log
doses of all-trans-, 9-cls-, or 13-cis- ret inoic acids. Cell counts are expressed as a
percent of control. Control sampl es had no retinoi c acid but were exposed to hypoxic
conditions. Error bars represent standard error of the mean for each treatment. Three
replicates, with four wells of ce ll s each, were counted for each treatment. Letters
indicate significant difference from contro ls (P<0.05); different letters are s ignifi cant ly
differen t from each other (P<0.05). Significance was determined by the Mann-Whitney
U-Test.
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Endothelial Cell Proliferation with
Conditioned Media and Retinoic Acid
U-373 Cells: All-trans-retinoic acid. Endothelial cell counts produced after
exposure to U-373 conditioned media were both greater than and less than control at
different retinoic acid concentrations (Fig. 9). When exposed to endothelial cells,
conditioned media produced with 0.0 I JiM caused a significant increase in cell counts
of almost 14% (P<0.05). The next lower concentration, 0.00 I f1M, was nearly
significant with aU of I (as compared to aU ofO for significance at P<O.OS) and had a
7% increase in cell count. The 0.1 and I JiM conditioni ng treatments were statistica lly
the same as the control. The 10 and 100 JiM conditioning treatment sample counts were
significantly less than the control (P<0.05).
U-373 Cells: 9-cis-retinoic acid. This retinoic acid produced increases in cell
counts very similar to the all-lrans-retinoic acid trial (Fig. 9). There was a significant
increase in cell counts (P<0.05) at 0.0001 JiM, 15 .86% above the control count.
Increases of > 8% for the cell counts at 0.00 I, 0.0 I, and 0. 1 f.JM were present. The 0.0 I
f1M ce ll count was significantly increased (P<O.OS); however, 0.00 1 and 0. 1 JiM were

increased numerically but were not statistically different. Retinoic acid at 10 and 100
f1M decreased the cell counts and at 10 f1M the cell counts were significantly decreased

(P<0.05).
U-373 Ce lls: 13-cis-retinoic acid. This retinoic acid produced a reduction in
all cel l counts at all concentrations and the reduction was significant ly different from
the contro l from 0. 1 to I 00 f.JM (P<0.05) (Fig. 9). The ce ll counts for each hi gher
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concentration of retinoic acid after 0.1 J.lM caused a decrease in cell counts that was
signi ficantly different from the previous concentration (P<0.05).
DU-145 Cells: All-trans-retinoic acid. The all-trans-retinoic acid caused
significant increases in cell counts at 0. 1 and IJ.lM , which had a 10.9 and 5.5% increase
over the control, respectively (P<0.05) (Fig. 10). The 0.0001, 0.001, and O.OIJ.lM had 4,
4.9, and 8.2% increases in cell counts, respectively, even though these counts were not
significant at P<0.05 . At 10 J.lM there was a sli ght decrease below the control values.
The I 00 J.lM concentration produced a large reduction in cell counts, to 23.5% of
control, and was significantly different from control (P<0.05).
DU-145 Cells: 9-cis-retinoic acid. Both increases and decreases in cel l counts
were observed at differing concentrations of9-cis-retinoic acid (Fig. I 0). Large
increases in cell counts at 0.001 and 0.01 J.lM were significant (P<0.05). The 0.001 JiM
treatment caused a 17.8% increase and 0.01 JiM had a 13 .9% increase. An increased
cel l count of 8.9% occurred at 0.0001 JiM . but thi s count was not significantl y different
at P<0.05. The 0. 1, 1, and 10 JiM samples did not differ from the controls. Only at I 00
JiM was the cell count greatly reduced. This count was significantly less than controls

at P<0.05. In addition , very little cell growth had occurred after the initial seeding of
the plate.
DU-145 Cells: 13-cis-retinoic acid. All cell counts in thi s tria l were
numerically below control s (Fig. I0). However, only 0.00 I and I 00 JiM sign ificantl y
reduced the cell counts (P<O 05) The 0.001 JiM sampl es had similar numerica l
decreases as the adjacent concentrations, but the standard error was sma ll enough that it
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Fig. 9. Electronically counted endothelia l ce ll growth after 48 h in the presence of
conditioned medi a from gliobl astoma cell s (U-373). T he conditioned med ia were
pre pa red with log doses o f all-trans-, 9-cis-, or 13-cis-retinoic acids and 24 h growth
unde r hypoxic cond itions. Ce ll counts are expressed as a percent of control s. Control
sampl es had no retinoic acid but were exposed to hypoxic conditions. T hree replicates,
with four well s of cell s each, were co unted fo r each treatment. Error bars represent
standa rd error of the means. Letters indi cate signi fica nt difference fro m controls
(P<0 .05); different lette rs are significantl y different from each other (P<0.05).
Significance was dete rmined with the Mann-Whitney U-Test.

Ill
was significantly less than controls.

TCCSUP Cells: All-trans-retinoic acid. As seen in the 48-h timed study,
endothelial cells exposed to conditioned media from this cell line were greatly inhibited
in their ability to proliferate. In all three trials with the retinoic acids, the nonserum ,
I0% CS, and 10% FBS controls had good proliferation. This demonstrated that the
endothelial cells were fully capable of proliferation, and the culturing conditions and
media were adequate to support the cells. All of the conditioned media from the
TCCSUP cell s resulted in suppressed endothelial cell proliferation, when compared to
nonconditioned controls. The all-lrans-retinoic acid did not cause a significant
reduction in cell counts until 100 JiM (P<0.05 ) (Fig. II).
TCCSUP Cells: 9-cis-retinoic acid. Three 9-cis-retinoic acid treatments had
significant reductions in cell counts (P<0.05) (Fig. II). These concentrations were
0.0 I, 10, and 100 JiM, with only I00 f1M having a large reduction in cell counts.
However, the 0.0 I and I 0 JiM samples were numerically similar to the adjacent doses.
The cell count s at 0.01 and 10 JiM also were significantly different from 100 JiM
(P<O.OS ).
TCCSUP Cells: 13-cis-retinoic acid. There were no significant differences in
ce ll counts for any treatment (Fig. II). The cell counts from the 13-cis-retinoic acid
conditi oned medi a did not indicate any trend in reducing or increasin g the ce ll counts.
See Appe ndi x B for the tables containing the statistical data from these
ex periments.
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Fig. I0. Electronically counted endothelial cel l growth after 48 h in the presence of
conditioned media from prostate adenocarcinoma cells (DU-145). The conditioned
media were prepared with log doses of all -trans-, 9-cis-, or 13-cis-retinoic acids and 24
h of growth under hypoxic conditions. Cell counts are ex pressed as a pe rcent of
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Fig. II . Electronical ly counted endothelial cell growth after 48 h in the presence of
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Lactate Analysis
The hypoxic sam ples from all three tumor cel l lines had substantial increases in
their lactate concentrations in the media, when compared to the untreated, normoxic
samples from their respective trial s (Figs. 12- 14). There were no apparent dose
responsive changes in lactate concentrations for each of the tumor cell lines, except for
the all-trans-retinoic acid-treated DU-145 cells. This cell line had increasi ng
concentrations of lactic acid in the media for all doses of retinoic acid and increased
with the greater concentrations. The normoxic control lactate concentrations averaged
22.5, 34.6, and 33 .7 mg/dl , while the hypoxic controls averaged 60.3, 73.8, and 103.5
mg/dl , for the DU-145, U-3 73, and TCCSUP cells, respectivel y.

Detection ofVEGF mRNA from Treated
Tumor Cells
Samples from 100 J.IM retinoic acid treatments were not used in the mRNA or
ELISA procedures. The total RNAs were initially separated from the 100 J.IM treated
sampl es and they were used in the RT-PCR, but with the ext reme loss of cell s from the
retinoic acid treatment and hypoxic conditions, inadequate quantities of tota l RNA for
the reverse-transcription reaction were ava ilable.
VEGF RT-PCR produced two VEGF isoforrns. The shorter form was seen at
approximately 4 70 bp of DNA and was found 10 be the sequence for the 12 1 amino
acid isoform, when DNA recovered from the agarose gels was sequenced and compared
10

all known sequences in the GenBank. This sequence had a 99.228% imilarity to a

known hum an VEG F 121 sequence which included exons 1 and 3.
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Fig. 12 . Lactate concentrations measured in conditioned media from glioblastoma cells
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under hypoxic conditions and log doses of all-trans-, 9-cis-, or 13-c rs-retinoic ac ids.
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The longer form , which on many gels appeared as two very closel y separated
bands, was seq ue nced. These results, when compared to a known human VEGF
sequence, had a similarity of93.962% and covered exons 4 and 7. The sequence was
identified as human VEGF 165. Whenever thi s isomer produced a separation into two
bands on the agarose gels, the bands were grouped as one due to the inability of the
scanner to separate bands that close. This apparent dual -band was one isoform when
seq uenced.
The GAPDH primer, used with the VEGF PCR, created a band of257 bp.
When sequenced, it had a I 00% similari ty to the human GAPDH gene.

VEGF of U-373 Cells

The gel scans from the three retinoic acid treatments had both increased and
decreased VEGF expression ofboth isoforms (Figs. 15, 16). The 13-cis-retinoic acid
samples had a decreased production of both VEGF isoforms with increasing retinoic
acid concentrations. The VEGF 165 band was expressed stronger than the VEGF 121 form
in all retinoic acid treatments of the U-373 cell s. The all-trans- and 9-cis-retinoic acid
treatments had mRNAs expression that was generally higher for each retinoic acid
concentration than the controls . The expression ofVEGF 121 peaked with 0 .001 to 0.01
J1 M ofa ll-trans-retinoic acid and at 0.0001 J1M for VEGF,"'. The 9-cis-retinoic acid

samples peaked at 0.00 I J1M for VEGF 12 1 and 0.000 I J1M for VEGF 165 .

VEGF of Oll-145 Cells

The DU-145 cel ls produced more variation in the VEGF expression than the
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Fig. 16. Vascular endothelial growth factor isoform 12 1 (VEGF 121 } mRNA isolated
from glioblastoma cells (U-373 ) after treatment with log doses of all-trans-, 9-cis-, or
13-cis-retinoic acids. The cell s were treated unde r hypoxic conditions for 24 h. RNA
expression was determined with multiplex, RT-PCR and densitometer scanning of the
PCR product gels. VEGF expression was standardized with the GAPDH house keeping
gene, then ex pressed as the percent of nontreated contro ls.

121
U-373 MG cells. One difference between the DU- 145 and U-373 MG cells was a
decreased VEGF 16,1VEGF 121 ratio. Actuall y, the DU-145 cell s were the reverse of the
U-373 cell s, in that the VEGF 121 isoform had expressed stronger than VEGF 165 .
VEGF 121 and VEGF 165 mRNA band densities for the all-trans-retinoic acidtreated cells had little change across the doses (Figs. 17, 18). These results were found
to be repeatable in a second trial. The 9-cis-retinoic acid-induced expression was
higher at all concentrations greater than 0.000 I fJM for both isoforms, but had a large
amount of variation in the VEGF 121 . As compared to control samples, the 13-cisretinoic acid samples were generally expressed less for VEGF 121 and expressed more
for VEGF 165 •

VEGF ofTCCSUP Cells
The VEGF 165 expression in these cells was less than VEGF 121 , except in the
hypoxic samples treated with all-trans-retinoic aci d. The difference between the
isoforms' expression was minim al in all of the treatments. Also, the expression of the
VEGF 121 and VEGF 165 isoforms was generally unchanged at all retinoic acid
concentrations and did not differ between retinoic acids (Figs. 19,20).

Detection offL.-8 mRNA from Treated
Tumor Cells
The IL-8 RT-PCR produced a single band at the predicted size of374 bp. The
si ngle band wa s strongly ex pressed in compari son to GAPDH. When the sequence of
the IL-8 PCR product was compared to the sequence for the human IL-8 gene from the

122

160
140

_,~>-------4/

120

.
c

100

....0v

80

0

,','

,'

,

,,.,'

_,.

.

\

~,''

\\

.........

,'

,

o-·····\::··-D...........;;..g.<..........

-!J

'

/

0

~

...

60

~

40

{.!)

:>

---o-----o---

20

---tr-

all-trans
9-cis
13-ds

0
Control

0 .0001

0 .001

O.Ot

0.1

10

Concentration (I!M)

Fig. 17. Vascular endothelial growth factor iso form 165 (VEGF 16 s) mRNA isolated
from prostate adenocarcinoma cells (DU- 145) after treatment with log doses of all-
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GenBank, there was a 99.25, 100.00, and 98.75% match, respectively, with the first
three exons of the IL-8 gene.

Il.r-8 of U-373 Cells
The di fTerent retinoic acid treatments produced different effects on IL-8
expression (Fig. 21). The 13-cis-retinoic acid did not appear to affect the expression of
IL-8. The all-trans and 9-cis-retinoic acids produced an induction at the higher
concentrations. In this experiment the induction appeared to start at 0. 1 and I J.lM for
the all-trans and 9-cis-retinoic acids, respectively. Induction by the 9-cis-retinoic acid
was not as strong as that of the all-trans-retinoic acid, 30% and 51%, respectively.

rLr-8 of DU-145 Cells
Variable expression occurred between retinoic acids and across doses. The 13cis-retinoic acid had no effect on fL-8 expression with this cell line (Fig. 22). The 9cis-retinoic acid appeared to decrease the expression across the dose range. The all lrans-retinoic acid had an induction of [L-8 expression at I and 10 J.IM . These results

were found to be repeatable in a second trial.

lL-8 ofTCCSUP Cells
Variable expression occurred between retinoic acids and across doses. The 13cis-retinoic appeared to depress the IL-8 mRNA expression at the lowe r retinoic acid
concentration s a nd the express ion returned to va lues near the control sample at I and
10 J.lM (Fig. 23). Both the all-trans and 9-cis-retinoic acid treatments appeared to
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Fig. 21 . !nterleukin (!L-8) mRNA isolated from glioblastoma cell s (U-373) after
treatment with log doses of all-trans-, 9-cts-, or 13-cis-retinoic acids. The cells were
treated under hypoxic conditions for 24 h. RNA expression was determined wi th
multiplex, RT-PCR and densitometer canning of the PCR product gels. IL-8
expression was standardized with the GAPDH housekeeping gene, then expressed as
the percent of nontreated contro ls.
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increase the expression of the mRNA at concentrations greater than 0.0001 J.IM .

Detection of Mid kine mRNA from Treated
Tumor Cells
T he RT-PCR for the midkine mRNAs was conducted usi ng a differe nt set of
GAPDH primers. This set of primers produced a eDNA product of613 bp. When the
eDNA was sequenced and the resulting sequence was compared to the human GAPDH
gene, there was a 100% match . The new set ofGAPDH primers was used for this
experiment, because when the midkine primers were used with the original GAPDH
primers, no PCR product was produced. By analyzing the two primers with the Oli go
4.0 software program, it was revealed that one of the midkine and one of the GAPDH
primers were a nnealing and being removed from the reaction.

Mid kine of U-373 Cells
Midkine was strongly expressed in all of the samples, as compared to the
GAPDH expression. There was very little variation in midkine expression due to alltrans-retinoic acid concentrations, with all co ncentrations being sli ghtly less than
control s (Fig. 24). The 13-cis-retinoic ac id treated sampl es all had an expression of
midkine greater than the control s for a ll sa mpl es 2: 0.00 I f.iM. In the U-373 ce ll s, a ll of
the 9-c is-retinoic treated samples had midkine expression that was less tha n the
control s, with no dose-responsive trend .
The RT-PCR results had a strong ex pression of midkine in a ll three tumor ce ll
types, with similar amounts of expression in hypoxic and normoxic samples. T he re was
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as the percen t of non treated controls.
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Fig. 24. Midkine mRNA isolated from glioblastoma cells (U-373) after treatment with
log doses of a ll -tran.~-, 9-cis-, or 13-cis-retinoic acids. The ce ll s were treated under
hypoxic conditi ons for 24 h. RNA expression was determ ined with multipl ex, RT-PCR
and densitometer scannin g of the PCR product gels. Midk ine expression was
standardized with the GAPD H housekeeping gene, then expressed as the percent of
nontreated controls.
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no ind ication that hypoxia had an inducing effect on midkine expression.

MidkineofD - 145Cells
All three retinoic acid treatments had strong expression ofmidkine. T he a ll -

trans-retinoic acid samples had very little change from control at any dose (Fig. 25).
The 9-c is-reti noic acid caused increased expression at 0.001 f1M and decreased at
~

0.0 I f1M . The 13-cis-retinoic acid samples had an increase in midkine ex pression at

~

0.0 I

flM .

Mid kine ofTCCSUP Cells
The treatments of these cell s resulted in less variation in midkine ex press ion ,
when compared to the other two tumor cell lines. All three of the retinoic acid
isofonns caused expression approximately eq ual to or slightly greater than the controls
(Fig. 26). The 9-cis-retinoic acid treatment of I 0

flM

had a increased midkine

expression.

Detection ofTSP mRNA from Treated
Tumor Cells
The expression of the TSP mR NAs was very limited when the sa me number of
PCR cyc les was used as with the three previous growth factors. There fore, the number
of cyc les was increased fro m 30 to 35 wi th a 90s extension tim e. In addition , fou r 4min extensions were added to the end of the 35 cycles. T he longer extension times were
used due to the length of the TSP product, which was 1260 bp. When the RT-PCR
product ofTSP

\\"US

sequenced and compared to the full length mRNA for human TSP,
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Fig. 25 . Midkine m.RNA isolated from prostate adenocarcinoma cell s (D U-145) after
treatment with log doses of all-trans-, 9-cis-, or 13-cis-retinoic acids. The ce ll s were
treated under hypoxic conditions for 24 h. RNA expression was determined with
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multipl ex , RT-PC R and densitom eter scanning of the PCR product gels. Midkine
expression was standardized with the GAPDH housekeeping gene, then expressed as
the percent of nontreated control s.

135
there was a 91 . IS% match with the first 533 bp of the 5' end. Even with the changes to
the RT-PCR procedure, to increase expression, there was inadequate PCR product to
obtain accurate gel scans. Therefore, no graphs could be produced.

TSP of U-373 Cells
Thi s cell type had the least TSP expression. The control samples for the a lllrans- and 9-ci.s-retinoic acid treatments had very weak TSP bands, and lost all

evidence of expression in the retinoic acid treated sa mples. Each of the trials produced
strong bands from the GAPDH housekeeping gene, proving that the PCR reactions had
functioned properly. The 13-ci.s-retinoic acid treatments had very strong expression of
both the GAPDH gene and, in some samples, TSP. The normoxic and hypoxic controls
produced TSP bands. TSP expression in the 0.00 I and 0.0 I J.IM sam ples was strong,
but the 0. I and I J.IM samples had almost undetectable expression.

TSP of Oll-145 Cells
The DU- 145 cell s, in contrast to the other two ce ll types used, expressed the
TSP mRNA s similarly across the normoxic and hypoxic samples. This expression was
low, but detectable bands for al l-trans- and 13-cis-retinoic acid treated samples were
present. In the 9-c is-retinoic acid trial there were detectab le bands for the normoxic
co ntrol s, but abse nt or barel y detectable bands occurred with the hypoxic samples. T he
ex press ion across the dose range did not appear to differ. The only changes in band
intensi ty seemed to have been simil ar to that of the housekeeping gene, and occurred
from vari ation s in the amount ofcDNA template at the start of the PCR reaction.
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TSP ofTCCSUP Cells
T hese cells appear to express the T P mRNAs less than the DU-145 cell s and
more like the U-373 cells. All three retinoic acid trials had detectabl e TSP bands in the
nonn ox ic samples and barely vi sibl e bands in treated samples. In almost every hypoxic
sample which produced a detectable band, the sampl e a lso had the strongest expression
ofGAPDH. T his indicates that sli ghtl y more eDNA was avai lable in these lanes of the
gel.

Detection of LIF mRNA from Treated
T um or Cells
T he LIF was very difficu lt to detect from the eDNA from these tumor ce ll s. The
first series ofRT-PCRs produced a band of approxi mated ! 50 bp. Th is band, when
sequenced, ma tc hed the human CSA-1 9 gene (222). Thi s product was produced despite
a 3 bp mismatch with the LIF primers and the eDNA fo r CSA-1 9.
Due to the aberrant band that was produced, the PCR conditions for the Ll F
primers were c hanged . The an nealing temperature was increased from 61 .6"C. to 64"C.
T his increase in annea ling temperatu re was adequate to reduce the nonspec ific binding
and produce a 926 bp LI F PC R product. LJF products could only be detec ted in the
sa mples that we re not treated with retinoic acid. LI F products were onl y s lightly
detectable when using the eDNA produced from l 11g of total RNA. The LJF band was
seen onl y faintly in the normox ic sa mpl es of the U-373, 9-cis-retinoic acid trial. When a
2-jJg a liquot of total RNA was used , the LI F band was st ill undetectable . The tria ls
wi th the LIF primers were stopped, si nce LJF cou ld not be adequately detected . It was
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assumed LIF expression was insignificant in these tumor cell types. Adequate eDNA
was not recove red from the LI F gels to be sequenced for the 926 bp product; therefore ,
these primers were not verified.

Protein Analyses by ELISA
VEGF ELlSA. The VEGF concentrations increased in all of the hypoxic

samples from the U-373 cells. Retinoic acid treatments further increased the VEGF
concentrations though I pM (Fig. 27). T he 10 pM concentration of9-cis- and 13-cisretinoic acids caused a decrease in VEGF protein in the media. The all-trans-retinoic
acid treatment induced the highest media concentrations of VEGF protein, followed by
the 9-cis-reti noic acid, and the lowest was induced by the 13-cis-retinoic acid.
Although the DU-145 ce ll s had very different VEGF media concentrations than
the U-373 cells, no dose-dependent trends were observed. The all-tra ns-retinoic acid
treatments caused VEGF concentrations to be less than control values at a ll
concentrations (Fig. 28). The 9-cis-retinoic acid treated samples had VEGF
concentrations sli ghtl y greater than control at 0.000 I pM and much less than control at

2: 0. 1 pM . The 13-cis-retinoic acid treated samples had VEGF concentrations greater
than control at 0.00 1 pM and 10 pM . However, VEGF concentrations were less than
contro ls for 0.01 to I pM . Compared to the normoxic control s, the VEGF
co ncentrations increased in the hypox ic controls.
T he TCCSUP cells ' VEGF concentrations were higher for the hypoxic control s
than the normoxic ones. The VEGF concentrations were fairly constant unti I the
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Fig. 27. Vascular endothelial growth factor (VEGF) concentrations derived from
conditioned media of glioblastoma cell s (U-373 ). Protein concentrations were
determined by ELISA. Conditioned media were prepared by treatment ofMEM-EBSS
media with log doses of all-trans-, 9-cis-, or 13-cis-reti noic acids, under hypoxic
conditions for 24 h. VEGF concentrations are expressed as a percent of controls.
Con tro ls were not treated with retinoic acids, but were exposed to hypoxic condi tions
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Fig. 28. Vascular endothel ial growth factor (VEGF) derived from the conditioned
media o f prostate adenocarci noma cell s (DU- 145). Protein concentrations were
determined by ELISA. Conditioned media were prepared by treatment ofMEM-EBSS
media with log doses of all-trans-, 9-cis-, or 13-cis-retinoic acids, under hypoxic
conditions for 24 h. VEGF concentrations are expressed as a percent of contro ls.
Controls were not treated with reti noi c acids, but were exposed to hypox ic conditions.
and control s.
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retinoic acid concentration reached 0. 1 pM (Fig. 29). Concentrations ofretinoic acids
~

0. 1 I'M caused increased VEGF concentrations.
Il.r8 ELISA. fL-8 concentrations varied dramatically among the rcti noic acid

treatments. All-lrans- and 9-cis-retinoic acid caused U-373 cells to have a dramatic
decrease in LL-8 media concentrations (Fig. 30). The 13-cis-retinoic acid samples were
very consistent and remained near the control va lues. The U-373 cells produced JL-8
media concentrations from 116.1 to 2388.4 pglml among the all-/rans-retinoic acid
treatments. The highest media concentration of IL-8 , detected with the U-373 cell s,
was with 9-cis-retinoic acid, which at 10 pM had 4597.7 pglml.
Media concentrations of I.L-8 were most affected by 9-cis-retinoic acid, with the
DU-145 cell s (Fig. 31). However, the DU-145 cell s caused increased IL-8 media
concentrations with all-/rans-retinoic acid treatment of I0 pM. There was a large
increase in the IL-8 media concentrations of the 9-cis-retinoic acid

treatments ~

0.1 pM.

The 13-cis-retinoic acid samples had no change in LL-8 concentration.
The TCCSUP cells produced quite varied results in fL-8 concentrations
(F ig. 32). All samples from cells treated with :S 0.0 I pM of retinoic acid were less than
the control. All-lrans- and 13-cis-retinoi c acids at 0. 1 pM had increased IL-8
concentrations, but declined at hi gher dose. The 9-cis- retinoic acid treatm ent samples
were all below the contro l.

Endothelial Cell Proliferation with Conditioned
Media and Sodium Heparin
There was an increase in endothe lial cell proliferation at 10 pglml of heparin for
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Fig. 29. Vascular endothelial growth factor (VEGF) derived from the conditioned
media of bladder transitiona l carcinoma ce lls (TCCSUP). Protein concentrations were
determined by ELISA. Conditioned media were prepared by treatment ofMEM-EBSS
med ia with log doses ofall-1rans-, 9-cis-, or 13-cis-retinoic acids, under hypox ic
conditions for 24 h. VEGF concentrations are expressed as a percent of controls.
Contro ls were not treated with retin oic acids, but were exposed to hypoxic cond iti ons.
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Fig. 30. !nterleukin-8 (!L-8) derived from the conditioned media of glioblastoma cell s
(U -373). Prote in concentrations were determ ined by ELISA. Conditioned media were
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Fig. 3 1. lnterle ukin-8 (!L-8) derived from the conditioned media of prostate
adenocarcinoma cells (DU- 145). Protein concentrations were determined by ELI SA.
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all -trans- , 9-cis-, or 13-cis-retinoic acids, under hypoxic conditions for 24 h. lL-8
concentrations are expressed as a percent of control s. Controls were not treated with
retinoic acids, but were exposed to hypoxic conditions.
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Fi g. 32 . lnterleukin-8 (IL-8) derived from the conditioned media of bladder transitional
carcinoma cells (TCCS VP) Protein concentrations were determined by ELI SA.
Conditioned medi a were prepared by treatment of ME M- EBSS media with log doses of
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concentrations are expressed as a percent of contro ls. Contro ls were not treated with
retinoi c acids, but were exposed to hypoxic conditi ons.
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each all -lrans-reti noic acid treatment, except I 11M (Fig. 33). Thi s concentration of
retinoic acid caused a decrease in cell counts at all concentrations of heparin tested.
T he heparin at I000 11glml decreased cell counts to less than the initi al numbers of cells
pl ated . T he nonserum medi a produced the most cell growth. The 0.000 I 11 M
concentration of retinoic acid had cell counts higher than that of the control at I 00 to
1000 11glml of heparin. Each retinoic acid concentration, except I 11M, showed a trend
of increasing then decreasing cell counts as hepari n concentrations increased.
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ofM.EM-EBSS media to prostate adenocarcinoma cell s (DU-145 ) under hypoxic
conditions and 0, 0.00 1, 0. 1, or 10 ,uM ofall-trans-retinoic acid . Cell s we re
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Cancer is considered to be a disease of deranged intracellular signali ng (223),
but for a tumor to survive, it must be capable of normal intercellular signaling. The
tumor must correctly stimulate numerous normal cell types to result in the development
of the tumor' s structure. Solid tumors are "organoids" consisting of highly
heterogenous populations of malignant, stromal, and inflammatory cells, as well as a
dynamic extracellular matri x (43). Thi s area contains the new blood vessels and is the
site of the intercellular signaling from mal ignant cells to the endothelial cell s of
capillaries. This signal ing was the primary focus ofthis research.
The intercellular signaling and associated proliferation of endothe lia l cells have
been proposed as targets for anticancer drug therapy (224 ). There are three compelling
reasons for targeting this normal physiological fu nction for the control of a pathological
condition. First, angiogenesis in adults is limited to two biological events, the female
reproductive cycle and wound heal ing (47). Second, neoangiogenesis is particularly
critica l for tumor survival (43). And lastly, inhibition of angiogenesis can be a
powerfu l anti cancer therapy not suscepti ble to acqui red drug resistance (225). The use
of an an ti angiogenic therapy is particularly attractive since inhibition of the normal
angiogen ic process in an adu lt wou ld lead to very few adverse side effects. Another
advantage of an tiangiogenic therapy is the potential to combat a wide variety of cancer
types wi th a single type of therapy. In addition, the same therapy might be useful in
combatin g other di seases, including rheumatoid arthritis, psoriasis, and diabetic
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retinopathy (224).
Retinoic acids have been studi ed for use as anti-cancer drugs and as
chemopreventive agents. These studies were directed at investi gating the effects of
retinoic acids on angiogenesis and the effect of retinoic acid on endothelial cell
function. This research was directed at the mechanism of the angiogenic effects of
retinoic acids, and the effects ofretinoic acid on a single function of the angiogenic
process, endothelial cell proliferation. Research in this area, and especially into the
toxicological aspects of retinoic acids, is very limited.

Preliminary Tests
During the course of thi s research, there were several preliminary experiments
conducted in order to val idate the experimental design. Each was utili zed either to test
the cytotoxicity of the three retinoic acids on the four cell lines or to examine the
experimental conditions.
Observations of the endothelial cell line during the preliminary experiment were
that after more than six passes after receiving the cells from ATCC, the cells slowed
the ir prolife ration, increased migration, and form ed in to spheres or clusters of cell s.
This appeared to be an attem pt to form into capi llary tubules. However, due to the
artifi cia l surface of the cult ure-ware, the cell s cou ld only fonn clusters. Therefore, al l
the cell s used for the ce ll-co unting experiments were used before passage number six.
Any trial s with ce ll s forming more tha n two spheres per we ll were di sca rded_
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Lactate Analysis
Hypoxia was used in this research to ensure that the tumor cell s were ex pressing
the angiogenic phenotype. Since an increase in lactate occurs during anaerobic cellular
metaboli sm, either due to lowered oxygen tension or hi gher metabolic activi ty (i.e.
exercise), this analysis was used to verify that the tumor cells were truly undergoi ng
anaerobic metaboli sm due to hypoxia. T he lactate concentrations of the conditioned
media from the tumor cells had a dramatic increase in all of the hypoxic samples when
compared to the normoxic control s. T he hypoxia-induced lactic acid concentrations
were not affected by the varied doses of retinoic acids, which suggests that the retinoic
acids did not alter the energy metabol ism of the tumor cells. Thus, the increased lactate
of the ce ll s cul tured under nitrogen gas verified that the ce lls were under hypox ic
conditions.

Cytotox icity of Retinoic Acid
T he concentrations of the retinoic acid isoform s that were toxic to the tumor
cell s differed with the isoform. T here is lim ited evidence about retinoic acids '
cytotoxicity at concentrations less than 10 or 100 JiM ( 172). At these concentration s,
retinoic acids have a detergent-like effect on cell membranes. This toxic effect may be
due to the di sruption of lysosomal membranes and the release of lysosomal e nzymes
into the ce ll ( 163 ) In thi s current research, onl y the all-trans-retinoic acid-treated
TCCSU P cell s, the 13-cis-retinoic acid -t reated U-373 ce ll s, and 9-cis-reti noic acidtreated DU-145 ce ll s had reduced cel ls counts at concentrations be low 100 JiM These
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resu lts are comparable with other research that revea led that retinoid cytotoxicity
depends on the concentration , the duration of treatment, and the cell line. In the current
research, its was shown that the cytotoxicity was also dependent on the retinoic acid
isoform. The 13-cis-retinoic acid produced substantia lly larger reduction in cell counts
in the U-373 and DU- 145 cells. The all-trans-retinoic acid produced this large
reduction in the TCCSUP cell s. ln each cell line, the reductions in cell counts from the
other two retinoi c acids were very close to each other. Another cytotoxic mechanism
that may affect the tumor cel ls' ability to remain attached, and therefore be present to
be counted, is that retinoic acid reduces the adhesion of cel ls by inhibiting the
production of fibronectin and thrombospondin ( 137).

Endothelial Cell Proliferation with
Retinoic Acids
The reti noic acids and any of their metabolites produced by the tumor cell s
remained in the conditioned media used to grow the endothelial cell s. These
experim ents eva luated the effect of the retinoic ac ids on endothelial cell prol iferati on.
The results indicate that retinoic ac ids affect cell proli feration, but are depende nt on
both the iso form type and concentration.
T he inhibiti on of endothelial cell proliferation varies with the retinoic acid
isofonn used in treatments (20) . In the current research , 9-cis-retinoic acid caused a
sign ificant dec rease in cell counts starting at 0.0 I fiM . In addition, 13-cis- and all-

trans-retinoic acids ca used a significant decrease in cell counts starting at I fiM , with
the 13-cis-retinoic aci d caused the largest decrease at I0

fiM

These results indicate that
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with this endothelial cell line, 9-cis-retinoic acid affected proliferation at a
concentration 100-fold less than the other two retinoic acids. In contrast, the higher
concentrations of 13-cis-retinoic acid had the greatest effect on cell proliferation.
These differences in cytotoxicity may be due to the abilities of the endotheli al cells to
metabolize the retinoic acids or to differences in RAR/RXR induction, which leads to
changes in gene expression (164). Human endothelial cells possess an active retinoic
acid metabolizing capacity (226). In the human endothelial cell s, all -trans-retinoic acid
was quickly metabolized, but 9-cis-retinoic acid was degraded slowly. In addition, the
endothelial cells had no detectable ability to isomerise the all-trans- to 9-cis-retinoic
acid and vice versa. Based on the differences in the cytotoxic effects of the different
isomers, the bovine endothelial cells used in the current research appear to have similar
metabolizing functions to the human endothelial cells on this aspect.
Tn the current studies, it was found that the culture conditions and passage
number of the endothelial cells affected their proliferation. By limiting the cell s to six
passages, morphology and proliferation rates were maintained, with the retinoic acid
treatments decreasing proliferation. In another study, however, in which endotheli al
cells were used for at least 12 passages, the cells had no change in their proliferation
when they were treated with I JIM ofa ll -tra ns-retinoic acid (26). However, the cell s
did undergo major morphologic changes.
The binding of retinoic acid to the various RARIRXRs and the induction of
these receptors will affect the gene transcription occurri ng in the cell. Information on
the effec t ofretinoic acids and their receptors in endothelial ce ll s is limited. There are
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studies on cancer cell lines which may help in the understanding of what occurs in
endothelial cell s. All-trans- and 13-cis-retinoic acids interact with RARs, while 9-cisretinoic acid interacts with both RARs and RXRs (227). All-trans-retinoic acid induced
RAR.Band RARy mRNAs in retinol-deficient rats; however, 13-cis-retinoic acid did not
increase mRNA expression at an equimolar dose (228). ln contrast, when 13-cisretinoic acid was used to treat several refractory lymphoma cell lines, there was an upregu lation ofRARu mRNA expression, which corresponded to the cell lines that were
inhibited by the 13-cis-retinoic acid (229). These cell lines that were inhibited by the
13-cis-retinoic acid and had an increased induction of their RARu mRNAs also were
expressing transforming growth factor-beta I receptors. Endothelial cells that respond
to transforming growth factor-beta I have a reduced ability to proliferate ( 183). Also,
when all-trans-, 9-cis-, and 13-cis-retinoi c acids were used to treat several human oral
squamous-cell carcinoma cell lines, the growth inhibition had a good correlation to the
expression of RARI3 in retinoic acid-treated cell s (230).
One important result from thi s experim ent was that the retinoic acids did not
induce cell proliferation when compared to controls. Since there was no vitamin A
source in thi s medi um and there was no serum, which is normally the source of vitamin
A in ce ll cu lture ( 163), the retinoic acids were not being used by the endothe li al ce lls as
a vitamin A source_ Therefore, the endothelia l ce ll proliferation seen in the cond iti oned
media experiments was not due to the nutritional requirement for vitamin A. If vitamin
A was required for nonnal endothe li al cell proliferation, an increase in endothelial cell
proliferation should have been seen at the lower concentrations utilized in the
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cytotoxicity experiments.

Endothelial Cell Proliferation with Conditioned
Media-Timed Studies

These studies developed growth curves of the endothelial cells and show that
the cells were proliferating up to 48 h. This verified that the conditioned media had
adequate nutritional components at this time, the time point which was to be used in
subsequent experiments. Thus, the 48-h sampling time would not produce resu lts that
were due to an artifact of nutritional inadequacies. This also verified that the effect of
the retinoic acids was detectable at other sampling times and did not occur in only the
48-h samples.
In the first timed trial , 72-h samples demonstrated that the various medi a were
still nutritionally adequate to maintain the growth of endothelial cells well past the 48-h
sampling point. The media with 10% FBS produced the most endothelial ce ll
proliferation, since FBS contains an abundance of growth factors. The conditioned
media fTOm the DU-145 had hi gher cell counts at the 40- and 48-h samples when
compared to the nonserum media. Thus, the tumor cells caused the conditioned media
to stimulate endothelial growth , which suggests the tumor cells were releas ing growth
factors into the medi a.
In the seco nd trial , conducted using DU- 145 conditi oned media, the growth
curves for all the treatments did not vary with sampling time, with the exception of
increased sample va liance between the treatments at 48 h. The samples had some
decline in cell counts at48 h, with the most decline being in the control sa mples.
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Similar experiments were conducted with U-373 conditioned media. The U-373
conditioned media produced a consistent growth curve, with the endothelial cell counts
at 48 h were sti ll increasing. T hi s served to further verify the presence of adequate
nutritional factors in the conditioned medi a.
T he timed study with the TCCSUP conditioned media produced similar results
to the ot her conditioned media experiments, with the exception of the 24-h samples
which were lower for all of the conditioned media samples. This appeared to be a
problem that was limited to the 24-h sam ples and not the entire experiment Without
this sample point , the growth curve progressively increased. This verified that the
TCCSUP conditioned media also maintained ce ll growth up to 48 h.

Endothelial Cell Proliferation with Retinoic
Acid-Treated, Conditioned Media
Although no reports of retinoic acids increasing capi llary endotheli al ce ll
proliferation could be found , there were increases in endothelial cell proliferation with
the lower concen trations of all -Irons and 9-cis-retinoic aci d-conditioned media in these
experiments. In one report, retinol -, retinal-, retinoic acid-, and retinyl acetateconta ining med ia were conditi oned with a mouse macrophage-like cell line , P388D,
and were growth stimulatory to bovine aortic endothelia l cell s ( 172). T hey only
presen ted data for retino l and w ith thi s compound the growth stimulation was maxima l
at 10 f1M . Retinol at hi gher concentrations was tox ic. Another research gro up tested
the hypothes is that retinoic acid inhibits the angiogenic activity of normal endothelial
ce ll s by inhi biti ng endothelial ce ll migration ( 174 ). They stated that retinoic acid had
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little effect on endothe lial cell proli fe ration. However, their experiments were
conducted with endothelia l cells at passage 15, whil e in this researc h this was shown to
be a passage number that in and of itse lf inhibits cell proliferation. These experiments
had similar results to the experiments without conditioned media co nducted during the
c urrent research_ They did not examine cell proliferation with retinoic acid-exposed,
tumor ce ll -conditioned med ia. Therefore, their results are similar to the aforementioned direct effects of retinoic acids on endothe li al cell s, but they did not consider
the potential indirect effects of the retinoic acids.

U-373 Cells
The U-373 cell-conditioned media cau ed increases in endoth elia l ce ll
proliferation with the lower concentrati on of all-trans- and 9-cis-retinoic acids. With
the Whitney-Mann U stati stic test, all of the means of the treated samples had to be
greater than those of the control s, to achi eve a P<0.05. Both the all-trans- and 9-cisretinoic acids had several concentrations that had cell counts that were greater than
controls. T he 9-cis-retinoic acid sampl es were hi gher, from 0.000 I to 0 . I pM with
0 .000 I and 0.0 I pM sampl es significantly hi gher at P<0.05. The all-trans- sa mpl e ce ll
co unt s were hi gher at 0.00 I and 0.0 I pM , wi th 0.0 I pM signifi cantl y hi gher a t P<0.05 .
T he ce ll co unt s for the 13-cts-rctinoic acid treatments were never greater tha n the
co ntrol s, and we re very similar to the tri a l wi thout condi ti oned media . These studies
demo nstrated a " ide variation in endothe lial ce ll effects for the retinoic acid isofo rm s.
In addi ti on, the concentrations of retinoic ac ids tested are of critical impona nce in
whether they wi ll cause a pro liferation or inh ib ition of endothelia l ce ll s. T hi s may
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explain the variable results reported by other researchers, which tested only one
concentration or one type of retinoic acid.
RT-PCR analysis of the mRNAs of the U-373 cells supported the hypothesis
that retinoic acid treatment was affecting the production of angiogenic growth factors.
The VEGF mRNA expression for both 121 and 165 isoforms was increased for the
lower concentrations of all-trans- and 9-cis-, but not 13-cis-retinoic acids. The VEGF
expression in the 13-cis-retinoic acid sampl es was almost always less than the control
sample. The increased VEGF expression with the all-trans- and 9-cis-retinoic acids
corresponded to the concentrations of these acids that had increased endothelial cell
counts. A surpri sing result was a fairly consistent expression of the VEGF mRNAs
across retinoic acid concentrations. In addition, the higher concentrations of retinoic
acid did not depress the mRNA express ion. The experimental procedure used for these
studies may have masked a decrease in mRNA production at the higher doses. By using
I pg of total RNA from each sample, the relative amount of a specific mRNA to the
total pool of RNA was exami ned. If the retinoic acid treatments affected the
production of all RNAs, then a reduction of a select mRNA would not be detected.
Therefore, protei n analysis of conditioned media for secreted VEGF was used to
reso lve this question. The retinoic acids ' effect on the transcription of the mRN As may
not be directly proportiona l to the protein secreted into the media, due to the sampling
used to measure the two factors . The mRNA expressions were determined at a si ngle
time point, which was after 24 h of hypoxia and retinoic acid treatment exposure . The
protein concentration was the total that collected in the medi a for 24 h. The mRNA
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production could have been affected by changes in the cellular environment, e.g. pH
changes, increases in ce llular waste, or a different protein production than may have
bee n present earlier in the treatment period. The stability of the growth factors also was
unknown . In addition, the tumor cell s could have been affected by a feedback system
from growth factors in the media.
If the mRNA expression were directl y proportiona l to secreted protein, then
graphs, as the percent of the control, should have been very si milar. The VEGF protein
concentrations derived from the U-373 conditioned media were increased with
increasing retinoic acid concentrations up to I 0 pM At that point a large reduction
occurred with the 9-c is- and 13-cis-retinoic acids. There was an increase above the
control samples for all concentrations except 0.000 I and I0 pM of 13-cis-retinoi c acid
and 10 pM of9-c is-retinoic acid. The 13-ci.v-ret inoic acid genera lly resulted in less
VEGF in the media than the other two isoforms. This was consistent with the cell
co unts. The resu lts of the VEGF mRN A and protein quantifications indicated that thi s
growth factor was not the on ly influence on the endothe lial cell proliferation . lfVEGF
had been a very strong or single influence, then the ce ll counts would have closely
approximated the ELLSA results.
IL-8 mRNA expression was fair ly constant for thi s growth factor until 0. 1 pM .
At 0. 1 pM the all-irans- and 9-cis-retinoic acid-condit ioned medi a samples showed an
increased IL-8 concentration, while the 13-u s- retinoic ac id samples rema ined constant.
The increased IL-8 at the high retinoic acid concentrations did not correspond to the
ce ll co unt s obtai ned with the conditioned media. With the ELI SA data fo r IL-8, both
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the

a ll -/ran.~-

and 9-cis-retinoic acid treatments dramatically reduced the IL-8 protein

concentrations, while the 13-ci.s samples were all simi lar to the controls. If the IL-8
EUSA test was accurate, then the all-trans- and 9-cis-retinoic acid treatments were
affecting the production or secretion of the IL-8. This may be why an increase in cell
counts that corresponded to the increased IL-8 mRNA was not seen. Another research
group, which examined the secreted IL-8 from human squamous cell carcinoma cell
lines, reported no changes to secreted lL-8 after treating the tumor cells with all-trans
and 13-ci.s-retinoic acids at I pM (24).
The mRNA expression of midkine, another growth factor, was analyzed.
Midkine expression, as observed on the gels, was strong when compared to the GAPDH
expression for all three retinoic acid treatments. When scanned, adjusted with GAPDH
mRNA expression , and compared to controls, the 13-cis-retinoi c acid samples had an
expression greater than the control, while the 9-cis- and all-trans-retinoic acids were
consistentl y less than contro ls. There was no dose-response with any of the retinoic
acids, indicating that this growth factor was not responsible for the increases in the
endothelial cell counts. Unfortunately, midkine protein production could not be
determined , due to the lack of a commercially available midkine ELISA kit at the time
of this research .
The mRNA express ion ofthrombospondin and leukemia inhibitory factor in the
U-373 ce ll s were weak in the normoxic samples and even more reduced in the hypoxic
samples. These mRNAs were onl y sli ghtl y or not detectable. Thi s would indicate that
the hypoxia had depressed the expression of these mRNAs. Thus, these antiangiogenic

159
growth factors were probably not influencing the angiogenic potential of these tumor
cell lines.

DU-145 Cells
The endothelial cell counts, from the DU-145 conditioned media tri als, were
very similar to the results from those of the U-373 conditioned media. What was
different between these two cell types was the degree of effect with the all-trans- and 9cis-retinoic acids. Both significant increases in cell counts for the DU-145 cells
occurred at I 0-fold higher concentrations of retinoic acids than the U-373 cells. In
addition , the decreases in the cell counts from the 13-cis-retinoic acid treated samples
were less for th e DU-145 cells than for the U-3 73 cells. Both the all -trans- and 9-cisretinoic acid-treated samples, that were significantly greater, had adjacent samples that
were greater tha n controls, but did not meet the requirements for significance of
P<0.05. The all-trans-retinoic acid-treated samples had th.ree samples, 0.0001-0.0 l JiM ,
that were num e rically above controls but not significant at P<0.05 . The 9-cis-retinoic
acidtreated sa mples had the 0.000 I J.IM sample that was greater than control.
The ex pression of VEGF mRNA from the DU- 14 5 cel ls did not correspond to
changes in the cel l counts as well as the other two cell types. However, the changes in
VEGF mRNA express ion with the 9-cis-retinoic acid conditioned media were
comparable to the cell counts from the DU-1-15 conditioned media samples. ELISA
res ults do not correlate with increased mRNA expression of sam ples in which both
VEGF isoform s increase above controls, with an increase VEGF concentration on ly
occurring at 0.0001 JiM In the a ll-trans-retinoic acid mRNA samples, VEGF was
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expressed the same as the control. The I 3-cls-retinoic acid had VEGF 121 mRNA
expressions below the control , which was consistent with the cell count data. T he
concentrations ofVEGF, based on the ELI SA data, for 13-c is-retinoic acid were
consistent with the mRNA data with the exception of the 0.001

uM

samples.

The relative intensity of the two VEGF mRNAs was expressed quite differently
in the cell ty pes studied. T here was a very strongly expressed VEGF 12 1 in a ll sampl es of
the DU - 145 cell s, which was only slightly less than the GAPDH . When com pared to
the expression of VEGF, 65 , it could be said that the VEGF 121 isoform was the major
form expressed in this cell line, whereas in the U-373 cells, both isoforms we re equally
expressed.
The IL-8 mRNA data for the DU- 145 cell s did not produce increases at the hi gh
concentration of retinoic aci d, as was seen with the U-373 cells. The express ion of LL-8
mRNA and protein did not correlate with the c hanges in the cell count s, except for the
I 0-,uM sampl es. Thus, the reti noic acid effects on IL-8 expression did not appear to be

a major cont ributory factor on the endothe lial cell proliferation.
T he midkine mRNA data were difficult to relate to cell count data, and
appeared not to be influenced by the retinoi c ac id concentrations. The increase in th e
midkine expression from the 13-cis-retino ic acid-treated samples after 0.0 I ,uM , may
have resu lted in a sma ller decrease in the cell counts for the I 3-c is-retinoic acid
cond itioned media trial.

TCCS l ll' Cells
The TCCSUP ce ll s produced rc ults very diiTc rent from the U-373 and DU- 145
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ce ll s. Fi rst, there were no significant increases in the endothelial cell counts at any
concentration of the retinoic acid-conditioned media. In contrast to the other ce ll lines,
the 13-cis-retinoic acid samples produced the highest counts compared to the control.
There was very little variation in VEGF or midkine mRNA expressions between the
control samples and the treated samples.
To understand what was occurring with the TCCSUP cell line, the data from
nonserum, I0% CS, and I 0% FBS media controls were examined. These were
performed during each of the endothelial cell growth tri als, to verify the health of the
endothelial cells. These treatments produced cell counts that were within the growth
range previously determined to be adequate for hea lthy endothelial cells. While the
nonserum media-treated cells produced a 1.9- to 2. 1-fold increase in endothelial cell
numbers over the init ial counts, the cell counts from all of the controls with TCCSUP
conditioned media were dramatically lower than the nonserum-treated, nonconditioned
samples. Thus, the conditioning of the med ia with TCCSUP cells did not produce the
stimul ation that the U-373 and DU-145 cells did, but had an inhibitory effect. This
could have been due to a reduction in the amount of angiogenic growth factors
produced by the TCCSUP cells. Al so, it is poss ible that an inhi bi tory growth factor was
being produced. In contrast, the production of growth factors may not have been the
contro lling factor , si nce the TCCSUP cell s could have released other ce llul ar products
that were inhibitory to the endothelial cell s. For example, ce llular metabo lic wastes
may have been greater, as the concentration of lactate fro m these cells was greate r than
the other two ce ll lines. These may have contributed to the effect on the endotheli al

162

cell growth .
T he mRNA expression ofYEGF in all of the TCCSUP-conditioned retinoic
acid-treated samples was relatively unchanged from the control samples and agreed
with the cell count data. In comparison, the ELISA results were similar to the mRNA
data until 0. 1 JJM when all three of the retinoic acid treatments increased the amount of
YEGF protein in the conditioned media. This dramatic rise in VEGF concentration
may account for the lack of a decrease in the cell counts in thi s range. An unusual
result, seen only with the TCCSUP cell s, was the cell counts with the 13-cis retinoic
acid, which were very close to the control samples, even at I 00 JJM This concentration
of 13-cis-retinoic acid caused a large reduction in cell counts in the other two cell lines.
In contrast, the all-trans- and 9-cis-retinoic acids both had significant decreases at the
10 and 100 JJM
T here was a possible explanation for the TCCSUP conditioned, 13-cis-retinoic
acid-treated, media cell counts from the IL-8 ELI SA data. There was a rise in fL-8, in
the 13-c /s-retinoic acid samples, at greater than 0. 1 JJM , but no increase was seen in the
mRNA express ion.
T he mRNA expression for midkine had good band intensities in the gels, with
the all-trans-retinoic acid sampl es being the strongest. There was a sma ll increase in
midkine mRNA expression at the lower doses for al l-trans- and 9-c/s-retinoic acid and
at the midrange doses for 13-cJs-retinoic acid, but these changes were not reflected in
the cell cou nts. There fore, midkine was probab ly not a major influence in the
endothelial ce ll proliferation.
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The data from the TCCSUP conditioned media trials would suggest that some
factor which was not examined in this experiment was inhibiting the endothelial cell
growth. There were strong expressions for VEGF, IL-8, and midkine mRNAs. The
expression ofTSP mRNA was very weak and the LIF was totally prevented by hypoxia.
Cytotoxicity of the retinoic acids, based on the toxicity trials, was not the causative
factor.

Sodium Heparin and Endothelial Cell
Proliferation Conditioned Media
The experiment with sodium heparin and DU-145 conditioned media with al ltrans-retinoic acid was a preliminary experiment. This experiment was a single trial
and could not be statistically tested. Thi s experiment did produce interesting results,
which show promise for further investigation . There were two results that should be
discussed. The first was the increase in endothelial cell proliferation at the I0 ,ug!m l
dose of heparin in all of the treatments, except for I ,uM ofall-trans-retinoic acid. This
indicates that heparin may, in some way, aid the proliferation of endothelial cell s. It
has been reported that heparan sul fate increased the binding ofV EGF,r.; to endothelia l
cell s at heparan concentrations of 10-100 ,ug!m l ( 159). In addition , heparin causes the
release of FGF from the ce ll matrix and increases binding of FGF to endothe lial ce ll s
( 155). When hepa rin was added to endothelial ce ll s, without growth factors in the
media , the re was a decrease in ce ll proliferation of I0-30% ( 159). In comparison, at I0
l' g/ml heparin , there was a 14% increase in cell proliferation as compared to
nonserum-treated control. However, at 1000 ,u glml of heparin there was a 27%
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decrease in cell proliferation.
The second important finding in this experiment was the reduction in cell
proliferation with 0.01 and I JlM ofretinoic acid in combination with heparin at 100500 Jlg/ml. This indicates a possible drug combination for cancer chemotherapy that
needs to be further investigated, because these doses are therapeutically achievable
(24). The reduction in cell proliferation at heparin concentrations of 500 and 1000
Jlg/ml could be due to competitive binding of the heparin to the growth factor(s) or to
the growth factor receptor(s), as previously theorized ( 154). This hypothesis warrants
further investigation.
At the time of the preparation of this manuscript, no published reports of the
combined effects of retinoic acid and heparin on endothelial cell proliferation or
angiogenesis were found . However, published accounts of the antiangiogenic
properties of these individual compounds (182), albeit not in combination, are
available.
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CONCLUSIONS

T here are several conclusions that can be drawn from thi s research . Severa l
experimental results from this research will help to understand questions of retinoic
acid 's effect that have been rai sed by other researchers. In addition, some of the resu lts
from this research indicate the need for further study. Several questions raised in these
projects were not completely answered. This is primari ly due to the limited focus of
research being conducted in vilro and the fact that only the cell proliferative function of
angiogenesis was examined. Whether the differences in the endothe lial cell growth
inhibition when treated with retinoic acids were due to changes in retinoic acid receptor
expression, differences in the metaboli sm of the retinoic acids, or effects on the
ce llular or lysosomal membranes, was not determined from thi s resea rch. Also, it is
possibl e that the increased endothelial cell proliferation of the all-lrans- and 9-cisretinoic acids might be countered by an inhibition of endothelial cell migration, as a
decrease in endothelial cell migration from all -/ra ns-retinoic acid has been previously
reported ( 174 ).
A defi nite conclusion that can be drawn from this research is that concentrations
of either all-lrans- or 9-cis-retinoic acid of Jess than I J.IM in conditioned media, a fter
24 h ex posure to certain tumor cell s under hypox ic condit ions, signifi cantl y increased
endotheli al ce ll proliferation in vlfro. This increase in cell growth was varied by tumor
ce ll type a nd retinoic acid isoform tested . For example, the increase in endothelia l cell
proliferation was not seen with the TCCSUP, bladder carci noma cell s, and 13-c isretinoic acid fai led to increase pro li feratio n in any of the three cell line used.
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Additiona ll y, this isoform failed to significantly reduce endothelial cell proliferation,
with the TCCSUP and DU-145 condi tioned media, except at I 00

uM

in the DU- 145

cells. Therefore, either 13-cis-retinoic acid was somehow aiding the endothelial cell s at
hi gher doses or was somehow changed during exposure to the tumor cells.
The trial s involving growth factor mRNA expressions, though not statistica lly
tested, did support the conclusion that the increases in endothelial cell proliferation
from the all-trans- and 9-cis-retinoic acids generally had increases in the mRNA
expression ofVEGF 121 and/or VEGF 165 . This expression of the VEGF isofonns was
varied by tumor cell types tested. There was a sl ightly higher expression of VEGF, 65
than VEG F 121 in the U-373 cells, whil e VEGF 121 was expressed more than VEGF 165 in
the DU-145 and TCCSUP cells. The 13-cis-retinoic acid, in contrast to the other two
isoform s, generally decreased the mRNA expression of both VEGF isoforms.
In comparison with the VEGF, the mRNA expression of!L-8 was increased by
all-trans- and 9-cis-retinoic acid at higher doses in all of the cell lines, except by 9-ctsretinoic acid in the DU-145 cells. This increa ed IL-8, induced by all-lrans-retinoic
acid , has been previously reported ( 11 9), but increases with 9-cis-retinoic acid have not
been described . The increases in LL-8 mRNA expression were dependent on retinoic
ac id isofonn , with all-lrans-retinoic acid being the strongest inducer.
A synthetic retinoid (E5 166) has been reponed to induce midkine mRNA
expression ( 115). But, the tumor cell types and the natura l fonns of retinoic acids
tested in the currently reported st udies did not produce evidence of midkine induction
except for the 13-cis-retinoic acid in both the DU-145 and U-373 cells. There was
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limited data from this research on the effects or production ofTSP and LIF from these
tumor cells. There was a very strong reduction in the expression of these inhibitory
growth factors after hypoxic exposure of the tumor cell lines. Thus, one must conclude
that these growth factors were not an important influence on the endothe lial cell
proliferation under these experimental conditions.
There are two conclusions that can be drawn from the sodium heparin
experiment, with the understanding that this was a single experiment unit. First, I0
J.lg/ml of sodium heparin was able to stimulate endothelial cell proliferation, as
compared to the zero dose and concentrations ;:::500 ugiml. Secondly, concentrations 2:
500 fig/m l were inhibitory to endothe li al cell proliferation. In addition, there appeared
to be a synergistic effect ofO.OI and I

fiM

ofall-trans-retinoic acid with the hi gher

doses of heparin which inhibited endothelial cell proli feration.
Did this research fulfill the goa ls outlined in this manuscript? The supportive
goa ls had to be addressed in order to va lidate the conditions of the experimental design
before the main goals could be addressed . The first supportive goal , or goal 3, was
addressed with the cytotoxicity study of the tumor ce ll s and showed that the tumor ce ll s
were not genera lly affected by retinoic acid and hypoxia until 10-100 J.IM , which was in
agreement wit h previous research ( 172 , 174). Goal 4 was the treatment of endothe li al
ce lls with rctinoic acid without conditioned media. The results of the experi me nt s, that
addressed this goa l, proved that the rctinoic acid would affect proliferation and was
dependent on the concentration and isofonn of retinoic acid. The results of the
experim entation that addressed goa l 5 indicated that the sodium heparin affected cell
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proliferation a lone, but also found that a synergistic effect with retinoic acid was
present.
The primary goal of thi s research was to determine whether reti noic acid effects
on the production of angiogenic growth factors were dose-dependent. Retinoic acid
was proven to be both dose-dependent and isoform-dependent in the induction of tumor
production of several angiogenic growth facto rs. T his effect was demonstrated for
three growth factors, but many more be could affected and should be tested. The
second primary goal of this research was to determine which growth factors were
affected by retinoic acid and at what level of prote in production. Experimenta l results
used in the investigation of thi s goal indicated a strong effect on retinoic acid-induced
growth factor mRNA express ion, was we ll as the secreted protein concentrations in the
conditioned media. T his area needs more experimentation, but data indicate that all
three of the angiogenic growth factors were being expressed. In addition , all of the
retinoic acids affected mRNA expression and protein secretion was dependent on the
retinoic ac id co ncentration and isoform .
It ca n, the refore, be said that retinoic acids dose-dependently affect the
angiogeni c acti v ity, in vitro, of solid tumor ce ll s and, to a degree, the effects vary by
iso form . Thi s effect also varied by tumor cell type. T he increases in endothe li al ce ll
pro li fera tion were unexpected and lead to questions about the resu lts ofsevcra l
chemoprevention studies. It is still unknown why the chemoprevention studies that
used beta carote ne , retinol , and/or vitam in E should produce such dramatic increases in
lung cance r death rates in heavy smokers and/or asbestos workers {8,9), si nce the
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concentrations of retinoic acids that produced the endothelial cell proli feration were
low and could be comparable to those achieved from a vi tamin therapy. Could these
patients in the c hemoprevention studies have had carci nomas in silu that had
angiogeni c activity stimulated by the low levels of retinoic acid convened from either
the beta carotene or retinol ? Thi s question should be investigated. This research
project should be continued both in vitro and in vivo in hopes of funher exploring the
effect of retinoids on cancer.
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Appendix A. Additional Growth Factors Examined

Growth Factors
Prelim inary RT-PC R expe riments were conducted on three additional growth
factors. These growth factors were considered to have antiangiogenic properties and
were selected because of the possibility that the tumor ce ll s could have been producin g
them. T hese growth factors could be affected by retinoic acids which could inhibit the
proliferation of the endothe lial cell s. The selection of these factors was made for the
same reasons as for TSP and UF, since the increases in endothelial cell prolife ration
mi ght have been due e ither to increased production of angiogenic growth factors or the
decrease in inhibitory angiogenic growth factors.
T he three additiona l growth factors exam ined were pl atelet factor-4,
somatostatin, and interferon-y. A set of primers was developed for each growth factor
a nd the n used in PCR reactions to determine whether the tumor cell s were express ing
the mRNAs for each o f these genes. T he preliminary tests for these primers fa iled to
produce a PC R product of the predi cted size, there fore, these primers were not used
further and onl y TSP and LIF were used in furth er tests.
Plate let Factor-4. Pl ate let factor-4 (P -4) is a chemok ine that shares 3 1%
homology with IL-8 (225) and is a n im portant modul ator of endotheli a l cell
pro lifera ti on and angiogenesis. Addi tio n ofPF-4 to endothelia l ce ll s
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vitro prod uced

a dose-de pendent inhibition of ce ll proliferation. PF-4 will bind heparin, and hepa rin
can antago ni ze the etTects of PF-4 (226) . PF-4 was reported to inhibit endothe li a l ce ll
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proliferation by blocking cell cycle transverse from G I to S phase (225).
Somatostatin. Somatostatin was initially described in 1973 and was reported to
inhibit normal and transformed cell growth (227). Receptors for somatostatin have
been identified on tumor cells and tumoral vascular endothelial cells. When these
receptors were activated by somatostatin, cell proliferation was inhibited. In addition,
somatostatin and its analogs may affect growth by inhibiti ng the secretion of growth
factors (228). Somatostatin has been reported to inhibit angiogenesis. Analogs of
somatostatin have been tested for antitumor activity. One analog reportedly caused a
70% inhibition in Lewis lung tumor metastatic sites in a mouse model (229). A
somatostatin analog may a lso inihibit insulin-like growth factor from sma ll -cell lung
carcinomas (230).
lntcrferon-y. lnterferon-y (lFNy) is a lymphokjne secreted by numerous
lymphocytes and endothelial cells (231 ). When endothelial cells are exposed to IFNy,
they produce a prote in, referred to as y!P-1 0, which has a strong sequence homology to
PF-4. IFNy was shown to inhibit capillary formation in vitro in a dose-dependent
manner (232). The [P-1 0 protein was later reported to in hibit the angiogenic acti vity of
lL-8 (233). This inhibiting action oflfNy was reported to affect growth of the
endothelial cells and collagen production by myofibroblastic cell s. Hum an umbilical
vein endothelial cells when plated on Matri gel (reconstituted basement membrane
matrix enri ched in laminin) had their tubul e formation signifi can tly inhibited when
treated with IFNy, (234).

196
Primer and PCR Conditions and
Preliminary Results
Platelet Factor-4. Platelet Factor-4 specific primers were generated by Operon.

These primers were 20 bases in length with upstream
5'-TTGCTGCTCCTGCCACTTGT-3' at eDNA positions 62-82 and downstream
5'-ATTTTCCTTCCATTCTTCAG-3' at eDNA positions 233-253. GC percentage was
55% for upstream and 35% for downstream. These primers were predicted to produce
a 191 bp PCR product.
The PCR cycles and temperatures were 94"C for 60s for denaturing, then 55.3°C
for 30 s for annealing and n

•c for 60 s for extension, repeated 30 cycles and then two

cycles with a 2 min extension time.
When these primers were used with eDNA from U-373 cells treated with alltrans-retinoic acid, no bands were detected. When these primers were used with eDNA
from untreated endothelial cells, there was a band located at approximately 191 bp.
Somatostatin. A gene specific primer set was generated by Operon. These

primers were 20 bases in length with upstream 5'-GGCTGCGCTGTCCATCGTTCC-3'
at eDNA positions 1260- 1280 and dovmstream 5'-GCCTCATTTCATCCTGCTCA-3' at
eDNA positions 2338-2358. GC percentage was 70% for upstream and 50% for
downstream . These primers were predicted to produce a I098 bp PCR product. These
primers were designed to include areas of two exons with a 876 bp intron separatin g
them , therefore, any replication of genom ic DNA wou ld be apparent by the lengt h of
the PCR product.
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The PCR cycles and temperatures were 94•c for 60 s for denaturing, then 56"C
for 30 s for annea ling and 72"C for 60s for extension, repeated 35 cycles and then two
cycles with a 2 min extension time.
When these primers were used with eDNA from U-373 cells, treated with all /rans-retinoic acid and untreated endothelial cells, no bands could be detected.

lnterferon-y. A gene specific primer set was generated by Operon. T hese
primers were 20 bases in length with upstream 5'-ATCGTTTTGGGTTCTCTTGG-3' at
eDNA positions 169- 189 and downstream 5'-CTGACTCCTTTTTCGCTTCC-3' at
eDNA positions 578-598. GC percentage was 50% for upstream and 50% for
downstream . These primers were pred icted to produce a 429 bp PCR product. These
primers were designed to include the majority of the protein coding region of the gene.
The PCR cycles and temperatures were 94•c for 60s for denaturing, t hen
52.3°C for 30 s for annealing and

n•c for 60s for extension, repeated 30 cycles and

then two cycles with a 2 min ex tension time.
When these primers were used with eDNA from U-373 cells treated with all/rans-retinoic acid and untreated e ndothelial ce ll s, no bands were detected.
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Table I Summary ofstatistical data from endothelial cells treated
with retinoic acidv and without conditioned media
Retinoic
Acid

Reti noic Acid
Cone. in I' M

A ll -trans

0

13 157.67

Standard
Error

1527.56

440.97

%Control

Sign. Diff. •
P ~ 0 . 05

100.00

13265. 17

1363.87

393 .72

100.79

No

0 .00 1

13189.42

2007.78

579.60

100.27

No

0.0 1

13 3 16.17

2059.35

594.48

101.13

No

0. 1

12709.00

11 85.88

342.33

96.93

No

111 5 1.42

871.25

251.5 1

75.62

Yes

10275. 17

695 .96

200.9 1

78. 17

Yes

1456.92

420.57

62.96

Yes

100

8297.33

0

8440.00

580.75

167.65

100.00

0 .000 1

8587.33

10 17.65

293 .77

93 .12

0 .00 1

7863 .08

11 94.56

344 .84

93.49

Yes

0.0 1

73 16.67

773 . 12

223 . 18

87. 15

Yes

No

6259.50

1115.50

322.02

74 .79

Yes

58 18.50

346.88

100. 14

68.94

Yes

10

5238 00

644.86

186. 16

62.3 1

Yes

100

5261.33

342.53

98.88

62.41

Yes

0

7648 .75

1074.20

3 10. 10

100.00

0 .000 1

7602.92

1002.93

289 .32

99.6 1

0.001

7077.08

892.50

257.64

92.83

No

6596.92

9 15.47

264 .27

86.42

No

0. 1

13-c::ts

Standard

Deviation

0.0001

10

9-cis

Mean

0.0 1
OJ

No

6272.83

963 36

278 10

83.40

No

5999 25

1222 48

352 90

75.34

Yes

10

1905 .67

668 52

192 .99

24 87

Yes

100

3 183 .75

103 1 27

299.70

42.04

Yes

* value dillCrent from 0 Retinoic Acid concentrati on
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Table 2 Summary ofstatistical data from endothelial cells treated
with retinoic acidv and U-373 conditioned media
Mean

Standard
Deviation

Standard
Error

Retinoic Acid

Acid

Cone. in 11 M

AJ I-trans

0

6325 .67

272.98

157.60

0 .000 1

605 1.92

83 4.9 1

482 .04

95 .43

No

0.001

6768.00

174 . 14

100.54

107. 18

No

9-t.:is

13-(,'/.,

%Control

Sign. Diff. •

Retinoic

P ~ 0 . 05

10000

0.0 1

7 11 5.67

111.70

64.49

11 3.94

Yes

0. 1

6123 67

577 72

333.55

97. 18

No

6376.67

52.25

30.17

100.93

No

10

5 138.33

197.30

113.91

80.75

Yes

100

4351.67

1478.09

853 .37

68.6 1

Yes

0

7030.00

4 11.88

237.80

100.00

0 .000 1

8 146.00

637.63

368. 14

11 5.86

0 00 1

765 1.33

690 89

398.88

108.83

No

0.0 1

7638.67

89.05

s 1.41

108.65

Yes

0. 1

7583 .67

1022.99

590.62

107.87

No

6445.67

354 71

204.79

91.68

No

10

5455 33

893 OS

515.60

77.60

Yes

100

5676.33

1068.06

6 16 .65

80.74

No

0

9054 67

403 19

232.78

100.00

0 .000 1

8320.00

665 .58

384 .27

92.02

0.00 1

8059.00

I035 86

598.05

89.06

No

0.0 1

8045 .00

854.68

493.45

88.9 1

No

0 1

Yes

No

8296.00

181 80

104.96

90 32

Yes

7508 00

212 25

122 55

92 97

Yes

10

6608 67

531 16

306 66

7296

Yes

100

1093 00

329 77

190.40

II 98

Yes

• value ditl"erem from 0 Retinoic Acid concent ration
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Table 3 Summary ofstatlstical data from endothelial cells treated
with retinoic acids und Dl/- f./5 conditioned media
Retinoic
Acid

All -trans

Retinoic Acid
Cone. in I'M

Standard
Error

%Control

Sign. Diff •

P !> 0.05

0

468.45

270.46

100.00

0.0001

11 258.67

479.00

276.55

104.05

No

0.00 1

11328.00

666.50

384.8 1

104.9 1

No

0.0 1

11 688.00

649.42

374 .94

I 08.23

No

0. 1

11975 .33

857.45

495 .05

110.93

Yes

11415.33

147.52

85 . 17

105.56

Yes

I 0277.33

221.40

127.82

95.06

No

Yes

100

2548 .67

72.57

41.90

23 .54

0

10685 .00

804.46

464.46

100.00

0.000 1

11 696.33

2046.22

11 81.38

11 0.64

No

0.001

12573 .67

960.89

554 .77

11 7.85

Yes

0.0 1

12 150.00

601.72

347.40

11 3.99

Yes

10271.33

211379

1220.40

95.7 1

No

10 137.33

353 40

204 .04

95 .36

No

9068.00

1055 10

609. 16

84.96

No

100

864.00

228.80

132. 10

8.22

Yes

0

8364 .33

290 54

167.74

100.00

0.000 1

8031.00

322.42

186. 15

96.04

No

0.00 1

7723 .00

361 20

208.54

9:i . l8

Yes

0.0 1

7790.00

898.05

5 18.49

93 . 18

No

0. 1

8083 .67

932 06

538. 12

96.65

No

790 1 33

363 09

209.63

94 5 1

No

0. 1

10

13-c::ts

Standard

Deviation
10830.67

10

9-cis

Mean

10

8 178 .00

82 31

47 52

91 9 5

No

100

2394 67

714 .96

4 12.78

28 70

Yes

*va lue ditlerent from 0 Retinoic Ac id concentration
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Table 4 Summary tistatistical data from endothelial cells treated
with retinoic acidv and TCCSUP conditioned media
Retinoic
Acid

Retinoic Acid
Cone_in J.<M

A ll-trans

0

2928.33

253 02

146.08

100 .00

0 .000 1

2954.33

140.55

8 LI S

100.87

No

0.001

2767.33

67.68

39.07

94.85

No

0.01

2809.67

104.56

60.37

96.37

No

0. 1

2875 .33

273 .24

I 57.76

98.32

No

10

9-cis

Standard

Standard

Deviation

Error

%Control

Sign. Diff. •

P!> O.OS

2568.67

156.22

90. 19

88.40

No

2614 .67

383 .25

221_27

90.48

No

52 . 16

Yes

100

I 521.33

71.70

41_40

0

4536.33

132_58

76.54

100.00

0 .000 1

42 10.00

356.5 I

205 .83

92.7 1

No

0.001

423 1.33

232.6 1

134 .30

93 .24

No

0.01

4202.67

203 .59

11 7_54

92 .6 1

Yes

4529.00

369. 16

213 . 13

99.76

No

4349.00

365 .64

2 11 10

95 .84

No

4 106.00

244 .88

141 .38

90.53

Yes

100

1391_33

981.11

566.44

30.30

Yes

0

5587 33

403.42

232.92

100 00

0 .000 1

5466.67

316.74

182.87

98.0 1

No

0.00 1

5856.00

122.28

70.60

103 .00

No

99.93

No

0.1

10

13-c:is

Mean

0 .0 1

5567 67

80.65

46.56

0 1

5779.00

283 .95

163 94

5537 33

205.53

6~

No

11 8.67

99.37

No

103

10

5939.00

156

so

90 36

106 54

No

100

5208 33

637 .60

368 . 12

93 .34

Yes

*value dillhent from 0 Retinoic Acid concentration
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